var title_f41_51_42800="Paraneoplastic plane xanthomas";
var content_f41_51_42800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plane xanthomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellowish-reddish, slightly elevated plaques on the neck (arrows), noticeable mainly because of the accentuation of the skin texture in a normolipemic patient with lymphomas. Plane xanthomas occur most commonly on the upper trunk and neck and also occur in individuals with myeloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Color Atlas and Synopsis of Clinical Dermatology, 3rd edition, Fitzpatrick, et al (Eds), McGraw-Hill, New York 1997. Copyright &copy; 1997 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42800=[""].join("\n");
var outline_f41_51_42800=null;
var title_f41_51_42801="Hand arthritis in HH";
var content_f41_51_42801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78740%7ERHEUM%2F51733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78740%7ERHEUM%2F51733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand arthritis in hemochromatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serial radiographs, five years apart, of the metacarpophalangeal joints in a patient with hereditary hemochromatosis. The second film shows loss of joint space at the metacarpophalangeal articulations, cyst formation, and a hook-like osteophyte on the radial aspect of the metacarpal head of the middle finger.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John S Axford, BSc, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemochromatosis of the ankle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 222px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain radiograph of the ankle in a 45-year-old man with hemochromatosis shows marked destruction of the tibiotalar joint space, with loss of joint space and erosions of adjacent bone surfaces (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42801=[""].join("\n");
var outline_f41_51_42801=null;
var title_f41_51_42802="Mass and comedo";
var content_f41_51_42802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75424%7EONC%2F66876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75424%7EONC%2F66876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mammogram clustered calcifications A",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spot compression view of a mammogram showing a high-density spiculated mass (red arrow) with heterogeneous linear clacifications in a ductal distribution (white arrows). These \"casting\" calcifications are characteristic of high-grade ductal carcinoma in situ [DCIS].) Pathology revealed infiltrating duct cell carcinoma with DCIS, comedo type.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa E Esserman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mammogram clustered calcifications B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnified craniocaudal mammogram showing linear branching calcifications in a segmental distribution (red arrow). Clustered microcalcifications such as these are highly suggestive of carcinoma, the linear branching is suggestive of a ductal lesion. Biopsy confirmed a high-grade ductal carcinoma in situ (DCIS).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa E Esserman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42802=[""].join("\n");
var outline_f41_51_42802=null;
var title_f41_51_42803="Caffeine: Patient drug information";
var content_f41_51_42803=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Caffeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/34/25126?source=see_link\">",
"     see \"Caffeine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/20/32069?source=see_link\">",
"     see \"Caffeine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cafcit&reg;;",
"     </li>",
"     <li>",
"      Enerjets [OTC];",
"     </li>",
"     <li>",
"      No Doz&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Vivarin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691389",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to make you more alert.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to caffeine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698178",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Grouchy or touchy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11289 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42803=[""].join("\n");
var outline_f41_51_42803=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144010\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011370\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011369\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011374\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011375\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011377\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011372\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011373\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011378\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011379\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/34/25126?source=related_link\">",
"      Caffeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/20/32069?source=related_link\">",
"      Caffeine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_51_42804="Ferrous gluconate: Patient drug information";
var content_f41_51_42804=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ferrous gluconate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/37/38485?source=see_link\">",
"     see \"Ferrous gluconate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/57/15253?source=see_link\">",
"     see \"Ferrous gluconate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ferate [OTC];",
"     </li>",
"     <li>",
"      Fergon&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ferrous Gluconate&reg;;",
"     </li>",
"     <li>",
"      Novo-Ferrogluc",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Accidental overdose of drugs that have iron in them is a leading cause of deadly poisoning in children younger than 6 years of age. Keep away from children. If this drug is taken by accident, call a doctor or poison control center right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Iron is most often taken during pregnancy to stop anemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702116",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ferrous gluconate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703226",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Anemia from a cause other than low iron stores, too much iron in your body, or thalassemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696857",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take calcium, zinc, copper, or multivitamins that have any of these minerals within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take tetracycline within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take antibiotics like ciprofloxacin and levofloxacin 2 hours before this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black stools.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If a child eats your tablets. Poisonings with iron happen most often in children. First signs of overdose include feeling tired, upset stomach, throwing up, belly pain, dark tarry-black stool, and a weak or fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, period changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695812",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before or 2 hours after bran, fiber, tea, coffee, dairy products, or eggs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694866",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11192 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42804=[""].join("\n");
var outline_f41_51_42804=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170833\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170834\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019343\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019345\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019344\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019349\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019350\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019352\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019347\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019348\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019353\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019354\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/37/38485?source=related_link\">",
"      Ferrous gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/57/15253?source=related_link\">",
"      Ferrous gluconate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_51_42805="Water purification systems in hemodialysis";
var content_f41_51_42805=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Water purification systems in hemodialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42805/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42805/contributors\">",
"     Richard A Ward, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42805/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42805/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42805/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42805/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/51/42805/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different water purification systems used in hemodialysis are reviewed here. Discussions concerning the water-borne contaminants to which hemodialysis patients are exposed and the methods of monitoring the various water delivery systems are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29190?source=see_link\">",
"     \"Contaminants in water used for hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/33/10775?source=see_link\">",
"     \"Maintaining water quality for hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR WATER PURIFICATION SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis patients are particularly vulnerable to contaminants in the water used to prepare concentrate and dialysate, or in water used for reprocessing dialyzers. Compared to healthy individuals, hemodialysis patients are exposed to extremely large volumes of water, have inadequate barriers to such toxins, and cannot easily eliminate contaminants:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated water intake of a healthy individual is 2 L per day or 14 L per week. By comparison, a hemodialysis patient may be exposed to 350 to 500 L of water per week, depending upon their treatment time and dialysate flow rate.",
"     </li>",
"     <li>",
"      With normal individuals, the gastrointestinal tract separates blood from contaminants in the water. By comparison, the barrier between blood and water in hemodialysis patients is a thin membrane, through which transfer of contaminants is limited only by the size of the contaminant.",
"     </li>",
"     <li>",
"      When dialyzers are reused, water is introduced into the blood compartment of the dialyzer during reprocessing. Contaminants in this water may be trapped in the blood compartment and the patient directly exposed to them during the next dialysis treatment.",
"     </li>",
"     <li>",
"      Hemodialysis patients are unable to renally excrete any contaminants taken up from the dialysate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accumulated experience, combined with the observation that some of the most toxic contaminants arise from municipal water treatment practices, suggests that",
"    <strong>",
"     no",
"    </strong>",
"    municipal water can be considered safe for direct use in hemodialysis applications. All dialysis facilities therefore require a properly designed and maintained water treatment system to safeguard patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42805/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHOOSING A WATER TREATMENT SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most dialysis facilities obtain their water treatment system from a vendor specializing in such equipment. However, the medical staff of a facility should understand enough about water treatment to critically appraise the system they purchase. This is necessary for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Municipal water supplies vary from location to location, even from one part of a city to another; as a result, no single water treatment system will satisfy all situations.",
"     </li>",
"     <li>",
"      Once a water treatment system is installed and shown to be operating properly, the staff of the dialysis facility must ensure that performance is maintained.",
"     </li>",
"     <li>",
"      The Medical Director of a facility has the ultimate responsibility for ensuring that the patients are treated with water that, at a minimum, meets the contaminant standards set forth by Association for the Advancement of Medical Instrumentation (AAMI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42805/abstract/2\">",
"       2",
"      </a>",
"      ] or other applicable recommendations organization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42805/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WATER PURIFICATION PROCESSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water utilized in hemodialysis applications is generally prepared by a number of different purification processes assembled in a cascade. The most commonly used purification processes consist of the following techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42805/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reverse osmosis",
"     </li>",
"     <li>",
"      Deionization",
"     </li>",
"     <li>",
"      Carbon filtration",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reverse osmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reverse osmosis (RO) uses high pressure to force water across a semipermeable membrane, thereby rejecting 90 to 99 percent of ionic contaminants and &gt;95 percent of nonionic contaminants with a molecular weight greater than approximately 150. A reverse osmosis membrane is also an effective barrier against microbiological contaminants, including bacteria, viruses, and endotoxin.",
"   </p>",
"   <p>",
"    Reverse osmosis systems are operated in a cross-flow mode (",
"    <a class=\"graphic graphic_figure graphicRef63776 \" href=\"mobipreview.htm?40/52/41793\">",
"     figure 1",
"    </a>",
"    ). The feed water stream flows parallel to the membrane. A high transmembrane pressure gradient forces water across the membrane to form product water (ie, permeate). The remaining feed water carries the concentrated contaminants to the drain in the reject water. Typically, the product water flow is about 30 to 50 percent of the feed water flow.",
"   </p>",
"   <p>",
"    The most commonly used reverse osmosis units for hemodialysis applications use thin film composite membranes in a spiral wound configuration. Although the capital cost of reverse osmosis is relatively high, the process has the following advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Its operating costs are low.",
"     </li>",
"     <li>",
"      It has essentially unlimited capacity for contaminant removal.",
"     </li>",
"     <li>",
"      It effectively removes a wide range of inorganic and organic contaminants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For these reasons, reverse osmosis is used alone or in combination with deionization in approximately 98 percent of water treatment systems used for hemodialysis applications in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42805/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Deionization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deionization (DI) uses ion exchange resins to remove ionic contaminants from water by exchanging hydrogen ions for cations (cationic resins) and hydroxyl ions for anions (anionic resins). Mixed bed deionizers contain both cationic and anionic resins; the exchanged hydrogen and hydroxyl ions combine to form water. They may be utilized as a secondary purification step following reverse osmosis if reverse osmosis alone is insufficient to provide water of the requisite quality.",
"   </p>",
"   <p>",
"    Although mixed bed deionizers produce water of very high purity with respect to ionic contaminants, they",
"    <strong>",
"     do not",
"    </strong>",
"    remove microbiological contaminants. To the contrary, they provide a good environment for bacterial proliferation and often worsen the microbiological quality of water passing through them. Therefore, it is necessary to incorporate bacterial control equipment after the application of a deionizer.",
"   </p>",
"   <p>",
"    Deionizer performance must be monitored very closely, since death may result if used deionizers are not exchanged with fresh units once they approach exhaustion. When the capacity of the deionizer is exceeded, ions that bind to the resin with low affinity will be exchanged for ions in the water that bind to the resin with high affinity. This phenomenon, which can lead to high concentrations of a contaminant in the product water from a deionizer as it becomes exhausted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42805/abstract/7\">",
"     7",
"    </a>",
"    ], has been reported to cause acute, fatal fluoride toxicity in hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42805/abstract/8\">",
"     8",
"    </a>",
"    ]. To guard against accidental exposure to water from an exhausted unit, the product water from a deionization system must be monitored continuously and the water automatically prevented from reaching its points of use should the conductivity exceed 1",
"    <span class=\"nowrap\">",
"     &micro;S/cm.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Carbon filtration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Filtration through activated carbon is the standard method used to remove monochloramine (commonly referred to as chloramine) from water. Because chloramine is acutely toxic,",
"    <strong>",
"     all",
"    </strong>",
"    water treatment systems should include carbon beds unless it is clear that the water supply is disinfected by a means other than chlorination, such as ozone. Carbon also provides nonspecific removal of organic contaminants from water.",
"   </p>",
"   <p>",
"    Carbon beds, which cannot be regenerated, have a finite capacity for chloramine. To prevent inadvertent exposure of patients to chloramine as the capacity of the carbon is exhausted, two carbon beds are installed in series. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Assembling a water treatment system'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The ability of carbon to remove chloramine is dependent upon the type of carbon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42805/abstract/9\">",
"     9",
"    </a>",
"    ]. Traditionally, granular activated carbon has been used for chloramine removal. For this purpose, granular activated carbon should have an iodine number of at least 900 and should be used in beds with a total empty bed contact time (EBCT) of at least 10 minutes. EBCT is a measure of the contact time between water and the carbon and is calculated from the following formula:",
"   </p>",
"   <p>",
"    EBCT &nbsp;= &nbsp;(7.48 &nbsp;x &nbsp;V) &nbsp;&divide; &nbsp;Q",
"   </p>",
"   <p>",
"    where V is the volume of carbon (ft",
"    <sup>",
"     3",
"    </sup>",
"    ) and Q is the water flow rate",
"    <span class=\"nowrap\">",
"     (gal/min).",
"    </span>",
"   </p>",
"   <p>",
"    An alternative form of activated carbon, catalytic activated carbon, is also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42805/abstract/10\">",
"     10",
"    </a>",
"    ]. This form appears to remove chloramine from water more effectively than traditional granulated activated carbon.",
"   </p>",
"   <p>",
"    Carbon beds are usually installed in series before a reverse osmosis unit for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carbon beds remove chlorine that can degrade some reverse osmosis membranes.",
"     </li>",
"     <li>",
"      Since carbon beds provide a good environment for bacterial proliferation, reverse osmosis units supply a barrier against microbiological contaminants derived from the bed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some instances, activated carbon might not provide adequate removal of chloramine. Inadequate removal of chloramine can occur when the pH of the water is high, or when municipal water contains high levels of organic material or additives, such as orthophosphate, for lead and copper control. Inadequate removal of chloramine can also appear to occur when naturally occurring N-chloramines are present in the water. N-chloramines are relatively large molecules and are removed by reverse osmosis; however, they test positive in the assays used for chloramine, thus giving the impression of inadequate chloramine removal.",
"   </p>",
"   <p>",
"    In these circumstances, other strategies for chloramine removal might be needed. One approach that has been used successfully is the injection of sodium bisulfite prior to the reverse osmosis system. Other approaches include installing anion exchange resin before the carbon beds to remove organic matter and other contaminants that may foul the activated carbon and injection of a mineral acid before the carbon beds to reduce the pH of alkaline feed water. A system with automated control should be used for sodium bisulfite or mineral acid injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other purification processes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water treatment systems may include other devices, such as softeners and filters. These components are frequently included to extend the life of the principal purification processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Softeners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Softening, a commonly used auxiliary purification process, is a form of deionizer that exchanges calcium and magnesium ions for sodium ions. Softeners are particularly used in locations where the municipal water supply is \"hard.\" Although calcium and magnesium ions are effectively removed by reverse osmosis, using a water softener before the reverse osmosis unit will protect the reverse osmosis membranes from fouling by calcium and magnesium salts.",
"   </p>",
"   <p>",
"    As with all deionizers, softeners have a finite capacity and must be regenerated by exposing the resin to a strong brine solution. This process is done in situ using pelletized salt to form the brine solution. Such solutions have a very high sodium concentration; therefore, all softeners used for hemodialysis applications should include a lock-out system to prevent brine from entering the softener's product water stream.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of filters may be utilized, both as pretreatment for the principal purification processes and at the end of the purification and water distribution system to control microbiological contaminants. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depth filters to remove coarse particulate matter at the beginning of the purification cascade",
"     </li>",
"     <li>",
"      Cartridge filters to protect reverse osmosis membranes from fine particles washed out of carbon beds",
"     </li>",
"     <li>",
"      Bacteria- and endotoxin-retentive filters to control microbiological contaminants in the water distribution system",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     WATER STORAGE AND DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since purified water must be delivered to its point of use without recontamination, the water contacting surfaces of all piping, valves, storage tanks, and pumps in the distribution system must be constructed of inert materials. No brass, aluminum, or galvanized metal parts can be used. Materials that can tolerate disinfection with hot water or ozone are preferred. In addition, as purified water contains no chlorine or chloramine to suppress bacterial growth, the distribution system must be designed to minimize microbiological contamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Direct and indirect feed distribution systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two basic designs for water distribution are a direct feed, which does not include a water storage tank, and an indirect feed, which incorporates a water storage tank (",
"    <a class=\"graphic graphic_figure graphicRef58319 \" href=\"mobipreview.htm?21/11/21680\">",
"     figure 2",
"    </a>",
"    ). Both systems offer advantages and disadvantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The extra capacity provided by the storage tank in the indirect feed system allows use of a water treatment system that produces less than the peak water demand. Therefore, the water reserve in a storage tank provides a buffer that allows for an orderly discontinuation of dialysis in the event the water treatment system fails. By comparison, direct feed systems must produce water at (or above) the peak demand, and all dialysis ends abruptly if failure occurs, since the water supply to the dialysis machines is interrupted.",
"     </li>",
"     <li>",
"      The pressure in an indirect feed system can be increased by means of a booster pump; as a result, an indirect feed might be the only choice if the patient care area is located one or more floors above the water treatment system; by comparison, the pressure in a direct feed system is limited to the outlet pressure of the last purification device.",
"     </li>",
"     <li>",
"      Bacterial control is easier with a direct feed system since it does not contain the large volume of semistagnant water found in storage tanks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whichever design is chosen, all water distribution systems should incorporate features to minimize bacterial growth. These include using a loop with continuous recirculation of water (",
"    <a class=\"graphic graphic_figure graphicRef58319 \" href=\"mobipreview.htm?21/11/21680\">",
"     figure 2",
"    </a>",
"    ), avoiding multiple branches, and keeping any dead-ended branches as short as possible. Joints between sections of pipe and between pipes and fittings should be formed in a manner that minimizes the formation of crevices and other voids that may serve as sites for bacterial colonization. While these design features can help reduce bacterial growth, they are no substitute for regular disinfection of the water storage and distribution system.",
"   </p>",
"   <p>",
"    The design of the storage tank should also minimize bacterial growth:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Storage tanks should have tight-fitting lids, have conical bottoms, drain from their lowest point, and be vented through a 0.45 &micro;m hydrophobic air filter.",
"     </li>",
"     <li>",
"      Bladder type tanks should not be used.",
"     </li>",
"     <li>",
"      Storage tanks should incorporate a means for adequate disinfection and rinsing, and be sized to provide the minimum required volume of water for continued operation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Purified water distribution systems constructed of materials that allow disinfection by hot water or ozone are now available. These systems are more easily disinfected than systems that rely upon chemical germicides because there are no chemical residuals to rinse from the system before dialysis can be restarted.",
"   </p>",
"   <p>",
"    The inclusion of a bacteria- and endotoxin-retentive filter at the point of use, such as at the dialysis machine, can provide dialysate of very high microbiological quality; however, such a point-of-use filter should not be used as an alternative to careful design and maintenance of the entire water treatment and distribution system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ASSEMBLING A WATER TREATMENT SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of water purification processes needed to produce water that consistently meets applicable standards will vary from facility to facility depending upon the nature of the water supply and the applications for which the water is intended. The detailed design of a water treatment system will generally be undertaken by a specialist vendor; however, the following process can be used to determine the basic elements of a system and to evaluate the suitability of systems proposed by vendors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42805/abstract/11\">",
"     11",
"    </a>",
"    ]. An example of the process in one hypothetical situation is provided in the tables (",
"    <a class=\"graphic graphic_table graphicRef72685 \" href=\"mobipreview.htm?38/45/39645\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78701 \" href=\"mobipreview.htm?4/26/4524\">",
"     table 2",
"    </a>",
"    ) and figure (",
"    <a class=\"graphic graphic_figure graphicRef81113 \" href=\"mobipreview.htm?32/56/33678\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 1 &mdash; First, the clinician should determine the quality of the water supply to the dialysis facility and obtain an analysis of the water entering the facility for the chemical contaminants included in the appropriate standards. This analysis should be supplemented by information from the municipal water supplier. The water supplier can provide information about seasonal variations in water quality. As an example, both aluminum and chloramine levels tend to vary seasonally. System design and evaluation should be based upon the worst possible case.",
"     </li>",
"     <li>",
"      Step 2 &mdash; The quality of the product water must then be defined. For chemical contaminants, the product water must comply with the AAMI water standard in the United States. If the water is to be used for dialyzer reprocessing, it may be desirable to set a more rigid standard for microbiological contaminants.",
"     </li>",
"     <li>",
"      Step 3 &mdash; The minimum reduction in concentration required for each contaminant is determined by dividing the supply water concentration by the maximum concentration allowed by the appropriate standards (",
"      <a class=\"graphic graphic_table graphicRef72685 \" href=\"mobipreview.htm?38/45/39645\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Step 4 &mdash; The desired reduction in concentration is compared with what can be achieved by various purification methods (",
"      <a class=\"graphic graphic_table graphicRef78701 \" href=\"mobipreview.htm?4/26/4524\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Step 5 &mdash; Possible purification cascades are determined that will provide the desired reduction for all contaminants and any redundancies eliminated. As an example, it might not be necessary to include both reverse osmosis and deionization (",
"      <a class=\"graphic graphic_figure graphicRef81113 \" href=\"mobipreview.htm?32/56/33678\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Step 6 &mdash; A water distribution system is chosen. Completion of this process will provide the outline of a system that meets an individual facility's requirements. This outline can be utilized to evaluate systems proposed by commercial vendors of water treatment systems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodialysis patients are particularly vulnerable to contaminants in the water used to prepare concentrate and dialysate. Accumulated experience suggests that",
"      <strong>",
"       no",
"      </strong>",
"      municipal water can be considered safe for direct use in hemodialysis applications. All dialysis facilities therefore require a properly designed and maintained water treatment system to safeguard patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale for water purification systems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most commonly used purification processes are reverse osmosis and carbon filtration. Deionization is used less frequently to supplement, or in place of, reverse osmosis. Water treatment systems may include other devices, such as softeners and filters. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Water purification processes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since purified water must be delivered to its point of use without recontamination, the water contacting surfaces of all piping, valves, storage tanks, and pumps in the distribution system must be constructed of inert materials. No brass, aluminum, or galvanized metal parts can be used. Materials that can tolerate disinfection with hot water or ozone are preferred. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Water storage and distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of water purification processes required to produce water that consistently meets applicable standards will vary from facility to facility depending upon the nature of the water supply and the applications for which the water is intended. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Assembling a water treatment system'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42805/abstract/1\">",
"      Martin K, Laydet E, Canaud B. Design and technical adjustment of a water treatment system: 15 years of experience. Adv Ren Replace Ther 2003; 10:122.",
"     </a>",
"    </li>",
"    <li>",
"     Association for the Advancement of Medical Instrumentation. Water for Hemodialysis and Related Therapies, ANSI/AAMI/ISO 13959:2009, Association for the Advancement of Medical Instrumentation, Arlington, VA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42805/abstract/3\">",
"      European best practice guidelines for haemodialysis (Part 1). Nephrol Dial Transplant 2002; 17(Suppl 7):50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42805/abstract/4\">",
"      Kawanishi H, Akiba T, Masakane I, et al. Standard on microbiological management of fluids for hemodialysis and related therapies by the Japanese Society for Dialysis Therapy 2008. Ther Apher Dial 2009; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     Association for the Advancement of Medical Instrumentation. Water Treatment Equipment for Hemodialysis and Related Therapies, ANSI/AAMI/ISO 26722:2009, Association for the Advancement of Medical Instrumentation, Arlington, VA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42805/abstract/6\">",
"      Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO J 1998; 44:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42805/abstract/7\">",
"      Bland LA, Arnow PM, Arduino MJ, et al. Potential hazards of deionization systems used for water purification in hemodialysis. Artif Organs 1996; 20:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42805/abstract/8\">",
"      Arnow PM, Bland LA, Garcia-Houchins S, et al. An outbreak of fatal fluoride intoxication in a long-term hemodialysis unit. Ann Intern Med 1994; 121:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42805/abstract/9\">",
"      Meyer MA, Klein E. Granular activated carbon usage in chloramine removal from dialysis water. Artif Organs 1983; 7:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42805/abstract/10\">",
"      Farmer, RW, Kovacic, SL. Catalytic activated carbon offers breakthrough for dialysis water treatment. Dial Transplant 1997; 26:771.",
"     </a>",
"    </li>",
"    <li>",
"     Leuhmann, DA, Keshaviah, PR, Ward, RA, Klein, E. A manual on water treatment for hemodialysis. U.S. Department of Health and Human Services, Food and Drug Administration, HHS Publication FDA 89-4234, Food and Drug Administration, Rockville, MD 1989.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1896 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42805=[""].join("\n");
var outline_f41_51_42805=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR WATER PURIFICATION SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHOOSING A WATER TREATMENT SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WATER PURIFICATION PROCESSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reverse osmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Deionization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Carbon filtration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other purification processes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Softeners",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Filters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      WATER STORAGE AND DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Direct and indirect feed distribution systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ASSEMBLING A WATER TREATMENT SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1896\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1896|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/52/41793\" title=\"figure 1\">",
"      Reverse osmosis for water purification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/11/21680\" title=\"figure 2\">",
"      Water distribution systems for HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/56/33678\" title=\"figure 3\">",
"      Diagram of a water treatment system for HD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1896|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/45/39645\" title=\"table 1\">",
"      Minimum reduction contaminants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/26/4524\" title=\"table 2\">",
"      Required purification processes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29190?source=related_link\">",
"      Contaminants in water used for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/33/10775?source=related_link\">",
"      Maintaining water quality for hemodialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_51_42806="Long standing Buruli ulcer";
var content_f41_51_42806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Long standing Buruli ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AYADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwChub5myepqUMcdSfxqucgnngHNWB+fvXimgoJ9Tj60qljzk/nScFsZ5FNkyCCCQPQUrgTI2SBk5p3JIwTt+tRRZ/8Ar1LnqDQNCluPvZ/GmqcHGSPxpCOSAc8UxW+bBOM+tFxl1OBwTz709HweWPtUSA4Jz096f94nI5oAkDFTnJx9aFIcfOSOKZkkhcc1I+VXHGMd6AI1Hy8sQKkDmMMNxz70wR425OCPemuwLHOBzikUSRh2O6QnrnjpU2W9f1qBXOBjt61LC+8kEAECl5CY7eckc560oY46nFMIO07fyNESkRjfjdQmFifcwOcnP1p4yDncR+NQjtyfSp4/m4wfTFMNhwZiT82c09GIGDnHXNZ2r6nZaTFv1G5SDIyqkEs30A5NcteeP18zZpmnPKvaWdtv5KOf1qkm9jSnQqVdIK536sehbilG6QHAY5rzh/E2tXsLKJbe1B4HlJz+ZyQaybqPUZ3zc31/LnkDzSBn6A1Sgzuo5RWqb2R6z5cg7MPXk9KVCSAcmvIhBqiqpg1K9TbyMTtwPzq7BrWuWxVxqczgfwzgOD9c0vZyRdXKKsFpJM9NkOGzuYD+dOTeCMNnNcVY+NnVv+JtaqIxwZrYE49ypP8AI111jeWuoQiayuEniP8AEh6exHY/Woaa3POqUp0tJIu5PXJpQT64NREuB8nNKm8klgMD060JmZI7Hd1PNOySp5NQ7iW55HpUq4xxRcLByeATmlBPPJ6etLtx9PpTR7UXESq5HLkjI45pRJnoBn16VXyD6mp4gnJPJNFwsSB8g7WOfelJ474+tQqxZ+cDHrSNkZA4BouFiddy/wCOafgjoSfxqvB905yMflU5YfLmgTDnuTmkOcMCTg0pHODSdBx+tFxDBgDG5vrmkG5T3bPp1p0nJGTQHBI9R3FK4xN/zdcGpVOO7VC4B5A5FJGSR3yPfrRcLFjJ6gmnBjkcmoweP609ew96dxHm7EZI96kiOBzk0gX5jxSMMHbz/hTaBEw69OTzSsclQaYGVX9RTYW3TEgcY5qb22GkTYy5yTzQMjggn0x2oTa7MwwTmpFDAk80bjAL3PpQU3MCO1SE8c4zRGMkn/8AVR5A2CkgjOKsIRzk8H0qA4Dk4p2eOTxTYbip80xx1FSP0479qjixhm7mnRctlqSGNdnBCtjHY4qM7mfn86skZZd36U5oV7EikO4kO0j9alCBM7fxNMiUIvr9alH1oF6CgfJz+VLtBXA5OOlQT3cVujvMypGvV3OAPxrldV8apFctFpdqLhF6zyEhSfYDkj3ppN7GlOlOq7QVzp7++tbCJZb+eKCPsXPJ+g6muD8TeMLq9LRaW8lrZfdDrxJL7+w9h+NZks1zqFy091GZ55D/AKyQ8KPRR0A9qrtZHeQwOeckdvpW0Ka6ns4TK22pVEJCR5m+ZVkY9TIdxx7mtBBCSqQqWPdm4FV4rNV2jHJ/iPNbumWdssiiZ8Acgnua6OWyuz3oUoQ+FGULRy24uQD2HUc1oafb3ZCbZCFx1Jrf/sqF1/dsSxIxngn8asfYxFGEIfcMkEDIx71m4ncqkHGyRzt3FcLBuhbzSOqHAx+NZc9lKQxkkypPRhjNdXNaoo5+8PTiq/2cHhQzZGcEfypaDUI20Rzq27RRBY0ztwF+bG2oY7i70i8W4tWe2uAc5HRvqO4rYmjCqRjDEnI6/lVRpVuEaGXDMB8pxQrPc4sRg+eL0umdv4R8Sw60kdvK23UVRndQu1SAf4fXjFdJ1BrxeeyubR1mtC0M4O6NlJyD7Y5r0Pwd4jOrWS29+PI1OPKsjDaZMdSB6+v51jODWq2Pj8bhHh5+7sdFx1HWnoCBknOajDnlec4609G5xn8fWsjiJXJVMkgY7ikV03bMfN1NNkcAfMcD3pqncc4H1FNsEiUbecg4NSBAuAM896iUbiBUr5VDnr0GDQDGEBXPf8KBtL8nr2pMEH5gaUn5zt+tAErDaowOtDHamdpOOw5okYkAY5pE+YZJIAGCDQSEUyzcqCD3DDGKUuSrkryvQUyTAYMv3hUZkDNzn2FK40h7HfhiMAUwOPUijerPyAO+KjfhhtBNFxlnbuU7hnng05QQQOPfihCPLpN2GG2i5I5cdeuKevGKjjbO7IxzSknORkjPQUwOCB/eEUrAFwB+NRcrIT0yafvUuSTn39KtiQjLhztJ47U21jbJLcZ/u0pG4lt3FTWx4x1Bz2qbDuLagpI2eh61aU5brUSqA2PXmiV9rYzyaA3JNmRkfypQOFpqyArTwc8Y4oGRTSHy2KDkUiM7W4aRcMeOKdcMF2gEKx7UMSQoNIY9SwUYzwKkjbb16VGV3qRnr0NPh+UBcbh3pgTA5ZDj6YqRzgHJxVdMmTHOAOlWF5YBjwRmkMMEHI6elI8kca7pZFjCjczNwAPenqwJ5xgdST2rj9Uvf7UuWUDZYwtnJPMhHc+3oKqMXJ2RrQoutLlRja7qtzrM+CDHaqT5cR9ujN7/AMqrwpb26Fp2JPGc9farXlBpnYDh+n0qSGyD3CDOEXnpXXGCSPpcLCFNcuyRctbMNBlJCsnUZAyPYUl1bj5W25BbkVeST5AMbsDAH9asQFEbLpuUf3hTbSPVw8Zy1a0KFppsjY3IV+XcCeAR0zz+VW4YoguJBlu2RwKmlLzSAcYPRieBVm1tg0i4ZpJyfkQAHNQ3c7FBNa6EYvWhYKqS7AflZhwfam6jcyuyhdrF1yWB4U+gq7ew+T5bEM0h3ExjoPx/OsxoW81VPyIOcj5sD2p2HTw8W1KKKcqTooBL8dBu6fhVuG5Z7f7yh1GOnNNmkYl0kcNuI2uRknt3qGRPLU7QSB6DGfrSaNnFvdEMyHO47CV/ifnms27ghLq9uwa4ILYzyv1FaNu6s53DBJ43DpUr26OchVYqcgkUklsx1PMyop5LmIpcxnPscDPqKoiKS3u2uvMuftkciyrufKlQMYUY+93HryK6Ca0RcTLHJGyDLEdD9faovFkM0UNpcau4tXuo/MiVRuYqOjH0z2qmkldnz2YUY1Fy7X2Ot0PXYr638wFThVLMudvI4OfQ1uRurgFCCD6V4xDrX9j+etreu1vcgefEqYIGQdp7YyA3GO9dxoOq74YZtxaGUfI+DtbHXFc1SFvh2PkKtKVKVpHXyqGVuh4qG0jeFNrHI9e4qS3kWVcrjHWpeOhGKzIuPikHO0ggcfSnu2QeSR7HpVWW1ZwZLZ/LlH5H6iltp5yrRXCbZF/iUfKw9qL9xW7FwFSFPB/lUJxu9ee1IC2Rg8dTUiIMZ60BsODcH5sik3BmzyM/rSAEtgkn2p6gc8c0CIZ2YP6AVECoJwec1afkbe/ao1TDMMcdzSY7kB3Bx5nBJ496mVRyB+tDgHbzuI9aRCcjnGfSkMfHuCkYGRzRhgh2/e9SKXKqcoR71J1PTg0yWNibIyeTR++WRfL2be4NSKNvIpQcHngZp3EeWWOr2N//AKqdRIT9xjg1f6KD1B9K8YjvGSU5PQnkV0Wk+K7m2VUkIljB5DdcV1zoNbGakmejxKQpPvVi2G3PHQViaX4h0+8UDzRFKf4HOK3BkAMuCp7rWDTW473HR8OW/SnSYMijaPwoiJOOOnqKJc7sr1FTsUh6quF9Rz1pdvPy1GAMA7qRpApxyR60r9ytyF/3k7EnG0YAPepY2Vm4NRDbkDrmpbWIecxII9s0hjrjc0JReGp8IIVQzDgfnTnUA88U1lyeoOORTH0Hx8zEqSR3NSM2OmTUNmwQ5JwD1qpreoDTYjKQGZzthjPG9u5+g6mktdBpNuyKnia9aKBLO3YBnG6VvRew/GseCLz9q4KxL8zEnG49cVAzTys808hknk+Zyf0HsMcVpWUix75ZiBhcKvvXZTjZWPo8HhfZ079SneJ5caABgznH09atQSrFbyxqi5PG8n5qiMrXl35uFUR9AO9Sxo0MyvGSG7scVo32PWoUNFzIntGCj51b5eCT1rSS3WdN6ZIz9088VnWpFxcMU3MMdD3NaaQyKcNkHkkg1mera2i0IYgm7agEgHc8fpWjaRJuUhtnUZHUGmIqCH5wfMBwuMY98irtpp8jMh+VQOSew+tJ66opuKWrLkcZjiwJW4jaMEDsc5H0NY00ZJ2spRANu5eM+1dHBCqSCdZA6hdu33rOkhe4laNMnByckAUtdjOlNKTZzN0kLSkNOkahXZWZSc4BIUe5OB+NZySM6ndlhjsOlbOraMn2+eGZ/Olhk2jymyhGMnB71E0clmVktoYmj2kbZUyCpGOn8j2IBq7W0Z6EZRcbxd2/6/Eo2gHzZPI6e1aVjCrjpwOhFMWFQxaMBEc8KvO0elOgm+zxHYqnceQeopM58RFyT5RNS3rIoEixpKfLbnOR9Kn8Q6e2q2NhJNcKY7e2MGTjnaT0/wA9qpy3KTqrSYEiPvGeavQJDqVtdiV9twhZ1SMgZB5yFPUZyOPWqkuaJ4uLotJPax5TrivIQ0iBR80TMg9Kq6Dql7oly0bZkgLqGhYnqRwyj1xXe6hp9vIyZALTDcqg8h/SuVMNvBOyXMdw9whHzznIXsfeslLlTjLY8nGYNVnddD0nw/rKzRI6MCj9DmuxikEiBlIOB+FeJ6LdJpwA37I3kxtY9CT29vSvS9A1IuoUkFa57WPnatN05OLOnjB2HqOfXFLKPmHTHrSKwZM5AOOOKaSxVecDOOKRkNffkFCCPQ06LrgnFL5eTlyTjt61IGxgKp/woC4bQpBZhx3xTdxDE/rTwd6kHDetAXA7YoANmVHt3HWlC/PknjvxTlPH09aVunGPekIgaMOeMfWo1AVwDwPpUqIBkrgg0khYEDHNIpDWXJ3DH09qki5yAOKYkmeO/pUycRZ4B9KYhAOOppyqM5x3pjEk9OP5VIvWmgPkp4W8w4x949KQI6nIHFRs7Bi2dyZPI7UeeQM817VmcuhajkZe3P8AKui0fxNfWBASQSRf3XrlRcnPIqRZ+QD1rOVNS3Q1I9Z0rxdZ3e1LnFvL05+7XQI0c6743V165U5rwyO6P1rY0rXrqwINvKQP7p6GuSeHa2NFJHryZPFROcyFeOOvvXP6L4xs7krHeAQOeN3Y1tJIJsyQnehPDDmuaUXF6mqsx+QJgDgDpVuJdsjPk5PGKpAN5qg8kdauHBJKkgiktxjnCu5LZH0pAQqHJzQineSM80sqERnAAzQ0Ndh1tAsscjzSxwW6fNJNIcKv+J44FcBfXcmo6vNO8u6BCUiOMBUB4/Tkn3rR8UapI0v9n7iY4cMY17EjJJ9/u4HYfWsRZAECDgkjjHauilFJXaO/BUXOXMzRRg6sV5AHB6ZqRMSSAluc9MVWs5YijRo+4gkVoWETTu0Z4AHJ9Oav0PsqNFRjr0E2skmQrKqkEt70k9w0kyIz/u+u0ngVe1FGjiwAMJwwHOTVSztPOmDuBtAOOOM4zTO2ioy957I07W3WZg9vMkPlwh9kw2mUsBwoyc4zkHj1NbkCZhTLAydSo/rWRa6efMWYoUkQZDLx+FT6cLtrsGJQUZivIz0GT/Sm1zbE1ZqOilsbCtGzhQvJ6Y5yaspaXs7BLS3lkZgQFRTg45OPpWMjFRcFd5O7LEfdTnHFaU2otC7iCR0lKgBlOCvryKnltuRzSfw7+Y2eV41K7sIOgxg/lVCWS8n3ywmQW8eFdwOASCcH8AT+FamnaHqmrJHJaWU04Zyhk9CME/oRXc3XhKHwv4f1Ge9je9a4h8tmUrhCWG0ID82eua3p4fm96WiOXE5nSw7VNNObdrf1t8zg9F1WXSbqK7h+zzNbneFmUMpOMfh1+tU9Rul1O7u7+0gf7Jt8wqUyYwSBkgcKueB+HetK90+1ESGIN5cqswQOC4H+1jgGuLVEWV3ec7GjClByzR544HUZ2j6mo5X8HQ7KEqdSTrJWlt8r7GiIJEZgFX+96g/Qjj9apvNHdWNtLFKiTtM8cqKRwAeDzjH51uXVvfQaZFPG8H2admxIjc7TwVI7HnFcvfW32bYNm4Rjdk8DJ747/wA6VrHbQqqs99f6vcqTHbO6Fj5qyHJz2H+RV23u5QpA52AMCBzxVN5Fk8uQDecfvSxB5P8AT2p8Cu0aMWIJHGOtSkaV6SlG5riyXVZkuVjwoXDiNj8rZx07ZHI9qdJp1peWrW9zbGWJ38tpz99Me/XA4FTeENQl0zUkkeISQS/uJo36srcZ+ozmtTxJayWT3trkFJUBjcOQc8EHjr3FTL3dT5XFqUKns+nQ861/Sra0n22crSpGQrAY5IPBz6+9aNjfvY33kl1cEK6sO4Iz+dU9ZiNtqEhkhjVHhVWDgHa4BBJH45z681ntcSPpyGaJmuIXCrIhzuUcHPtjH5Vm1zaHhZhQfKprU9Y0rV98Kq5HTit2Eb1O08NXlnh/Ui3l5PT8a9D0S9E8Izx/Suc8i5pbdv8AjUe4q2M/jRNIx+UAD+lOQZX5SMjqMUDHx8ZxhqWR8pkfrTNhT5xkjuDUoTcFbBHPSmK4iEFRk/Sn4BHPBo245oz6jApBuNY7cc8UxyCAQcHPWpyeM9arklE3HlSenoaTBDWjDAnkGpPleERk5xxSIcqM9KdEgHocUDuMU/JjqR0xU0WQBuIyTnil4OMYwKAMMtCEz45EjJK+3oTyOxq0oWRd0ePeOqzD5m5Gcn8acqlSCGHXqK984ycJnIHbqDR5ZHp70qzI5AlGT/eXrTgzhcjDp6jqPrS1GNCscfN9BUiuynjOMUizKRyKUSp0OKgZYSfnkCtXTNXurJ1a2uHAH8BPBrF3xnAzg9qVXGcg5qJRUlqUmeo6H4rt7jal6BFKT97sa6uEoyb48Mp6EV4UkwAxnFbWk69e6e4EM7FO6E5Fcc6FtUaqR6+ZPlznr0qnrV6bPR7qdFLTBCsYHdzwP1NY2l+K7C6hzcv5EyjJGCc/TFJ4muEOkPchle2Cq4LAqQxyeB69M+mazjBtm1Nc0kjm7pBYW8UGS7kqpcD7zcliT67j+lVRKouGQIDIQcN9KsXEoEVqxYtLtYumPunPH5iobNAk7NIFyGIUZ5FdFtD6rLsOrczRqaWpR44nYvkDLHk/5610BiC7fLjOGbOemfWsuAjyUcYLn5cnrWvZTuyKXYEoNqhj0qUe5O8tV0J9Tmjh0yP5f3hXBIAHGT+vSo/DgNz+7MmIgShbrn2FPuGW8nZVZSM+WBjHJ61o6RCtjE67G+VscjIp7srSnRa6s3YTEkXlsQTwPm6Ee1TyW1spxHAm49Hxk4qCwQ3Mx3gYAwFUcVqxoAoMpBc8bR29PzqlueRLSRyeowzL5yMpBHP3eSB79q6fSNMtfD8c0uuW+n30csBuI285sCPbjaDgjcWOOehWquqTTW7/AOkx+WioQAVxnjpn15rDv9Pu10C3tYrQrd3kzStKSp8xEDMAg6gYDFj7CtqV4tu2xrUbrQUHLlTf9a3VrW/Qvx6vqWv3lvY6VA1vawyFYkhRiIg75ALfiOeOlWV/tbThKt+rx28Lk+YARIeqq2xzkjcDnAzwao+BJVmlng/thrF7hSAsbtulAwW3EAkALnb05NdJplnrF1btpbWttJe36C5bUnHmzqjL8pUlhuxk9+OfSt4w5kpO92ZV6saM5U0korvv5u73/E5SfUZtvnW5idhhFSQMzSkg9Ao57k+g9a5OC3khSOaFEdwjKPKYAq3GMnqB+ten6D4Slnj1C8TVI7FdNiNvbzxqXO7ncVPGM4Y4GeHrmtdn0mDQBDDa/Z9TDogmib5XjVMFmBOd5YZ6d6ynSUVq9TvweMj7R06Svsnbpfvt+Fxmjx/bNBmuZBaxPb5MpRlV8e655IyPmxXNazK90kTCNTMVKMyEgEduvfj9amtr+3uZoI7i2klXd8wjIBdQQOnoeeRz6Vs+KBZyarKNO077LGFAVJCHPT7xJJGeTx24rFRTjzX2PTpp0a9nHe7XZficTBC1w8MEMimWV1jiDDALE4HJ4HXnNbMGnyW0tylwIzcwyFGWJgygjg4IOD+FRSabFJdNFcNHDBbRorOQzEliBkDueeldLbabHHZN8yfKQAFXAH+feszrxNZRWj0fl+v6GH5ZhXcsr7g25vp7GtnS7tbqS0lvQZ8K8Ks53fTj8TzUV1ZiEQI88WXyQFPTPY1nJvttYgELkbzjjoCeuc1SZ42JhCsn3GfE+2mtYbaSGBkuIHDt8mQUHX8sc5rnbeaEPHcN5m6ZeNrbc7uOMcc5Nex31hBqJlEpVtilVfGcj0+h5rzDX0sriErDHDb4ibADbVjbPT17cVnJ2Z8y7Tg4WOYEg0/Wbm1tWl8iJ/3Xm43Fe2ccV3vhm8nuVTD+WqnkDqa4DVmVray1H7Rb+cr/AGZ4gf3jYG4Njpgcgn6cV0Xhy/KqMOBzzisKsbO58/OPLJo9VtwzxKeWarUC4b5qy9EuQ8QG7JPetlccHGCfaskJjzjpilxkUhAwOhIoA56/nTZI1lJZTztHbFISfu/rUjHHUY9KjHPNIYE4xnj+tRvtMZG4Z6ZxRKGyNucelCFWHKgZPekMeq444/Knp93NBGBkgE9qWPjqOP5UAOZcHpSDBYe1KTl+evbmjowAOaYj44dvnYDBIPYUAjPTH0FIcCQjnGTTc9geBXvM4yQ8nHX+lEbNGcpnpTQx6Ae1Lu4zjp1zQMsF4pG+cBHH8a/4VLdQC1KiR0kV13B4zkfQ1SBDd6fC7KW2sOOcYpeoE6pGw4cU4oo4LdOlQFYpiGU+U/6GgiRMbxxnhh0NJod+hY4HO6lV8dO1Vzu7HmrNlBLdTCOIdeCcVNikbnhqzkv7oOxMcMbBi4PTntXd+NdSi8QRRxRTB0W6nJC/NkgKSxPBPOBVn4VWskN3MLEQlkt5zJ5hxuRYiTt6/NngY55rj/DNjJJNLdtvVmiIZQu0YABz9Tt5rlquzsepgIK/N1RbmiRbuQ7C3loEO4FSffnqPcUxWJuZGIUjI2kdhjFaFmPtWpyzSTh1Kh138bdqn5fz3fnVdhujlnZVBYluOw9Kb20PosC2rplyCUiMDsDjNWSx+zySOF2DJQnIJNZ6OQoyccDFTzSLLbDcc88jqOlZ6nuUZFjRLsySiQhQykh9pzn0P9K6q1uiZDKDIY9u0g44PpXC6eDBG3ACK/GOpGcDNdPZ3e1FYkYHVR1prQ1xUFPY7XTz5UTEOcscBh0FPM7lvLAwQcs2eQR6/hVHTdato5kVstCTypFVmu7e3vtRCTfaBdN0cY2LjkD8OM1XmeWqcnJprU0tTvYLm2MMkhuLiYFkzl88deOcnA5/GuPv9aubuzjsbu5uZYbRXS0it0UlA5zJ0GWGB0z+lO1mZ4szQLhuM+Y2zaMdv8Ko2N5GsUUNwj3qSQ74YopfKFvPIdpLnBOAFHGeeK0g3c66dCEIppX+7T0+Xppc1vCE0GnNaanJfQ24mvPsc9vsLeXDhS0jKOeewHfPNdfpOrX+m6Tf3Wj3l1Jo6FIIAX24jDt/CcspODjHTf0riIo/tMdp5yN5BKxtIBgxgEnK4wCcZHzZ61oJq99pmmXVtYXkkjzAgr5SsrLtxyrAnOPTpj3rVTSVjmxOF9rK+7b2e1k/Jb+Z2F7cvf6Vcvp00MVrZQiRozJ85YsASc9ycDrXN6t4fjNhBLDeJbzSwpLtnYKQr4DDGO2QeCWAxxzXP6faiEn+0LW+1B1sj5FuhMbq2QWZhjOASR64weldt4naC6true0tWsx5GHEyHMg3gAbwS3mdyoCgZ+bOBVwgmm5bmN5YepGnSlo32/4N393l5nBSaf5J+1WocJGpVJAwBHIxn9DmmpcTq7iIIz7ApkaQHb79Oa9JtfCES6PZahp94IZp7GSWUSMCmw5BX1Hynn3rn9U0q0iSeFYZoL2N0VUMYZJFIyzq3GPYe9YTpO1z1cNmdKpLlettPPfr/n99jDWUwTRLOsTNKA7kdfbP41dn1BZCFEqpb53tzxnpxVbxRYjSre5msLtVilzaqzId10F2ksAQcfMMcHjpmuTeRZuZSUwpO0YPb/GsZxcXY9GEYYmHtFt/XQ6a41J2eORIImzI0YkAG4AcZGefWiMssn2qJWKKxIJJ+YdxXJWEb/bFjLuq47d/1rtorlLXRktnZSRnJ/ibnOM9qa10Z5eLp+x0hrc7jw1fW+oaeSXXcEyWbBzxyPYivO/HttpyaheQgKrAJKoHAPHc/XOfwqTw7qDWN7NLtRY3HzKzYXH1rG+IWmtfwW+oWrKJ7RmhJxkEH2/HipnFPRnzVWlKjVbictqNikmm3Ely2yZP3kb5yAVxwQOxU9fWo/D96DsB6eneq8Uc0LQJcnfCymFl9sf55qxq1pa6XqNv9jBjV1+eIybsEY5B989PasW1Jcp4+MpNT5u56j4bvBtAB4/Ku3tW8yIHOR6V5N4buzlcdK9M0aQtEoPQjNYWOM0mA2n+VL2FDkjvk0dKQgNRICVOB3qU9B60n8JI4NAxpIPHUj0pkikLuGCMilTkgng9sU9sleaQxzLlQVPPpSADcak24BxyMZpCPfNMBhGSKAP3g9qU8ClHGCfWiwHxmx/eOe+Tx1oDZPPQHpSt/rGwOdxGTRyPx/SveOIcOW5x60E5UelNOSw5z6mkzjBA4pDHgfl2zSls556UwEkg9D2PtSqM5Ixj+dMEKM+n9KmimZRjOVPUHpUQ5JIyTiprW3a4kRFzg5ycUmPcsRRiZx5Hy5ONp6D8a6LSoGQSfZwAVwoYj7zf/rqhBAtrCyxksw7+prrLa3XTWskeNnRGQygcZLEcVlN32NqUW2db4KuhYWiu1p9pZYngQs3l4L5BY8HPUiucvrj7NZ3BLMZZWeWPaeFU7sD6jjj1zXcactszxkSGOTcuyOFsSbQSW2Z4yoB6+ted6pA5lmigkklaO5kdU4PX5sn8M5+lc+Ijqme/l1JczRJJDHMyEsh5BKK2TxyMj8fxqe8QrbttI2+wqpo0Qk08F2jSeN2XaD8w24BGKtXW+VY0QOTnb1/LFNHsUHaXIVixVADjgVaSRHhUqwII6CqsQ8zMbqQoGOeCaZpYeOV9o+TGGBH6iovqepGHLFlnzGF1EpyUjJYFV9a14jhl2naap27B0Kt97PyEDGPqaUSAPluRjJOM4oNOZ3Rqo+X6/OB0Hesi61YG5MUJ+ZSQXVcjPPHPXPSi+mW1MLSmMtKMrvz8o9fpWV5IkSBWjXySxO1MjcBjv6VVjWlJy1Oqln+36RJeXVzBOYAAY/MYyMcgMenIBKg5PcY9tTSRZ3Xhya7t7+OLUUuPMitlTZM+wElj82FUDkH1XGc1xEkKedKscURiyu1GUhwD1wcEYGP1qxJYxQyOIndyg3YQfmCcccd61UkuhMsPzR5VJrW606djs9P1yMQeeLW8W6QfvIQA8TkuMZB5UfMOpPNTWF7frqjzWVv/AKQrM4QN5cVygcZAbumVIwvUZ5rB0KGzv70tf6la2k8nmfI6kFH2naT8hTbnAwBnPTFdtbXc8vh3SbeH7NfXv2RUYXEojFqig4jGO56+vSq2XNc4MQlCTjy797/8M18zV1XT7qLTdU8Tb1stfnc3GxAY3MTLHGixsOqLg7gRznkjqeWfTEeaS50273S+UxkMtwIZIm+UKEXzM/xbcE4wCe1WtG1X+0FuLDV5pPtNtE11bvO4REaPGArNnepG7cCOcDHPTR13wamoappO9JLjUtYh82a3jCR/Z5ANxyMgKpGfUjaetdGtRXRw0pfVKjhVlb5aWte3TRa9fvMeLxPdS6db+HvIsbWO1ikLiGQSFiCd7FiTzjJwCQeo7VtXltb/ANjRpaW9xHerIJJ5JYwm7KKqxqOWP3SfTOT3rDuPD0s/iCVP7LW20q7uRta0KTNasj7QFkbOeoJxw2cdq63WY7Xw7r8WoX0U97aXHmRqLclHRowACGGBuJxkZ45OOlZckmm3/SNK9alGUFRWru7LW7631fnpf7znriQ6zpdhHJJeQx2yTmSS5R5IvM3j/V4B+Yk8j1rjfF+nRWt3LBaNO8iEvKkigbGzjrgH3x716/4M1+8smuI7+B7WOO3lmJufMRTK5LESAj5pCNuMkccjNeY3+oJ4gl1O91cO+qTNtheEhEHOTn12gbQMc+vqpwXKu51YDF1KdWUeW0I9mn8T9Pv10Mbw9bxOomnKyvC5Xy2O3GRnPuQePxq+8izysZY1SMdAvT6VAkEthLNdwMpdhiUMqkc8ZA/wpyMk7xpHzuQEE9z36Vz7bnbWaqSc4u/6DbyIZZbfacfLkcg+9SakrS6ZaETgx2o3ShB1btu9OMj8qkmh+ywSeYhCAZAzz9SKX5ZdMu2IeO2liHmE44x3P6ilU2PMqQUo37HBT3tsRIEhll3loww5259/yrEvZS11alg6hYgmGXbyDz9frXqGkwWRtvsO4AFCyLjC/wC9n1rF8a6SW0TdKB9qsxvVhzuTvWFOyZ4uZUbppEfhyUFl5r1Tw9ONqYbPbr0rwzw/eIhUM1ep+GtQiVUG/wDWsZqzPn0ehdTnrQW9ec1XtpUkjBQgmpSexqAsOLEY/KlBwOaj7Z9qa8gA68+lMZLgBvrRjLDpxVSWbCknt1qeGQOoYHINSMscZPPakwRjNKuQMUu8g+/0pgMYgkc0oGcA0EZNAPIz60AfGL5Lvydue3Wjr1z600nDyAepoz8vJ5r3TiHKQeAc5oI4OVNJg5GPwNKOnJzRYBVHHPrUmCQRn/69NJQBdu4euemc9v0qWCKS5kCQglv5e9K40PtYHnlWKHJYn8APWt6GGK1iCLy5P3vX1qS0ihsUZVUlsfMxPU/57VVluGO/5jjIIHWs3LmdjVRsrs1PD8S3niCzglB8oPvc+wrsNavRBdRRW7ouQTIzDOSSOv0rjfDFysOtxOCVaTIXgH+da2oIJZvJiUFFZS8rngAnqaiTtLQ6qMfd1Og0O6lj8TM4dZMwMwGNoUFeeD78e9Mt9HDzy3SnEQLO7sCoK5+6PcgZq14QZJruV5D5kk4CxngeXjjr3GM8VqkzHTriyibc8TB97EHcQWUfTqBWdS7R7uHg6ab7nOXNlDaeJop4gpLxByAPl9Qp/lmnazaTWdzC5QLbzAyREHIwe34GmX15Npd7NDqCLmFhEZVU4c4Hc9Bg1vMV1LwdepIH32TxTQkjJCsSrrn2yprGDs7M7VNxcZ9Njk0YrdEvEYvMAbaTkcjsfzqOGIxMwjY7DwD2ArUuoxCjwyqpDgMrj6VDbWYKEiQKVPp1FaWsz2FVi48xJbHysx7tvBwfXNMhXdEMABs/MCanhiEcj+cw4+6R/OmXUFwgV4VUgnoOjD600rEKqtiGZZ7mW3SNAsUeNzsNwOD3H41ElhuuDKrsrK3yscEDJHAH51oQKECSBHZXJBAOPw/+tUji1abKqCM546g0+U7KFdNctileRSm8DrOX/dBN4Xbj1GBx36mtTwfp41GfUENvJcPb2j3ERturvlQEfJ27SN3y9SMjnNZd3cyRRKuFUnJRmHSs+01SW0ufMtLxoJtoZZFbb+BwOepHPahNRldnTVvOi4Q0ff8A4Y14L6PTtXhLxmzlLFLsPAEKAsd4EeegHbj0r0ux8T+Fm0K7XTorqW6u7l2V5YOJZuWjyNxC8clQRkZGK8g1x5NZv4ppy9zdyndOynBb6E8E4Gc+9dR8Mrexls7ybxDrT6XbWTRz2yCfy5JJiGEbAnj5fX3PvXRRm1Jro+55WZUISgqlS91bbrrttd67GTNc3W1dTYTea7vaTHydkA3qwwGHU4/hI/lWjpHizU0jRNQnjudsgm82aBS3owLgbiDgA8+oqrLcW0+mavFe3qxOs6pbwQ25JlZSdzlmIKA9SWBJJ4xzWfDJdRzw2ECOkt0qMhFvvkZWwVKd8n2x1qHeL91nZGFKtF+0itNr9rX0dunl6Hs3w61FbjwvJNHffY4YLgPdL5SOA5+aIqzkYQBQAScelQfZIr/Rdeur8G2uCVureSScOzq2ZNqqOpOSWOeBjiuZ8KMPDF1qHh3xDpt1ZfaxEVkMazy8fLsUFgNrZcZT5ucdquP4qsNMtrWDTIhLHC00zWsuUTcQQFfJ+YEE8cEY25Oa6VJcq5j56rhZuvJ0Fe7TTVtt9/XTW5T8dTTQ+Mb22e7OpQptDSvMqozeTkMfmILAEgE+mPaua09rjT3hkiuoo/tEalmTLsNxHJ44OcDA6AVXvtRbW9XkndrWO4lOZn2CKNFVQAFxxzt7Ac1b8NXNlDr9rLq9p9ssnUiSPzArqCuN4GOoxnjng+tck2pS9096nh50sPyzjey1SW9vwLEiptltlZJNjMvmqcqwB6jPan2qW1q6FZN1uFJ4PJPc02dLOLVr97eSOW2jci3lRW2yLxg4Iz+nPPatzxBOddht7mSwj08iERs6JhZ3B+cgAAAZ7Y46VL95vXVGK9zlVnZ7+Xy/qxQZoJoS8pLLKQAByMH+mK7DTNDtJ9LubeaJpBLtVIwu4EZ5+nFcTayBUEEcYG3Gf9mvYFmS103T1Ef+ubZlBknCg4PtWcno0zhx7dKKUerOJuvC9hBCfKs+jZG5mOP9nOelcr4x0wiKTzgcNbPgKMAfKcA/kK9heJXDKkYUEcKexxXnXjopHdNaCYSXLIHYbf4emPT1ofLbmR5Dqynoz540oEypzg46V6R4bXlMnivPnT7Dq80I+6rfKfY8iu68PXOSgByKyr66nz0lZtM9V0EkIpLfnW0xBY8Vzeh3QWLg4NdEsgA3M3BrmGKx2jI//VVa4V2cMnI700DzZhlvlznirTAkcDJNF7hsV8Bl2Y65zxUlphBtUcU2WPByoIpIGIkFDDdF5WBGO9GSecYpuD2Oe9Kv86AAZ3U9MA4NMGQ3FSYG4DoaaEfFrDDvxzmgAgfSmvxI31NBOcHJ564r3TkHZH4/XrRljgjvwBTepOenpV/TNOkvZDnMcI5LEdfpSbstQXkR2NnLeTBIxhR949QBXU28UdpB5UYODzn+8fWnwrHbwRxQjCD06n60yWT96c84GB3GKwnO+iN4Q6kNzJhcZ5PJNU2JLOXy24Z+tSXhLBR3P5VVdykXynJJAGBTgipo2/CMcc2v6dvAKPuHTnJBArW1IvY3iLKCPJkx83OexrA8OT7fENiV2/I6n52wMg55Pauv8SW8sVxO9wyPM25sdiTzkfrU1NHdHXhleJa0q6ht5LGNHBWXBxHxg9cj8q6P+zJVM9zE6CG7JGCCSB1/nXAWIV3yh2yQr5hZh0I6CvQ/Cl4L628iQBZhwd3AIPU1mj26c3bQafLsrkXN2v2mOJfmSRuFGMZUdMgnOTWZ4E1GAX9zp0wlnF3C4Vw2Sj9QGHp29q0721e9mnjw5jWNjtx2HJrm9F006pDDf6IUhuoW3OAeRz271hKm+a/c6fZRaepdu7chjbyTER5wFYDK/jVKaCeIFFCuB+noa7PWWi1JI47q1Sw1CMKGmAyj8dT/AJ9afY6ZYSzQzXV1HtaMmWJMk8dN3HGfY961TXLqjaOJjCCckch9mlMSISm/kiPqWP8AhSWySRs0asu7dgwO2dtbmoTxXF7KlrIUiQfu9/UDso71mfazb30bzx70PMmE/eJ2yPUcDis3VSsX7WVrlOcEyyrCrBgMsmOD3oieRlRZInjAOMldvNeo6dpentINQs4gWASZOMbhgiSMjOOQQR7isHxNpEctq5tsSbyXUgYKj6VopX2HRx0XPliji5kBXDqk3zBgrEgZ98YJHtmufktzayASNG67tuxgRx6nHbpXSRgEKCvThvWpIbNb3P7nnGN1Ddz6ClUSV+hgxxSrCkMw3NCS0a7sqQcZx6ZAH5CrdncW0N1LPq2nhFnWTyNmQYJM5QgHgjIAw2RgngnFaU9jeQYKKqhfUcgetZ0s73hHzMvBBPGCMc9fp9fSqjJp6EVY86dtvWwyG1vNUu75p/s1oYYWuJo5pNhlKj59u7gyHk46ntRpthNDM09pdRSgQpILgBh5TEZ2jIHzKeM8jPQ967bTNI0PVJ7qG91eLStQOxo7I2jgQkMwdGLZ+6qhi3A+b2NU10a8fSbq906GR7OBWlnvXQJHIokaNdnOTkryCBj0xgnb2T33OBY+LfI3bZWastfN7+VvxH2lxa3UZk8Q2y3KQOks9ybry7uTdkbEyTuXd8xwPqRTdX1/Qltp7Tw/Y3dml0oguzJKJAY1kVlcj7u84PygY9zXNX8d7NZLqTWsn9myyLbR3hXCiTaMKTkgfKOlXksbePwyLj7Uk96blQse85KKjb/lIzxlcMD0zxQpy/4JusNR0cpPe1k3ZPzW2m/Sx1MvhPQdQ8V6rpuko2yG1/0WJblZftEwQtu3AFQCAcjP3jgHHTn7qx06ziMFiktxNDMzeezhon6YGwjPGOTnnjtWRa3xglUwExSY2jaxyM9QD9P8K0ZbO7ljczmFCwCkyziNgclcn6YHHXpWc6nOtFqdccPOg0qlRtWW/fq/n2/4Fn6MtxeX9rp8V1DZ20r+VLLK65iYkfNjqCMjnnjNdPrRjt/KtZbr7TqBmcTSeZngYBOD97J5DA4I9MVzGlWUd1dWlr5kGZ0RVmaLYsRJK/vCeQa6PWtMttB0bTN6Qy3tw8sEgXG2N1IA2EH5xz94ZAOQaIR912RwYlwdaKvq9klvvrft/wAATS4Mqbh8FBJsG3v3JI9OK9Kt7lWt7aONwyxxlYyeNmTliP0FeXeHIrq7klaJcjZjbj7wA6Cuj043unJ9pktTHAwwkIOSp45x75FYzaaucGNpc+jeqOh1LUfs/wBjiE2GdlZgBk4z/TvXJ/EG2Vp5bsZL42KR3GevsKt6jK2rXtu2mybNpBcyDGcAk/8A6qseJrYTWJCgHC9ewNZQi5qV9jya0fZ8r69T598eWaW15Zzxja0qEP6ZB/wNP8O3B+StP4oQNHbWWR8sb/nuHX9KwPD0gDAZq5L92eFiVaqz1rw9cH5cnP412SkSxAE8VwPh6QbExnOe1d3p2GiAPOa5TFFyCMHBA4qyeFPSmIO2OKHGcrQLciYeWFOck9abtyB3/SnyR4dfmOCOKaisJck8H3oGWQcgdOOKFJUmmL1z2pwNIEOB4/lTskkU3FPQdD+VAz4rYjzG9Nx6UADHJp5zubj+I1qaVpnmstxcACHPCd2/+tXutpas41qM0nTJLkiaX5Lc9z/F9K6U7YkEajaijgCopJAgVEIAHQDoKQ4Kdfm9Cen0rCUuY3hCw8t8+/HT15qBiS27IBPGMcYqRAVUkDOMnmo1A34JyPWpeh0xVytMPmDHBHYVXkUnG0YU8HFWJSA45xjv2p8kYUlQfvDvVRdhShfYdomnT6ozRWRjSYEFmdtox6iu18SPJM9vHcFkMIClu5IGOlZWg3Mdvp8URijliyfMH3Xx6Z69K0ooNqMZVIcsAgdug68n+tZ1JczudlCnyqxFYW9mkEAeU/bzlCr9M54PFb2gT3FncYaMFCw+bP3ccfj61zkV3Fa3as0K3Enmbsg4Az3JroYLjzLVTvQSrISUAxuX1B71Mbno04pyUZHapKLq0EsTFpkJ2L/eZjyPrVCCwQbruGErcRA4MZxnnnI6HmrOgrBeCFfLbeqEyOD95j0AA6YH51e06AwTGEb3LMcYGcd+f1NacrtqdqtG6KOh3jX9jcNITuMxVmYDcp9vpmpLu2ia2ks2EgNsu3dsw0isSV+YEeh/lWgtqJY2WNQWLbvMAwp5zn8aoanFfWmoQzpkxj51RXILspB2njpxnFZTbjG25En/ACka+H2jigiiRWEsWPNOdytkHvXP+IdJnivbV4UkjnhYM0q/MkgOcduDntXZ2F8l1ODqEkscfzZC5z5h6cDtyPyrE0TTpJfEfk3M4kmSPEQlm/dMrc455JGPwrCV3oZxqTjdvoZU99eW9vNbcvcQFZ2XcFBzjPTqRnpWhJq8n2eS3RMoTuST+MZ7H1rMvYoLC8ljlvY90z+SkzcI7Lj5c9QR0zTLuCa0eGeRnRVQ7wV+Xgcc+oxSpNwjaW51YaVO6UvUW7s1njLtlJhznH+famaNdOlwttKcEZAPtUyagZolQ7DnrIOp/GqV9Gs0sTwnaw6sM/ma0ue7SV1Y3NSnKwKpXmP5Tg7t3pXKXsCvKfKYBmPQcgH2xWlZanbx/aLXUPvS/LvJ4AxyRT7i2inkK6XDPKkYC7o1yN2M4HHvWidyOb2UrbGJd6dfSzO807ys/MrNk7/x7n1zUd3r9zDpkuiPIywxgKVinkAfJy7EZ2ndiPIPAKDGCTncuptTh06SKGF/PzsVCNzBhztPvzXA2Ok6zN9o1k2cz20Eu24OMEE8kbevQ9cU4yktiJyTcedJq+n+Z6z4J8fz2Ph2PwtZ2Nq9q1rJ5kl/MuyF23F3U7eVwchSCcnAJGBXI3+kX2mtHDqCwujyCOG5D7opjgE7XztwAyk+mea5WW9ltZ28uVpEPTB6g10vw/tYdV1+wguYhPbz3McMfnSNtRywPAAIbONpyCOeavn57QZpShDBSnWpK19ZLq99dy1YaHPqhnkhina3tLb7QxCceUGCs46ZUHd0z901Y1KfTUvIBZQkWEkAbbcOSGlwA2D6Z7ckV6D4t8UafNpuoaVZPcaLd2u3TpXU4icLuMiY+99442qOOTkg4PB6NY6ffCS3u7y6tr2eFjbSKsflBgpJDkncMgHp6itKlKKfLFhh8dUxEHXrpxS2WuzW7799NtRmh2l5cMkNjZtdzxsyutuTIxIyR8h7D1GeOtWtSkSR7Awz+bK1uHkDPnyjkgoBj5fXHvWxo5vfAlxBDpdz/bFrfwecENvJF5QOQ8kTOBtfEeAwBzwewqna2pWLVF1W2uprsOoiuImGFcklvOJALMfw5BqeRRjbqYxruVSU9HHp3fR3Tts/+Bc0PCWoCxvfJeFrgYBAT5PLb+8Of/112UM376VLyFtyqN4Iwcc8fy61heBdHibxLCZypjIUHHbnOCfwrodT8+6udYnUgFGaGNl5AA5JIx16YrnkldHj4urF1rLsYGlSQWrtHFKkl1OzP5YPzIMnn6da6Sa2VrQbxujKDcR3NcnpFtcQaS8lzNFiO6PBXDycHIGOSOg4pbTVxYCC3ikNwJJD8u52EasSRy3bAOPpis6EuTVmWLp+0fu6nB/E3Sy+k3GMDyjvUHk4XnH5Zry/RZtkw617d4iL3ckkcgDR7iBn+NTx/iK8Nkt2sNXmtnHMUhX8O36V0NJ3R4OOg01I9N0C5/dooOOelelaPLmIbiM15F4bkJKeleoaHL2xzXBJWZxo6UEcD1qQdaZDgYJHGOnpTs5bsKSAJCoUhsD3qPqQBT5VyMrgt70wR/vAzHJHahghyDjB5Gfyobj0IpUGOTjOaHAA56VIxU5zk8VIMbhjmmxdBn8jTl4fPUZ/OmgPknTdKG4z3qnBOVT8e9a8jnBAHA9OlE7/ALxucEH1qFO5I7c817Em2ZwgKCSvQYNLwQQAAKRQTnBwOvtT2HyBSflwD0qTZKyHBcx4KlT0A7Z96rzZUbtpA+lW9mY+OcccVXuE2vtbA+nalI1gVJAWUMvOa0NCV59XtoVi892zhMZ5AqpblXcxSEIvTPYVY0y+ayvk+zMUdmCF+/NJ7Dja92zpYrD7O267sipBJVQcClvJbmWC4eWN0ZsAKeu3HUkcela2m6Rqmp3Bt7RpXjRtzORlAB1OfrWzqXhe2tbKPfdl2YMrHPBPFRyNq56NK10up5/FBBCVmvd7RNyoHByO9a8N0uoXFuUPkPuCfO3De9Y2uiG2h8u3uEkBXZw2cDPWpNFeCSW086dYIw4UuRk8e1TE0nPlne56z4ZtLqwH2ITo8jfvGlbCYOecc+9dNIhgS4twrxyuQrZYoQvOc+uQcfjXKzeJLeKO8hlWOV0+TLx7Q+R2B6DpXNanqurAxxrcvIVUtHGXJAP49TW7mlsae1cndbHqJKpGiR8AAL6j86glhErxyOGLxElS3zDkY6V5qniXXrm28mIIEK7mKJ83HX8RitHRPF9xp91JFOWmP92Q989M1g5K92W27XOpeJ7HUHa3Qo5+aNlHQ4/KsbxBZXerXkNyJWsr0HIlt05z/eK5wT1rdPiW2vlG23eG4jG4H+E+1asdtaywrc2cm9VwTGzcg+mamrBboujVW7Wp5r4i0uXVxLFqLyTTEBmKrsErY5YDueKraJZ3en6ckPkyOofAA+6VBwSQe+PT0ruNbEkuzzdsciNvRuwPak026dP9eqsIyTIM7RtJ+99ahpTOlN8lrHLWdrFJeXMNvMttMg6hAwYkcYHHBz9QRVG7hvLQubqEOq5+eMEfXg123iPRLa/ubbULF1RlIyNpG9cc9Ohwe/f1rj5nv9I1P7LqyedATmOQtnAJPOccjkcnOOlJXSHRrzi7wfyGaV4YGsXDi4jVAeYyJAXxjPY8V2Xh7T5dHeeKxcrC+FcMN24eu714rFjie0tjei3kjiWQBwBjZnuavJ4htEkFrFPJJKzhR5Z3Bx7fhmr9oklzFTr1K91e6NS786zubeZ2V4rdshD2HcZ649qxvEPiG0NvcyWmjus0yiISQnB5PyjaAdx69PWug+y3Dw+cQFiDc8ZyPcCp9TawuoIhLZW3mRfI7RyspdT1Xb0PsT0zRGbvaLHBwuna78jwrU9F1CC9v47qCL5GbakThixH3mTGcgc5qjpVxPDdRz2pEc0IDKyDBBH8QxyDz1FeoJ4Z0/TdSmsVgE2lagxkix9+N+ehA+U9v+A1wd/YpoGvusob7MwYRnGflIIwcjkjIptq+h7OGq+0Xvb/ANf1YzpLp2lj8lSZlZmMmCWbJzk9a9D8M6NJd+HxeyeIbDzbRpJ30/cyTGMna+JCPvHAwq569c8Vx8Udm9pcOtszzPIjpcMdqR4zuXYPvZ4+mPepbGCOwlia+dnjLBQ/OI/c45NXFpavU6MRCc48qfL8k7+X9WZ232m/ur5lv2lmZo0BWVeSgHydvQ9R6k96uSWMkiTXNy0pmkkzINhAA9S317U3w/qcLXM9xdSzyzqihGCg5UcDOTwBx0BrSm1a31S7W1FyJEULJMoHT0GfStJrS7PFdSSnywja25oeAJ2j8S2tu7YhlJYhx99QpwP1ra1e/XQ9K1Ke6j2WxuXACodx+bkjHrxximadCItdt54kBRAAhb+AYycVoapL9uSNWfHz+YhP15JrCVrXPPrpVK6lbSyuc7cWz3GlCRXaOGS4bajDOP8AaHp6VH4YSG0a/j1GEsQAEwc7gc5wO3P866B4J3RY5EQQJuI29ck5ziqN2GWd5B0WML8qcn0J/lUUo8rTY5S5ouHc4zXbY+ZO6oUi4Kg815F4/wBONvfwXoXG/CP7nnB/Liveb+Fry1kBUbQQCfX0rz/x/o63WizR7iJo1DLkdCORz710SWvMeZjY3hY5Hw1KRtDnjNeo6A/QnPavHvDc+UUE4Oa9Q8Oz8AE9q4qiszxUz0CLHlKM0/sAeRUVkQ0C55FSMeelZgOI2uWU59BSsd2M0iDJHvQ3XjigBQBmmt6HnmpOCg9ajXljk85oaGKDgcU9aTHAxTl4xx1NJAfLsgyzHHBJpOvBP+92qV4+WwBwT1pu3Of4ie/oK9cuKAAbMHueMHipI4w7ICQoPTPWmAByeOQaeiNuAI/2fpU7lEq/Kj7mwex9agngOwO4JUjqO9XRE7w/ONu0FlJ6E02ZACV4+Xqe2adtATd7GO67SpAqu2PM3Lng5J71oywMgDBQQeM575qGC2Juk+VSpYZDdGFCaSDlbloeneD/ABFeaJ4Vkur90nSVgtpIW3MR/Fn6e9TXOv3n2e51D7KWtV/dpGE4TjJk/HNMmihns7O2dIYbFAMxKC2CR1H/ANer2n3dvp5e0trp7m4QbXRlyFSsm7vfQ9CmrbHm16Fnl8xVV0lG8Mo/lSW6wJGpC5IOSCpyK29W0Kc6sRpNvIluwJyCAit6Z/pUcOg6haw+ZPGJ/VUPzY/xosNp3uaLXX2+NHEwiuEQnYw+9jnpUNnrEShUmZNxbCuP4R9TXP6j50GZ50MZ+8qhs4qkkLXBhO3ZG75GDnPPPFLcvn5TtLidi6LablZmP7zPA9ciobuRGkhjhi23kakS7jnfnoR2GB3rW8M6YltEUecu5bcRKcZ9q5/xTqptZ/KtQscjB49w5OPY+vvVcjl1JqVuXVmtbyXDiMLDOWUDeVHPX1qy2sXNvIoR5EXou/rjPRh64rzSPULvYI1ubgB+ieYRnt61JZa1fWdyrrcyTQg/NFK5ZT7c1ShJGKxai00etHXLt40YxLI6no4yuMdeufap9G1YG/Ml6YkifgIM7R7euK5DSvGGlC2ZNQWVZsgqFXKkfXtUWqaxps8025ng2sGjkjIk69FNQ6el7HVHH9LntvnYmjW1wyAbjtIx/npVbULWe+eB4o4S0RDhZFyGxg4Pt398V5Npmpus4nttUjlYvhkHybgegx068ema6eLxJqVqxVThyMhWYNkcjGM9eKz5WJV9bl7VtJuLM3Fzp11JaQyIHnjZ8x+YpOXAPIAH8J45rnE8H3Mklte6fcn7ZHI29j8vmR5yBt6Aj2x6VqaL43lXUWh1WBGSRSPPVMnb6MOjCuxs7i0vJo5NK2gMixhgcAHH8/1qHc7o12loZmnX11p8dvDdgQyyHKlQSr9+/Tr0Nba3G+SCaS2SVSPLlj8nB4J6Gm6/ppt7eT5JGidiQ6ncV+pxXOWst2m6OO6aMs2IY3bcZh6bh0bOOvqKyk+TQ0ptTV0dBqem2c9q19ZS+VLZP5hhZMF4+NwyDyP14rzT4mTQzafbhHLyLMRFltxC455/Kum1fWb6Py4NXtlVpImjkVR9/Pcgd8cVyHjJDH4cMqwKsYlGxvQ/3R9B2qqc73SR6+BhJPmm9OhWhiuINCtZHtx5ciEEJyzHPrjitHwFd+G401VdfW4e6lhdbSIRB41bacZbIIO7HoOOTWjpkEsuhQNfxmK5ZNpjP3fYj2IxVKfw9tJlW3Tbjqv/ANauiDcWmerWUMRTlSlJxv1W5nadfwLawgs0Vwo2yuy4QZIwwI698/StbQ1jgu5GE32iN3KrcKGCyhScEZAOOtRSwwLpENlZ6VGGibfcTuS7OSegGMLwBxz0Jq9ZvJIyI4i858Ii4+7xgYHYfWrk76HLOjypyWl/NHoujXEt5eqVmw3kjZb7cb16F/p2HrXQX8DQ+WsaHapBOB06YP51B4RtEgxFa27yyAiIuygEkHG4+g5/lWzrMQMZiEiRupU59xnPP5Ukk4to+Yq1l7ZRS0MO7uI4Aok3+aB8xUfcFU5iPnclmJAGR3Hqasadaz/armadlkDEGItyE9V9T0/WmEGeSRIYzEgYhkPcev59qiPc2aitEZ90quIgrFUdujdDXPeLbQzwiNgcsNnAyCOTkf4V2dxahYdzEHB45/rWVr0Cy2Me2IE54YDrW7VlqcFZKWx8ztG2n61NC+QGckdsc8/rXoHhq5GV55rF8WaY0urLsQEyt8p6fP6A++Kg0O+jhYb2I+tclXXU8KpBxk0e16ROJIwO2K0mI6Vyfh27V41ZWBBHY10pcnawJ5Fc4izGVyCelP2hhnpUacD5utIT789KVxCorqp8w5z0+lLjjA9adnjB6Gkxjg0wALgZ5IpQQGA7/WgnAAoHbI+tIaPmcQmScoDg5PPXmoiNq5+XI5qViyyOVbBJIzUbquQAAATgivWZohdpxt4wamjASNmBBJJFR7fnB6duxFSo6Kj7kXdkN9aQ7MmQlEC/MyAZOenTp/KmcD5Spwe3pSmUumTubrkenpTrdd7licAdcjtmkNaMgO8tDH8pYngDnJqe5tHEQM0OHA3KV4FFs+yZ32b32fLhsDPrntV2CQyOFQliFzLzlcmod2zaOiuJpl/eQBkDDegyhPOPz4rX8NRR3Vx5jQOPObLIeSW96wYLhUKmSPIYYyeh7dKvpry2sTobNZLh2VkfeUClTu/h6dPyp8jexccRGL1PSLSyCIY7mNpCzcYXgAenuDmsPWilozfZwfKhwwAOMH0rnG8aalcDddLC65G0RsVxkenfmsK0N74h1eLfJJI7yDhCTgZ9P50ezbOiWLp2XKehy6fYXdjFLdRhEaPzT8mcYGTgfgawdX1XQ7CwkWCNpL9WHlKEwoUDk57c4qXxjqb6dCtvZytviYlgOx9vbrXE3c9vdqZihF2xySfu/Uev0qo01bU5a+JfN7oXut3d3CDLLIsm8k7W6jtVG9u5Lva1y5kkTCqR6e/v71G9uyszFGBJz7H3qRE2gMR1HI9jVpJbHNKcp6srMC6rsXOcgH0pyoY4ljkJ/vsOCM4/nVuNfLbEZDYGOe30qZo1ch0XaSOgHenzWM2urKLorogiDbsnfk9fT6UCN0TbgfNz/n0qzPqcawlbkiQ4GCCRtx6AVkSaqocmKJiO25sCnZk80UXljwVZTgn/AGv84p7SSgZSSTc3JIY5zWK+pTsu3gAnORVXz5MEb356/NRYXPbY7rw/qc1rPIr3GLYoTJG5B5A4PPf6V1Oh6uplQNMoXeGMikjGOcHtg+teX6Pcm4k+zy5aVuEOOTx0rQhmNrISdwkwBg5B9wfbHFRKnfY6qOJcdGfTmj+IUuYIY7jKjywcEZ+UnqR0x6EVB4q0KzuoHu7dWgliPm4Q7Q2B/F9OOfavF/Desm5mKNcSLPAoMbMwHy8DZyeR6c9q9Y0XxRDqFlHaXUyhmAjdsYznOTg9ua4q1Gyuj0cNiuWS1KZvW1YJBf4lvLf92rpgbu6nd3Hbr1rkfG1rqN9olrplrbPJGt55nT/VEjH5Hufat2XTh4f1FbKaVxbOQ6XQGAemFbnoABjHrXRwaaNyPaTpO78lN3JzyMjtWNNyjLlZ9JRqUlHTZ/18jnYbe4hs7azkZpBbxiPd1z+PpVlIygdQzEBeSCcGtm5tZbaKQzxmKRmA56Y64qCFLc6e5mkAu2Y9MYwMYz9c11pM9NYhSjp+Bhh5UTyWLPbE7mRemRnBP5mut8A6RFqUone2hEUIJUKvzMxzg5PXvXP7bjUNQigwWaVgBgcn24r03TZbTRLONxalWuCsZVPuIc4J+XOB7+tXCVlc4c1xPs6fJBe8+xf0+AW64i3P5gxvZh+7IPTirN/GphWNH3yO5Dbh8vB9fpVtL2BrN4YUEzgnY65AU/T8Py+tc/rerzWtnHGRskOS0rgHcfRR+uac5wgtWfNU+etNNLW5JIHlIRVEaLglgQenpWPfTeVLLKg2u/oPve5x0rT069nu9PS8nh2QupK54zg4wPU5qnqJSUEqEX5SxB7VnJxcbo7qd1JxkjNa9XzT5+WQcYB6Gop76OaTbIWCxfdGOCKfb2+btlmVccEZ56dau3oTcqvH8uOAeCfWrjU5o3M67gnY878WWCXEl5uCIzrlCoGAMYx+Xf3rx28WWyujDIecBgM9jyK9y8YXunW0TwXFxtMilF28sCa8e1uGW50mOQYZ7HK7gvLRMe574Pr60kr6M8LFr3uZDdL1y7sJFeCV1I6jPFem+FvH1rchLfU1MMjEASL0NeMRSjALHNXIp146fnWU6KexyJn0wrKyB48OjdCtJICR83rxivDND8YajpI2QSl4v7jnIH0rtNM+JVs+F1C2kQn+OM5ArndOSGpHomR34wOlND5PHTpWfo+sWGqoXsZw+eME4NaRjI5Oc59KjYBMHI29O9Sqw475NMP3h/WjHzD0zQB8zyriTBGMnAz3oKc4AJIH51IwG5gVyc4XJ6c0sar3+7nJ5ya9U1QAAwgNghiMH9DmnyxbsphF2jB9xTm2x7mZDuYkKB0GOtPsFtpNQs11CWSOxaVFuHjGWWPPzFfU4zigF3KYGcqDk5/nViGQJbsQp3dduP8APvVWR9sh8sHYWOFY8gZOAfU4xUhZSsXXgc8YyOhoLSHDOGEbcA53fh/9erlvExsygZUABYLjhj/hWdGfvElScjj1q88kn2bZv+XlSuen+FCXYbkrFP7SFG/G4Ywhx0PrUhjVtoVgzsAuw8HPr/KpYYgDiMLuGWGR1xSXTSMqkLyzYCjO4H2xW8WrHDPcs6TaRx3yyNsa3jILhhnK9yM10evaspv9L1HwzGsFgd8RVotmCAN4JXlx0Oc98VytvDd3k0MMCSSSZIXHBbuQc108UmnR+HbeQiW4nQu0mwDYpP3QGHGc4JU88e4ptAqjskcyifb57h7m6WErl18xSQ/tnsaptEquNka/ewBjite1sxJaO77XLdd3HHsfWnfZoQuEyD/Cd2ce3FYSZ0wV9Sn5Xyr5YXAAyrngE9cGq8qrvJMKbwNpAPOR3rUZo0AXcQQwPQHP6VWuJF4y/wApJ44AzQtQloZNztHCxHj0HNZ93IRgycL1wKuXM/DbGAfOQQcAVi3kyou1j854BFaLyMZtsp3bIiqBwerY71TaQAdAe3WmPM7M2WLehPYUgUtkEYAyc5qjMczcdvp603PQhSOfpU8cA+XP4VMsSqcAZP1osK5VUtu4BHoc9666xnGoafHIV/fREKc8hiPX61zyoACcfWtbw9MIboqeRJ/Cw4/E0mVF6k97I++N4t8UkZBjPcHOcg+xrtvCt4uu2d1/aLmG9hIkF2OVfJOVfH3SccN04wcZFYFxayTRMIWH7tWaPI+96iq2l30mn3q3KlYN4KOdnUHqSPwPtRvuaRbT0PRPE86DRLFr15ZVgJMcqHG9eOT9Dx+Nbnh6/srkaLe2syIr36RHDEsYyOPl/wB4Z9txrn71H1mytZrWENEw3mCRjs8osFXAGfXr7VT0GaXw/dyRGIRxwyGMyMmQkmCAy47Zx07VxVsPGL5j2sHjG0oHrepagbm4Nh5eZTtVZSAUY5wBntWHeaZNDPNHJuO1cHAPUnp+FT/8JppKSRSrEZ5nkHnzY/dLwBuXIBznPAHbmun1O2gvGju5JVKOnmHyTgHrhhkjPA9Kw5m3vc9zD4mdBpWsmcTo97a2V8Jb6O8Zl3KvlSBcHaQDn6449K6rwxqaXeo24uYlaFISrNuIZju6/U5H5VU0rS4NRlmgWaBkX5twHzbhnIHvVrQo1S5tneDyZYwEAY4z3B/Piui/uWRvjJ06yk/tW77HX3qzxcW8flpGyF8jHfDZPrVTSkS61iEzJtkclQJhkZz6HoMY+ua1/wB9M6I0TySv8iYyeh5Of1qzrOkLDFFNMfLdcHzVXJLHt71HsuZXXQ+djWUPcluxywL9puoJI4hbrIQFB456/rWJLpMVpPIQqspbaQx3HBrZLzLM+SrREcADqSSTkHpjOKYI3CqXPOD0Gc1crPoKnUlDW+5wXieGOW7azglME8kZMZQ4O73rltJ8Rz2VpfJqjSXF1br5cJxnHru/Eda3/FxifxIskRcSQrw4bGG/z/8AqryjVpsC8mgQi6RiXyc7wScnBpaLVIVSUpaXMPWLsXd1NOxcneSMnJxRPatFJbOWKxToCGByDuHKnH48VWs4U1G5WISOjkHDBcjd2B9uvNQy397bE2Y8tY4W5BUGlC71OSvrozBmCw3EkWDlGK0LIAfTNS69Hi+EoGPNGSP9rv8A0qigOe9dCjc856M0ElGcZzViOdce3SsxRzyM1KAeMCk4dhcxs2169u4eCR43ByCDg133h74h3Nmix6ojXEJHD/xV5fFIQPm5NWUmBGD0FYTpJjufRWk63p2qx77K4VmI+4Thh7VrKvIyPpXzRBcGJw8TvEw/iU4NdloHjvU7GWNLmT7VBkDD9QPY1zypNbF3OKm4d3ORzxU0MbM4YoccjIHGfeo3yXyQxKtx+FWBKwhKjcC3I54HtXoI3d+gxwTMFaVZNi4yg4xSTKZAARjPGBSrwc+oxT1OQoCYIByeucUJodmiPy42mG4kYUkYGartknJACk+mMe1TuoB3jkHsSeTUbqXjJw27ofejcYifM7fexyef6/41b2CUoXwX7lh149aqxSDPJPzcHPGfb6Vdto1EisI+cYAJzj/HihEsR92zemcFfm3emOnrQyCQruxG20Y5xu+n4VoQIkg4ycjblhyBmmFGF4Iv3Si4wvmuw2A9jn+HrzW0WluYTj1RU0uP7TcpAJ/KjYndKc4UYyc4Gf0rf8QQKt1HZ6Vm1sUjT5uEEzYGXZRxnn8hWtYJcNYX/wDaDSW6QRLDE8KhSRvAOWIyM8gYzkmuZv45YrhoCJRJA2yPe+QF64z365+pqpPQxhG8i3ext/ajl5LbyyBn7OjLHnHICnp+FRHZg48pUyRtzjqP61XF5sIBJHAXEjFgfqTzUazFmyMKAei8DGOxrnk9dDtgmlqJKIypbcGPQYBwayboEMvTPXHJrQuJSISrbSCAxIP3fxrGvZn84+YNu0dhgAUIUyleyAK2cD229a5i+kEk5KsT2OO1aWpTkrtPO/6mswQksTkAk8YrVaHNJ6kKJu49fQ1cghPJGAPSnxwAHpge1Wo1AGAKdyGxiphgQMU4KPy/Wn4/A96QsAOaLiADBHOKltjsmjbnAYH0qFWDSKpIQE/ePQUc4kJY7U7qPyNOwXsd/o0m+cqHVZmJeN8naWwcpx68D64qBfMjnEN8kxj3hl8sAfICSdueDjB4PFV7O4OyymSQLJkYwenoT6Vb1JH817geXvSTaJXl44GeOxyMYqYuzsbSXMrmpoWp2kt3Npty728PzGKVQcxyb1wHx0DdD25FdNHpyyS3KyQM98rqxDZZsEbg3cAEd+c1waWTXVjE0DE6tCwPkGXYGGPlYHoXzgbc9q6Twn4we21KKK9sDJKymFmJw8TgjgEcLg5wuBjJ69lVceR3N8KpuS5EaWo6I1rANQtIzHaTiN1My4G/kNt7cf0r0DwDdt/wj7i6VXtUuI4wv3mB4IcH0z1FaWneGofFfgv7PMwQxOZEXPyiTtj2INcdANS8K6rPp8wZlZFO3ZgOMAHpx2rxZp02qnRn1NKaxFJ0r+8nt5Ha6/oy3GoSa14cmt7e/gPmyhVOyc4wdwHQ47gdetGh6kus/Zrxk23AYJPEx5Djr/KnWusC5sRJb+ZGp3CXYBujyBwRVfVLG60jULO68OWyzxXTZvLZ32DcQMOGPQ5zkdD7VrSr+0k0RBNL2c9+n+Tf5HoVrhdQiddyhWLIwkJIB524755rcunyHEalih3OZRwCenWuZ0d9sURB+dWGCRnk9c/Sta6lijAlurcjecFl7e+OlegppRZ4Van+8S7DNRuM2ssLshLAY2cbVzyRVK0hK2+6LzJCDglj2xUTvvu/3cjT5+VSRgAe4rXYNbRpEdoD8DngVzKbqTv0Rq17KKiup4V43h1DRtfFw202lzKSoIyGbjIY/TpXFeObO7Fwt8LHzEMHnzSQtuhdRgZ4+6y5GT619AeMdIh1OwmtLlBhhlXAztI6EfSvKbJ7dtJ13wnq8Ek9zM6W9okTMCxYkx4UHhAcsTz1OQa0pJTfIyq07RVRI8duJYbe1kkieVnZlI3L0Vhzu9Oeh7+lZCzM0kpy5DdATzXV+OtNbQ7i5tYUktonSKJ0kBxPty29Cf4QcD865KHrk7uwOK2dPk0OCVTnJ7795ZvIf+WeDz+tZ0Uy9v0rZt08wOjkbWXGD3z1rnfK8qV484ZGK47GiGuhzTujQEo9zT944x+FUkyrc/nUo9/51bijLmLAcH/9dL5gHOOtV9vX0pRkc/ypOKC5djnwc5/GrME/zryOtZYqWJv3ic85FS4DUjbkU73zng/jipHkCuWjCkDpn/CkfLOT0BJHFNILEc5yCOanU9GxISQXJX5R0B7U4BVz8rZHvwT/APqqJASzYHzH8qtLg8H5SR0qkwkU2GXYBSAT60jJkY3A57njPtVtkKqSo5A3A5FVWK52nGQOeDighq25UZyGXkAsMZP9aswu+xhGcx8DluQf8KhnLMuGQk45I65FT28ZDA3COy4BUhD8wPoR1qorUznOxu26A25kKsMDcATkD6Ypk1vFfQSCbduj5PljnHTPoKvWOmeZptrHDdW08FxvkSNiUlRQcYz3x1/pWlp1jpVjqtsizzXFpPCBdPJwFDD5ggBG7jjPStUjn5mVtDvWKX9lJPd3tnBCJXV53w5OCqEZx1xgetYbStLaRRIhjwSZ92SWfPZvStjUtQ0OXSbm00g3zwRzhIpnBAChiSCvvnOeTwKxAdzrtcqoHPynkAZpTlpuXTjd3JZolMpkJDs2DycbSPaqc7KucOq85ww4+tEko2kYJYDIzjFULmYrlGk25wSNtc9rnVdDbuYchRtUjO0NWPe3BAZck9ifb3qW4n+QtyRnJzWBqd8oZo4iSTzk9vatYxOac+g6VjJKxJ9qYCufmP41n+bJJxk9e1W7eBmGc9vXvVqDe5g2W0ZQABQZsDAyP6UqwnHcD+VP8nAA7VfKRzkO5j9fypyKRg5496n8sLjcDn3pSoz8vI/OqshcxB5WD8ynOKegKZwcZGDjoRT93AHGM56UmRzjA5/KiwXfU6zSxC1spGzhUfdndnqCP1H5VfuDCNpuVEnkuGYoclhuGB7cGsLQZADDH5inr24H1ratkhdFacY8yTYWGcgZ6YHTqB/KsHo2dcNkamlQ/bfEdnFbq0bLMGEo/hG4AZXnI6Hkn2zXd2vh62t7+aLUYESS5m3ec4OI5FON4x09yPypPBegXbJcQ+asc0f7veRwVySMHrx3yM1r32rQutxaXcEZlBCEoSzBgPvZP8q46tRSlZn0+UUbRta9/v8AU3vCGpXGmW8ulTFg5OYZARtcdeCK63ULPTvEFu0MqMl0IwBI4Bbf2IP4V53YLJHpsc8ryN5IxDKOqg9senP+Fa1lqyi7W4UtC8WWaMfdb2B+ua5NYOy+F9GbYnC2m5wdmuqMvVtOv9KupVjlaMq2XUJkvxnpXY+FdXXXtHaON2MrxGOVD1Un+LB6cjNLeeRrVjDfCZ4Jly24rnI4yp9T16VyGl3kOgaqZfPfy5CVzgAFuxPPHpiohF4eomn7rHL/AGqk1Je+vI7+0aG1+VodoZeSSRz0rpbyGIWKTQp5yuMIshzsPrjNYSlr+zDQEm6dSHUMCVboPz65qvpGpaw7Cz1GEwXEPzRpIBkgdQT7jmu+UlHRq6Z5NSDqe8nZrdXOhFkXgieRGjYjGwcD3JHYVJcxwxw74bhS4AHC5JP+e9SSpN5SXXnRZkIVinJKnryfSiCFZbiYLMqxqPTk1UIKLslucfO3q3sYWoTu8QW4O/avyHGMCvGdQklj+K8G9f3bQpDIVG5zG3JwO5yuM9smvZ9Y866uWMaqqIuAAOMD2rwj4n2MsGuLqfnyQwzjy8IdrKQh4B9xn8zUpqM0ztdPmotdyP8AaPZZ/wDhH5zHCkoWaLO3ZIyB8x5UdOC3XvnpXjIJOGJI9c16h46hX/hGhKIpprqSXe1zcSB90QwgK9wMYzu5/CvLl25wvqcg+nauyrLmdzyIwcI8pdttv2obM47ZrL16Hyb8OB8sq7uPUda0YWG5SWUbuWc9j3o1yL7RprSLljA27P8ASsYu0hTV0YkMpUANz9atZQ/d4PpWcuetWEyQpxz6963OZljdgkHPFKD+tNSXJw6kjpk9RUgRW5jbOOOalrsFwDA5pUf5178gUgjZjgDNPhhLSccFSCc/ypAdHOyrhFCghju5ppIZs9l5+tRO215NvQtxnrUjDcwJGAR0B6VCPT2FiIxwPlHIxViNjgk8YHfoPSq6M6gENtfgjinLgsOWDN0GO/aiwpMsTbZPkCcEfd9PWoWtyrgPjBHDDof8K09OgM1wRGGKp8zgEbuuMDPXqOKl1KGWxuJLaZWALADGCMn3A68U+W2pHOnoZlrYytcANGkcmMjzH2Fl65X1+grtdM8NSw2cd1PPL9kdDKViRs4OQG4OV69cYqt4f0yea4svMeO2nBxmZgA6Dtu7fSqmqPqOhXRltmlETynbdfeTdn7ob09jx7VqjnqJ9TVuL2C1F3az2wtdOj2GGUDe5fnMigAgk88E9K5fxMtrbTBbSdZldRIZD/rBnnaVH3QuTiotR1S4vCB5v7uNcAyEu3PqenuPSsu4KIVjEvmbzuZsY59MU5aLQzgnuIiRIU8gZJyRkc5PepncJuZ2JO3+F+pP+FVpcICVO5cnHbjtUE0vG0OuWGc4zWbZutAmnYIQp3EDlhzj2rPuZvl6/L29qWaRnAUYznPAxms28mSJJCcEjkcZpqJM5lfULlhCwVmweOPesdkaViccjtUssxkyTkE9Rnj61LaIhP8AF+XNaxRzuT3LFlZbsMwO3rnHNaiwqi7SAR1/+vUKXGEwqkEdxUTXOckrye/pV6GOr3LLMo/nx2pjuoXOR6YqmZCR2xTSxyMNjtRcaRbDDkHIyPXNRGTjsPXFQ5PegE5/nSbHYl8wZOetIW4xk5qMAgjinr0xjpSuWkamhXHlXOQeVOQfXsa6vSvskl+WvmKWzqSXY/dx3/3q4eyYpcx4/wB0gn1rudMgtrmC7EyszR2zSKh4O4dPyrGerOmjZ2TPXtJlRrZjHLNDaud+5zvZm65b3p95Y2urahbSQNNHhB9qlZOrdMjHtis/w1LFHFAl6vmzoreajsRuIGMZHccH8K6RbmKx02/vI45SIgnzE5A5547V50veZ9/GDo00oJ3W23XQZcWh0u/ggeXzEI3Rg8b19cfiKQWIk1WW9t5pHt2YZjbHB7kd6wp7+XVLlrmG6eZSMBG6gY4x6Vv6EVvbVZDIFlAEZx8rbs/lWVWlzRsjOtCdKPvvXqaFuZwDCzqI3Ta4jYphtuCRkdDxT10TTioZVyxxlpOfnxySPfmrWpo1rao0iGSNtu1Y1+YN6f8A665HTvFVtNrH9mi3uba43FU80Ab8ZOMj+Vcs5tNKWpy01OcXKBtSyzaLeXP2ZnihaLzgFOShXqfcDrXR6P4jW8gErXbyhMHzgnOT1B46e9YID3khW7nUzxuc/LxtxymfoatwiOzsxAtruiYBQFXAHoQR9K6IuX2XZGVSMKitJXkbd1rdnas5M7+ZIfcqmfQds1fg1PzLaGGE7ijZkJ44PTmsW301dWsmQLCZARhZOqjPPI+ldbFp8NvYrCWt8Kmd6kljn1FaUlVlK6ehxV/Y00o63uVBPwyJt5GW2jOfQV5L8cIGh8PRTIvC3MbjPTHIx+uK9MicQSgOzDkK2OtVfF+hwa5pFxp95HujmQ4GBle4YH24rqT516ENKDt0Z4FP9g1HwlHHcWsovo1bfJGdxK8Y3H/PUZrzCVTHKwkG3jco/HH49DXp8FheeE9an0ua62Ryx/6/Gd0eCMfzFcF4mspLW9AYTJGeFEq4O3rx+BB/GtYSbVjgrUuVsz4W+UI2ShORxzWpZFLiJopdwWTI5YY5rOaNkPO7n5t55BHQH36VYiBWVQSCMd+eeuRQzla0MR7ZoZ5Im+9G238qlij5GP0qzrJFvdJK6Y80ZxnuOtUVuuRt4rRXZzysmXFixwV/Ol/dJ1PPfFU5JnyQTz6ZphOc5JAHSnyN7kOSRfa7RMBFz35pn2xzIoUbcn8qphsZ605GG9PXIpqmhOTOoZSZCfVjg0m0AYPQ/eBHFSMOS3BGTmkYfIvJIPJXtWdj0OYXsFBG7oMcmtzRhoM9pNDqv+h3Kx5imDOd7D9BnjisMcMd3T+Va97pJisBeq0c8TYZYm4bGM9R6YOatLyMaki9Noc9vOYFdZ45YRPDKo270I5Jz0xzkcmmTSJZ3SJd3U0kcK5hVRuDknIyTzwTx7Vdfxha3CvDLa3UnmxokcG7JhkHG5X/AKY9jXL3Ed09y7tcKJY2YON/TH9fpmqd76bBCcVF33LurX9zfztb3DqscZIVIlXbk9/c+/NLqV0zadDYCCJII1++R87c56/WqAl2j5ECEgnKt39fWnQv5ivnI3dQec/jSVthPXUhaJML+6+fGCen51DOochAqgsBkkYxildvlIXAx39KrTSZU5wQOhzQ+wLQZMzKSv3cjrwc1VlkKsRjCj1pZXDDAAPv/SoixZtoBPtSsDkQXMgRWkY/d+ZiTXN3d01y+Quweme1dPFYyavJHZ2o8ySZwu1fWszxF4c1Dw9rMumarAYrhQGGejqRkMD3FWmjGT7mPGm5uQSBV6Ndi9TmlSHZx1bvTscZxjHerRne4Ekgfzpo5HPFP9eox1o29lFFw2GjIHOPSlQbjyCcfpS8Y5Bx3oHHQe9IAAB4AxmnAZHGOnTFNB6ZJx0Apwx257elAxR1AxS44P54puDnr+RpQCc8+1IYvTnjHWuv0j/SHsszRhZjsJycrg8ZHp/PFciTgYyK39ButssDJjMbAYPbuM1FRXRvh5cs0z042l0Ybd4XYyFxH5hYbnbGQduc44POP1pdRv8AWEt3trjzkEce6eJ/lBJYY4/OtXw6lpfQWOoyStFcSOzjcDu3DGcY6Cur8Z20c2g3MphT7VMpDupLMwB4znnvXmn6e8dFQpu17/gcV4ZVtssxh3IwzntxXZaZEArXUZ3CdWYxrztbODx+R/CuX8NvLBpki8OuwqwA4Iz69q2F1KQ/ZWtIo4UhTDYPXJ+99RVJXRhjourUujttO1MGwjMwQuvDSFwM/wC0ewrP1jw1Z3GsQaxGsizICMpgBiRgE/hmsuxknhvL+a7tYGsZWj3MX3ncQdzhSMY6ZHua9BtDFdaYscZRozGBlOOPUemK8+tDmbR4lS+FldHmupWpFrDM0zSxiXcwQ8q6ggMSDkjnkV1fhSWC+0r7NIJlljGJIW4YHIG4ZHHXkUsmji0aaEbCsKgBiueTzz+lNsrudJ0mdlZ2VQ0jDczbcfeI78Dn6V04aNld7iqv2sfc9Tc0ERrMB5+J8ZZTxjnp79K6OWIR74pXAxg8e/pXn2rsmnahHNaTCVpGBMSoSXX25rtNEuTdzqrxrAuzhW+83pWtKUXJwtqcWKpOyq30IdUsZoHjcBWZ+p/2f8arXAMgAVvmA710t+jiyYKISgO4BW5FcyX2yO5xg9fauipDkenUwo1XOOvQ8m+K2jzT3izNGgQRbUcDoeuK8o8S3KXkEMkq/v4QsTFRgOFGA31xgHFe5/Fm7iTTYYT1bJx9O9eJ31pJcWcqR9CokKIN7kDPOewoUuWRNWPNG5yWRHINrFSFxwMA/wCRVqMykKqKDtJbk9hz/Kq7x+VeKk7EAHLA+nUf0qS3yyopyGY4yTn/ACK13PNa1DxGjXOl+dn/AFL5yR69RXNREgY7+5rsnVp7e7t3lQoyFAnUFscn25rhYSdoBHPcVpT2OaZoIcoeaXd83OOO2aZErOQD+YqdUAOO47VqZN2I8ln+UHB96lijAdC3XI4pC4x2IpY3y6Z4ww79aLhuda+TIevWhvvAA8+mKQjLtjrnNOXpjHB7isTvbGDqeta1jfXflLawYdPvBSASPz/lWVx2zRu2jOPp7e9XHQylaRfvrdoSkphLJghZFyFJzjOfY1WnuZ5jvuXMj4C5KhcAdBwKRL25jjEYnkEQHCk5X8qs2ggu49kxMcwGF29Gp2vsZ/DuUJGUbWjJLA5Jx1qJrh0Vtn8WPqK05tCuFUvDJFImMnDYx9ayZ7eSCUrMUDDqN1DT6lqaZDI5PI5561A8mF+6ce1LKRlSsgPsB0qJAzttyT1qbA2NwzsDnk8cVq6bAsZwkfmzyfKFPPXtXO3906SrBa5yMZbuT6D2r3/4B+D4NV006/qcWZEmMSo3QEY5/WplGUtERKSirsm8AfC19Js4dat4iutlt0Vs+ChXqQO+4Cul8XeFtJ+Ifh4LqMXk6pblkjniHzwSDqMd1OBwa6HxNdvHr1pDG2xYY/MRQcYJPX9KLqSWQtqNnOUkVf8ATbS2RSzrniVc9CO9bqKat2MU2veezPkDxZ4W1bwpqQs9atWiZwWik6pKPUEfyrD2kZ5x3r6+8ceEbTxv4Zls0u5JpyPNs5ncHy5McZGOAehr5Lu7O5srua1v4HgurdzHLEwwUYUl2Y2ralXH+PPem+g7VJnr196TGc+p4xVWFcQcDHNAX06fSkHY4xnv70oIwD19qAFPPYYpVIA+X+dIFGOmT0pSAM/TikMBxgfw0oJ6dfek3DsSe/SlGcnHH1qWyrC4y3y9TV7SZAkzxnA3jIJ65HaqPQg7sfSp7acwTo+0SAHlG5B7Y/Wk9UVF2dz23wjLFHouli3kmCoXEr7gufm+7j2BHvz6V6FqVws8Vk9ovlqYtrjdn5j1z9a8n+HUcF3Fc2sj7ZeJELkr02jAx3zittvEVyjMPJMHlqCgfB81ejHPrkZ7EZ6V581Z3Pt8HzYnDLk3idJZaJKhvrWKMbCDKGJwCqkMQD64rl7u8uz9ou5IlBcjZtOAeOwr07wndrdWNxFJHgTxEo5OTgjnHtyK8w1drewItJHL5dykjEA4Q4IIPep1sejl2JdWs6dRa6G94c1yR7NsukijHmRyjnPTj2rvtPv0sblYYZV2j5dm7JX1U+3avFdPmFvqsTecWjYYMf16H6V6ZYpJe2UX2IgyIC5kk+QygH5gD3x9azcLrzNMzwkIvm2TO3v9Qt5oh5rrFtwMHjPPauetHV2Pkkgq7bh2JPUe1cX/AGxfNrKLqTRDDbFDjvngjAxn+td1pUSvY+ZZ7Q0R3szDJYHvj86ujzNtM8t4VYWOvX7iVYJbq5gZwqxx9CxB2kdRkcjv1q34haGC3JuMwo6hjIJAPlPUe9IsdqixMziZigLyR9G7cj1pt3ZWWq2AtL63STZgqx5DDtyPY0Spyinfqcc5ap9EXdFSzazCaRerK0TbXjJ3Y79T0qa+2i0lKllkTquMk/T1rjYbS+0n7bFpunfZfs6LIkaYdpyBgID1OcZyec1ratrTWOjRtqdtJb3ckQbychnXI5A9SKug+Z8rWxhXXK+dSv8AmeSeP9euri7Md/bNCYsqGYdRnr/n1rn4pFWO3kt5PKhRdssnUlWI4x378Vp3Nhe6/fOnnBoJgflmIXGegJ9fpSXHh+300nTBKJC6s8iEFeVUt+K46nNbcj5rnBVqxasjzPUIvL1GeJ3+YMQWPHIyAD+lLbzAzAsOAeu3HbgGn6rHO9/cysMhX2sQAAp5AX8gfyplk+wHo4Y7ME8DcuDx69wfatdnY4pO6LNo20uUSPKPneR6jGPf1rm9btBZ6pIgBKH5weg+bnFdBFH5DuJWQgAqCDkHPvUGvWhbT4J3YttYrtDH04z265og7MyqIw4mK8DtUu7IA5zVSI4bHQ+pqx1PvW5ziliBRG3zIccZpABkdh709BiRMdN3Siwrs69wd54yM9+9N3nYecH3pZOXI6kZxTDyNwP0rI7GP3/NjH5UfN6E44IziozjvjntRn2I/WqJFyBk4NIZHRyyErjgGkZvlzj5RULuCcE0bE3GvJJyPMbDdcng1A3KsD17808Ebhx7YprABWZyFQdSegoC41UMnCgYxWp4U0SfxZqB03SgT2lmJwFHc5rLsrC+1+Rl0+NxpyECWQHaZB6LmvRfC0E+iPu0YS21uVLKJEAPXjnvxQ1puVCDk0mnr5FOy+HsWl+LZtP1bcz28ReOTHyzYI5H5ivd/hB+78LXixxlLYXr+ST0bgA4/EYrgLTSb3XfEPhm0tbgl2guzc3LtlghKkn3POAK9xs7OHT7G3srNAtvAoRB6Ad/rVQ7o56j5VyPdHJfEq3gFpp82Cl35pQSI2G2YyVPt0rP8P6qiXkEnVowVK5wGU8FT7V1Pibw7b+IIIUlmuIJ4CTFJE2MZ6gg8EcV5DHNNpOp3FpftJvhuGTcV28A8dKbdmVRSlHlPWBb2toypDBEtrIN9sR1A/iU/Q14n+0R4XgksIfEunQP9pikEd8wJOYiMKxHseM+hr1fQ7yPWbZ7N7oW8oG+2k7qxxkYPqBWddvBeWd1Y6t84kUwTxnjKkc/pSb6oah9lnx83HJ79hSHg57+1a3ivR30DxHqGlruaKCTELt1aM8qfyIrIK8Dcw+lVzX1M7W0EBGMZ+lLlSvAJ/CgIBgAEntmpUik24IKnPpRZhewwkk8fKB1zSfL3y5x0qdLVicsDycfWp4rJtp4PtjpRyi5kU1LAAqKXY7HqfrWktsMbj/48OfzqwsGFK85z/eByPp3quQnnMgW5IHP0yetSi3XaOCPxrSEOR+75DfdyOh9M0NEu47iNxz98Yz/APXp2DnOs+GD+d4j0+1ztWdvKk9SO4B9yBXc+KJn17VjpEWmPNLHJJLDKX8swsxXzNoHB5UDBz0ryzQLpdO1exuY1k82G5jdRnAOHGf0r2X4p7bbWJ7yCQoyyLNDs+UurEZB9utefXvFtH23DclUtG2tnb1Nf4cXgkVoLpvLntv3LI2Rkgdvy6VyXxBIOu3CgbbUAFgoBDnqW6dak1vVXutNaKOJoL1D5gkJwW6cEjn05rmdNv5NSjk+0nc8QIcHnJ65rmvpY9TC4edLEuu9PL9S8uk2drAs8u+KQEKUOctkZB/I9K6axu9ltGtrLISuSpU8ZI4wPX1rmIA9xbFGbfI8hYgn1rW0bT3e4hhmSSBZVM0DNkCUA4OPpjFTvdo92bU4XqS2LSJKL5pr4ybi4wWG3B47V1nhzVH03VpDbBriKVQBk8R9QcD3rIvf9LvIbYMoZUyS5xz2rc+Hdq0WsXSsBJNHhAAM4HPI/KslTbnzp2PIxjhOlKc102O4l0U3dvHJAqqrDcdvG8+vFUpobq0E6woY4VjB3qM7vp9MV2eiRMbfdcbfMAK+V6fSuY8bG5jjiFkojWQlWG7acY5B9P8A9ddycJpa7nxssVPmcd0clPqt6LaeeeUwywBFKIg8xiwJVQcY+YjAPXrWHPc2/jPwvB/aLzm8t5WJZTl3JIG3t+FS2G2w1yGG/hluIJTtG5cnJGMDk5wTkfp1rk9Lv4tE1m/tJLpfs0jA7jGQ0OJhtL4GQc/MCtbwiopWOStV576lqPRZormaK8diheNE2jeVyx5bB46dxU/iNLDQ7/TZpllnVC6uEc52PHt3A85ODkjOPzpsniGO4g4lhR47cMkiyFZHYcsvGCSxkB5zjB64OON8R+J9Q1K5itrXLRWkrmMD947HAXOcZAIVfl6ZrXlS1bOZSbdjn5kifVpn3CZI5xO85bjhiFyAO5K8VmpEzXTuFAwS5YDjnn6V0Fl4X1y7SKOPTplRsDe67AAT1Pt3/Cp9X0LUNNuo7SSEtu4UlMBh0De2axupPQvlaOUeMuxwVQKCzE9KVonfTLi3aMurxmRA+cHHTHvkGpniaPfDKz5QELzgbSeagikZRGjs7hBtVWJ+QZzx6dTU7MHqjkImOA3JPrVtBu6Z69alks86lPb2+SoYlWkIX5Rzk/hTI8Ekj8q6FI52hwUbcdee/eljQl04x8wp/JBJJxilU5deM8jFFybHTOx3t1PJ4qMsCeuPXApzn5mI5OTjNRHGMnOMUkjpbHE9+vHWm79qjB5HNMZ8dcY7cYqF5QOSRz19qdib3JWfB+9wOtQtIMnPY+tQPMACd1VZrxYRuZuBRZsVzSDIqtLK4SMDLM1dp8OPAN34waPUbuDboYb91HIcfaCP4m77c9qzvhr8Pb7x3cx3Gp+ZbaOpyiKPmkr6Pk0/XdEtI4fD8do+mwIscVktuBImPQ5AbPXt3q1DTU551bPQq2fhWHQbC4mitYJSEGEEYC9MKAO3JxWPqnhe2sbOD7IkgkV13DdkEk/NjPTqfar3iPWPFFrpqWF9DYW9+ZEmkkhJAeNWDEIDkHpg+larajBqmjNqMLL5BOT8wPluDyp981MoLobUsVJto5b4dWctn8Vbi2bJjt9PdgD/AAbmXj8cV69t9elcJ8OYPtPijxXqzg/65LJCewjUZ/XNd72HrTirIwqTc5Nsbgqcj1615p408C6rq3ieW70l7WO2u1V5ZJ2P7twMHCjrnAr1DaSo9cUwow5OeKbVxRk4u6PJ4fhz4ljcY1uxXn76xtkD25rU8Y2i2en296yAT+Z9nupASCzgfK2PcCvRGUnHGMV578X7yOy0pYZZUU3syeWGHBKAk89uMUuVWNY1JOSueCfF+xS4FnqcagSBzBIwySykZX9a8+ist2Cy555Oa9L8bSK/huaRWyEljO5Tnnd1Fcf8i5LtG3yZGR94fh3p01oGJ0loUorDaCFUMARnaw/zmp1s2UYYMo/2lzyKleSMNgPE4UcHYQWHp+FEdzHGchZD8hztk4PvzWljmu2ILcIhbbwe23IYf0NIhVcYRnAHQjaarvOAAMAYGABJnP0qCW5JIBaVtvHzenpRewJNlwuN3DKr9OhJP/16jkm2Z5yQc4Kdvb0rPa54A3nGcjFRmf5shu1FylEvtPuGGJL4zgnHPqKY03yHhtuc7Qcj6+1Z/mg9OPb3pDJu+v6/SlcpRNezutt0vzOdjB1BPI9a9R+J2otey6a6XHnv9nSOU4HOw8HHv+VeM28rLNGVzkMCAB1r1fwxbw6rY2tqoMtzGG8yM8tx/TABrixK6n1PDNeNPEJSNrSrT7e1mySu/mqc7zk4wc5rlNchXSdU86wYLDJgMjcjJHNerXGlwaFa6PqNm5+z3C+XIVb7h7j+dcT4w0iSQXLRxkRBlkiIOTsz/PGa4o6xPpvrMXW5k/d1X4i2B8wRx4yzAFTjHXqKu6dO9nq7Rb2CozNGCM7dw5/z7U3yUDokRJfBZHVhjnrn9a1tPsYbiSGaWNg4+65zwenSqcTvoYiHI+ZaWMmO+eS4F2z7sjLEDsK6jwdr0VvqEd7E3ytww6455zTZNOCRyxxwpLP8y4XAByKraJpf9k3TRT2Akt/LBMmcKCP5GkrJWMK06VaMo2+Xke9JrNtDFBLM0aJNgJIW+8T0x65rn9f8zU7i5to42hG9WSdyCrHOSB+GR+NYmk3sTeEjcoPOVXMTxsf9Sf4cHtn0Pp1rRs9Us9Rt/IiWT+0EVmmj6qQBwQegzWcqNaL0em58dLBqnKWj0djjPFUH9m2csJuL+4l3l4EsrUtJuwR5e4fdBzjd9K5zVfDOualfxXQsblZkgDCaQeW5fcCCwPORjGB9a7q11K7ha4uNOlS2SFli2zyASMe4A7kdzUelX817qxnkmZ13EOWkw+4A9DjoeBXdGo1FdzN5W23JvRGVovwnga2tpNcvZpXRVMcSSABQOgYgZ3Dr1rqNG8KaP4fcm0tY4tw7DJ/Oruk3TLNNHcTAyEZwSCB0rRkhEszB3425Bzjr6Vm582rMXh/Y3i9i3Yw20pyED4yBkcflVDX/AAlp2o2rrNbQ5cZw/wB0kdAR/hWvpMsNpKUCt5gGC3XtU09vJqNmyrDzvADo2D156+1YzdnbqedVU4yvA+XPiP4Im0CczwxuYZHZm43CL2B9D+lefuMxljgkAnpg5r63ubMa3p17Hc7XZJpYod3dAeM/Wvmjxbo0ul6osbLtikUjDLt2kdV/A/nW1Kqqqv1NVqef6uireK4bLSJ82O3bFV4wDx0FX9fiaOJHCkBTjPXiseOXnJOP6V0x1Oeas7F35TyvXpT1I81SPUVUZskcnNOU5lUZOMj+dXy3IudLK4EjDOOc/rUckhA6DH55qKZ1LEk9z1qvLMQCM1VjVse8wBHORjH0qrLMFz0qOWQk4zUGxipzjGKaQrg8zOdsYyfQV3ngr4fJNbS634n3w2cA3pA4xvHqf8KufDDwkGmg1nVsQ2MeZIi/RyO5/wA816RqMy6/cQy3JMNhEB5Mbj7zf3m/zxVpWV2Rdydkc9oU11Z2+Wu7iBWb93HExAjHYAdq9x+HerTat4ff7Vl57WXyTITy4wCCfzxn2rzC6CxRF4FjeJjgFRz/AIV13wbhuYo7+6uDA9rOBGDHISyuh4DKehIbrSTu7BVgox0O11ext9Rtzb3sK3EBzww5X3U9jXjviDS7PQJNehhF0luNht4llYrI+FbLDODk5OexFe3XBAIGfpXmvxOsYDaS3sszp8hTAQsN4B2nj8qJJ2ujmglzps2fhFEYvCCyvu8y4lMpz1OfWu4T5gOMD3rmfh60Mvhy3MI2ooVMe6qAf1FdRxSirJFSd2SEkJwcetM3jkDmk/H2pGOAfemJDwxYYyAay9RsdP1lWg1G0guo4JP9XMgYBsdea0FPzD1zTY4DGZnyCsjbsenGKmWxa3PEvjN8OLS18Ma3rei3Bs7eCEXD2CR5RmDjleflGM5GK+eWucjIYgNznH8vSvtL4jQfaPh/4nhxndps44/3Ca+GY5C0Sc5yoJ9aVN20HPW1y49zJypkbJOflHQ1Ebli2GLNzn5iMVUkk555/GmknGMcZ6VpzC5S0Zic5Ax6djURkLYyTkelQk803J2tnHH60XHYkLc9/b3pu85zj8aaCQev1oHHJGM0rhYdknG7gUE9Pmz+FMzx607oMdKRSJNwPHcV3Xw8vZft9qsMzxzxsFDg9OetcF0JGT+da3hq9FpqSs5YDI6HuKyrR5otHXgqzoVozR9hPo8ereE9OaHYnziQ5Y7Q2SG+vfHviuW8TaQ6W00TSIViyu4DqD2P4GovBniuPTbSxttSmuJLaZw6xld2EwS2PoQD9GrtLTUdE8S69qljZ39pKs1sGQI4Y7jkbcevr6V5VL4uV7ndUxk6U3CTvZ3PILOKFBHAVMcg+6CemPeus06J0he5dMW4fb8x7+1ZOr6Mq200F0/kX0Ev7k/3scMPy5rXvpZG8M2cRYpMsYdh03c8foa6G7H0NDE+0irPcngZmmbYVUk8FOa3NRg87SdobaJOWHrxXGWV+Ld7ccvNJJ5YXPfqT+FdE0zyRSK+5ioO0Lj7+OM57VindnTXpSTUuxyZee2AiEj+SXBkVDwQD0+vWul8I65b6LqOoSrBeTWU0ZjjgcIS4zwJO34isLVLYxu+W3qx/wBYAQCc9QD0q3oN4iwsRuBYYOAMn2reE+WzR3YiMK9B8yumdYbDTdTvbfUfLngtpn3PDgts47njIJGKkki0+EXb29tDCUBSRJ5Cio5OAVx976Dp1qrpWoxb0h/eKu4hlYDGD3xVO+EAmlDRhjGxYSh9u5ef4T6kj8qrnV9keP7KTlytuyJrCPzn2qgTkkAcDpXV6fMJISGdC0fAG7rXMwXNvHFbxxkB2hG8HJ56nB7Zp+RbWrNbMxmdjvDqMAZ42n1rGyuZ4mn7VWeh3UQ3ruU43Daff0rS00q9syFmjmjO0kHGT24rztPEMkVt5BcJcAhdznC4J657CsmHxtPbarJDcKrLuwQjZBI9xwa1drXseY8or1U+XoehLstxcmbLAvulKjnk8mvE/jFC2of6TbLus7YbGlxhyS20A/gK9P8ACeu/2pNqBmYEo4RU9FxwT9TmuM+JOkf6NerBg2yFbhkdj7jII4zkjg/nSw1oy5bbnnToui5U5fEj531i1H9nzIAW+UnB6jFcdExIGPSvSNfa0gu7iCxiuEt3wU85gz428kkDGCcmvN9vlXDRnnBrrpqzaOOp3LsS7iPpmp0gIdd2Pvd+aZBIBHyRjHalNwS4EYxkjkmttDDUuyt+8fHqahOOeePeklPzvgY5NNVZJZFjiUu7nCqBkk0Gtxx25AwWJOAAMk16Z4P8DWcFmNY8aP8AZbAcpBnBY9gR1J9hV/4X+BQk63urWYnu2OIkY8R++O5r6U0jwja28MEtxAslwoyPMG7Zn0z0q4xS1MZ1OiPnmfUrXUpfs8WbfSFI8mBwFdwOhb/AVsWccMEbIwLxg5Tc2cfQ19Aala6dbWEkmqR2/wBlUYYSoGB9sY5PsK8evtF0afxLHKUbS/DDsTcRu/z7u23GdiHgEfyqXdl0qi6ooW2ga1qOkvqOkWwv7J5TCsaMEcFerDJwwzkV33w0sJbHwwy31tLb3r3cjSrMuG4woP0wBXXBbeztYbeyjihtY0CxpEAEUe2KhZjs3HrVRiZVKznoVrmUmUL6dMCsbWMXA8tymyRgu0n7wPXFatw5RnZhtGBk9hXm3jHV1l1nT2094rhLY7w6HcA2SSDjp0FOWiJjHmdjsPhuNmhzQj/llOy5zmura5gF0LUzRi5K7xEWG4r64ry3wjrWo29hdQWKQJmYvukQsfmGfX3qjqdne3N+bqaeZ7snPnD5SPpjt7VndJGypOTPZjxjPX0pG44NeOv4r8Rw6e1u13GrKcLJtzIR6Emuo+GWuxTeHpk1LUIjcxXL7mmlAYg8jr25oTvsKVKUVdncKo3YFcX4l8cXGka7aWhskSwMqrJM7ZaRTgZUDpye9dhPKv2UyRyIBjIcMMfXNfP/AIuvoJddup7dVHlyCRikvmbirA5yeO3bihjpx5j2zxpiLwhr7elhcH/yGa+ComItouTnYAfyr7X+Lmq/ZPhR4jvozgyWGxSeP9Zhf/Zq+JyQFAJ6DFKOjB6kYGeetBIJHWlLAHJ6gUwlc5zyadwsHAOc4p3Prg49aaT82OvrS5zzxSGGT29+tLjoMcZx60BgDkjPsKAc7s5FAxcHOSOn60cj2B96Dg4PPpSj1OcD2oAAp6CnBSpyuQw5GO1KuR1J/pTh7HBpXGeqeFdXkvNGsN5UmCbaN5GfukEE+4q74Uhg0f4nWU8zvBHOy3CvEu48Nyv04rhfAV2V1KaxKqftYHl5/hlXlcfU8fjXceIJLuTQrXVUjAvNJuBPyB0GAynHODgcV5eJUoVFy7MurVvNSl1VvuPYfEyWus6rHd2jB0ZzKxTgAnpn8v0rCurlZLaaMqRIr+WqDjIHfFegLPpXibwrb+ItC8rZcxI8iRHkMPvBgP4gcg/SvNLobtWk8vcY2bIx6/xGq1tqe3k9RTlyvoZumX8cV8IZoVBySGOOCepx+Fb5vEjkCIQznkgHt61j6tYPArXCgeUFznHP1qDSL6OSWGV3jeQjAbGNw+tY2aZ9g4xrQ510OklgF5ayGGGSZ4xkYBJPuKyLSyut/wDoyOXD48or831r0bwtZth7rZsSRccjGfcVptZWrQiMhpAM/KuRuz1JxWkdTynmioydNK5xZsZ4XhuHZ/uEEqu7b7YqlIJrmX5MvGQAuFyB+Nd0NGkvLTfvMY6RxochFHvWVf2U+nXdukFuzwOm13A/iGTyPSm1YmjjYzly31M6x06U7XKqsWcH1H/1q09YMVvGjpKVBACNjqw7e1WdLWO7tZfJuI1nVWkEWwtnngZHqKx3iGr3EEfnIWK4ijXJAOex9Mk1Sjyq5HtOep7zsluRXVlNrNkBDAkU+CvzEAOvU8kjsOK5fVrC5sSzsjJ5kYljaUYZlJ4Pp0Hau6urK3ubNLW3IdUizI+Mj6Adj71k3emXepXMt5ISEiAZF2YAwBgAdAPaqbilrub0MU4PdcpneAL7y7zdIPllkALevoK7rxNpa3UDyPCsocbTDI3yvzxj/wCvXK2Fu1pqcuoTSpK8knmOBgAE55x9c1219Ouo6CyWzJvbhTIdqjPHPpWKlyz0PFzD38QppaPc+X/iGlvba/PBBAVRURV5xtwOf0xXl2qxlb9nGMPgjHNewfFG3iXxEV2SKyRRRzZPDMV6j0GAK8u1yFRJGEOQmRnpXoL4rnj10k3YzIizEDAwKtIAsiZ455qONAvXHXtUycuufXpWvMcjRta7oepaLetBqlnPBLuwAwyGPsR1rs/AvhkQx/b7s7bnAZUyMqPf0rrPiDf3Wlx6Q4AnMOFEU2CQAM5Brf0LSdP8R2mka1oRt7DTp2+zajas+Ht5Vzlh3bcuDj6Grirq6IjWi3Y634UaRNe3J1Sf5bSLKoCOHb29hXrZbPAPJrCsNT0fTtPitLedYYIl2puBAApvi7UlsvCmoXltKgcwlIJAcqXf5VOR7kVWxErtnE+NNfGp6wY7Qh7OyRlR8/K8ucMw9gBgH3NcjLcyOHLFSRgqV5/So/sjRRLBA/yooUKBwQAKmkg8pslHGAFAI9e9Zt3OyEVFWOt8EaubwWumiQyNGssszt2AI2qPzzXXO+6QnsDgV5/8PofL1i+uVG0Jb7SOwLN/9Ymu1s7mG7Li3mSURHDbGyAfTNbQd0cdWKUtDH8bXIg0CdiQBLIkJJ6YJyf5Vw1lapHmYxgbiTgd+K6rxzOt1d2mmJhgv76RevJ4XP8AOo1sWSKJEVdpO1iR+tZy1ZpD3YmT4YiaJLgf3pi3P5Y/Studd/ykZB70tpZbbiaMY2thsf4VpPaMUACE+gNQ0bKRx2p2kabmI9x6muN1W0ieGeR02EZLLt4r128slii3S7z2AUdfpXJ6j4dvFdLjahjjcSrCy7gSOQG9eecUnGxSqLY7O8vpRoOns+EV7IPKhjzztGMj+lePWlvp2s6m8F1drZ2bZee6CYUDuij1P5Cu4jvbnU9K1BdTkElyfkIYbQE7AY6CuQa/01NUFvLDO3kzKJMAAEDBI/pTbuTCLSaNX9pvWIrP4eWWkW7jdqk6YHfyYxuz+e2vl3auCPSvQvjL4qk8YeNJLoQCC0tIxbQpncBg5JJ9cn9K4Rouc8kY7DmqUTK9tCDYvTNNMaDvz9aseT0J578Un2ZiR156U7C5iDao57E9KQhQef8A9VWfKIJ/oOKaYSW6EA+1HKHMVxt3D174HNKuATjgfzpzR9xx6HHFIVOeP5fypWsNSHLt7gYHXNLkYz1FRn5QclfpShQep6+2KXKO5IcDOCPpSbh6/SovmA69+9O29Sc47HpS5R3LFrcS2txFc27lJomDqw7Ec17Y0iar4QGtIcQ3rCO9ij6LJgHcfQE14Yo45yeK9E+E+oO9xPopkA+1jYgPQE9D+B/nXNiqfNTb7DS5/dv/AMOem/AeZtHbX9DmZ0Q7bhIzxjOQWHsRir+uwyWerXNuEDFj5sfH3lPfFZq6bex60s9k2NbsU2xgfMl1t+WSM/UAkVpeJb6b/hItIvFSURyx+W2RjZuHTP1rhozesZbnbk2J5qum/X5E+nTLcRqNuQ3ACrlff6V1ehaHpx09o7m0RgDhN68Gjw/qMVxAInMfmIxjOzGcjsa6jyIRb9yp6L6fSrSblqexiMdK3KtDN0WSCKL7NtEW3PkIr5Vl7Y/wqbUZl054mWQfaJUOxZDg+pUHvWdrEc8Bi8gjKOGTP8q5/UvIuNZsYNQll+2GfzoIwM7doIP0U5P1x7U5T5XaKPNlUXNzX0Z6f4fkWeyWVfvE9Mf0qDXbFrmyljRpISwJBTqDjiuMm8X2ugTLAJFkmZ9pgY/Mo65x6V1mm69b30CvNKkbEZ25659Kl1knySOONaUZ+0R5zML7SryX+0Jiu1R80Q2b1HXBHOfan6bcNaXpm0yTz8DKjAKovYZ/H68V6TqWlwX8YYDJHKsOo+lc6fDs0TBLcKkY6gDrS5mtnofRUs0pVo++rPr2GaHp0cUCs7M7TKzS4GPMJH6DP6Vr36K+lyqk0aNFjIJ+YLnr9P8ACqt5aX8Fr5keGdcZGO3pXO6ncJMF8oSRTkfO7Z5b/d6ACtYtdTJRdeXOpFOdSwleUuU2YRjwT+FXPDDXt9BeWVuxLgfuiDglvTNY6LNcXMiwLI1soyNxy2e4zXSeDgLOaWa5R1V1YmNB8wO042+9YtKTXqa4p8sGo7niHxStLp/EbSl45PNVcoD8zgcZHXkDt6V5nqxB804YhG5TGAccZ+teo/FGK3tvEs4jkXG1gVcYZWxnkdjk9K80vYkbS8gEzHhh/UV6fWx4OIvzO5gowzjggdPep0xuTHUkcVRjYcHPGcYHUVbiYnGSOo96tI5GeoeK9Zn1zUZvLhZszyLZwRqSwjJ+UH3xxXq/w38OHw/oKvPj+0bsiSfnIXjAAHsK5j4U6Kn2dtWmKvc3KlYlxkQx5/meCfyr1WzRlVS3JPJJrRvoZUKVnzNEV3b/ALggqCNuAF4z71yms6pLaaLd6dOsr2tzPCY1XkJKsgOfYHGD74ruLgYGFxgVl6jpMN5CgkRm2zRtj3Dg0Jam09UZ2jWUstysk7blXnBGc+1atzZodzMOQM4xWoYVhUBAoyc4FZ7uWsrtmTkbtp9qaRLk2zk7zV0tdBkt4JSHmmeWd14wo4VM/mTXf+HbW30vw9bxpcwvGq+bNOrDYWPJ59ulef6joyPoskZG45+YY7UzQ5nm8OWekwjbbqztIAPvMW4z7AUlK24pR5lobIvLGTxPf38ckklrP5ey48s+WGAwRn8Ac9Oa3dZJtbSSZcsixHhBk88ZH51Jpdii2yRRoNijGDWZ4gP2Wx+xncsMrmOPaOc4+5zxjvVR1ZlPRGXp3iGdLd0t40luLaIwozKAzenGcdv0rX0PxdJK0MF1p8kksgAEgIAB6EH/AD3rPsbaz0wG9v7iOCGYgnzgFi54BBHRl6c1U0zxLZalb3H9m2ztdJKYpnZSNpzjr3z1rTlv0MlJ9zvbS4W+klfymV0bYF6he5H1q1MowRsxgd64TT/HGlaM+oWk/wBrkmikCRdH807Rn5vrxk1XfxJrGopKUkW2aJPOfaP3US543NjJ7dKylZMuM1t1NXWdLubn+0YtJgEs8sAwHO1WOehPY4Ga8x8d6QvhWyh1KK/ju5rpWW7CsAUnA6hey44/Cu71zXxDLYJa6qLbUr4xtP5Kj90AOAc9Mn1rx/4yaSdDEDyOZTfzM+9zksep6e5qXZaHRG+srnnLSZZpDlpGYtvPfPtSbSylidp7seg/CojMpIJZgOhYDp9Kcs2Du34fpyucitdNjBkiw7Rltqr146n3FPjiUkYV3H5bf/r1HFKpB2ltnfaOR70/zFYndI8hwcjOCDRoBIyZQZydvTKYZR/WiSIZXLryM4U5H/1jTReSsUfz2Z0G0NIeMegqRJ8kAM2xhliFB/KnoLUhe1YdAgJGflOSR6gVD9nDDOG56gjGT9avLsX5lChW/wCeiHI9wRUTSqufKeR1PqduP8aVkCbKDQfOwUZOMYC8VEyKvzEDPQksTk/SrgPmjO4uq8newGD9aryH5SVYcjHAzj3NJopMjKqw6ZHckdDTTGw5OPYk5H5VOh+QYwMcBmwFNKVJ56nqG60tx3IMZGOBgjr0q7ol5LpWq2t7D1icMeP4cioMDqGB9P8A9VLgYxjJ6Zz/AEpWuNM+g77Upbe90vW4sNZ3DrOz5+WHGM7j2B6V6Je2UWp26XUMebeVfMRcdB3XPqK8k+B/iNTEulaiBJbrkBTyQCMEY7gj+Vej/DzWbS1v9Y8NbXWO0uTJbJglQvpn868StF0JPsZuHsayrQdr7mVpdjcab4hnkiUi3dgWHTr0JHsa7WfV/JiEkkbHudvOMUye2Zb77TCgZGADIDn8agu28nUwgUfZ5BuxjgZqlNNcyPe9uq1nMreONYFh4PutTEe8/Ki4PRmIANeR6d4uurnVrq8eRopjhDtAO7b0PPIr0T4u+VD4BkjZwFeaMgHocHP9K+f7W4d52xweCT1yOe9Z1LykZez5oycTuGkOoan9tvXxLvwNxPzZ+len+G9Pu7a4lZ5UnsZYw6g8snr+XWvGZLwSRqo2iU8AdBVnQfGOp6fH/Z7EyDcVRifmQeme4pODkrs4J0nNLuj6L0bUZ7cpFqLQrKP4Yydrc9VzzyK3Y9RjuC3lMWGccdq8W0bxgLuyA3RSXcC8oRgnj+vrXQ/DPWvtV1e6dcho5txngEh+/H3A91PH4ipw8lJtX2JdKdNpyPVTGWgViOWFYGoaK18zhSkav8oJ9P6VtwEeVt+YFeSc1IqERFlI4O4giuuUV1OynVlSd4s5nS9ISyD27J8yHGD/ADqrPpNtb3d1qd0d5tbWUBNxABcgZx0yOevrW3fzxxXRkldFLAYycZrnvFfiP7J4K1aW2V47uV1iQsv8I5LdemAaVJfvFF7HbGdVrnXXc+evHE0N5rUsktvIxdnJYtl3JPy89OOBkelc9KsP2Q27RTKwYZLAKdmTwT3bB6ita9Ma3Mq7vPhwzfvhgk7eT+HoOuKh1eSGKa2ihmVwobdIc/MMgjg8Dj+dduu5w15c8rnmE37q5lVD8oZsHt+dTwEbl9yO9O1+CWK+imeNljuE8xSRjcAxUn8wahtnJKbR3H1rVHIz7I8OWht4kRQNgGAiqBgdOtdJGBgcAD1I4rG0CUPyoUhjgY/+vW827yyUxjpVmr0Kzx+Y4MZzgdfWrU9sVsmkwcxlHPrwQTTLW3+yF5nUvC5BYLk7PfHp610kBVo+NrJ6jkGtIo55yMG+idI2dMkHoR3BrLiCz2Q8tmi3LhgRkZ6EVe1rVIdMuv7PYMXcZhIGVx3XPtkfgRVXQ5nureVZhGu6RgNvIIyaOR7kqaehha84stNupJjlRGT07gf/AKqx/BSK0Vu7ZDeXvZT2Jre8Qwx3Dx283+q8uUyIO+1cgfyrnPBVneXF/BEREbIPGJ3bPzg87F+oBPPas3uawejPQ9OmhZ3SORHKEBtrZINcj4vu57y+jW3t0kt4JPn3kkDg5b0z16+ldreachjT+zvItHR8oQmFweoIHasp7OO/1GWznsx9uhgLSESlIWV+h/2s4/SnGSTMpxckcX4jv9D1bwzOuolFVF2eSjDYGGTnb6nHT3rklN3qFos8jO+qXEqRxMHEJCZCoDjgAAV6L4m8KaPf3VhpdxCLWBLfKz2jbSSjDK4Ixk561i+IPAFjDbpNpN7Layl0jCTv5gckgfgaU6qdkjN4eo1dIrzfDjxEk0BQafJCykcSnKt7nHIrqvC/hLVNLkuFv72CSK5KLJFCCcBeQM+mevFXfDWja1oFz5f9tw6lpjD5Yp4SsiH1BBwB9avXV/FbXBWbMcGfknAP7tj1D+xPeodu5rRoWd4o434l6PBYeJbfUZdPhubO4UZZ04WYHndj1GMZ9K8F+LHiOXWddSxiKixstxiQZ+Utjcv0GK968X+K5I9C1a2vdht44WOc/eI5XB784r5S8xrieW5m/wBbKxkbHqTUU7uTZ310oUVFrX9BucZUcZoEjDIBxn86ew4B7ZxioTy2BjpitrnBa5J52ecgepzginLKwA3YyvQ5xVccignOef0p3HYtNO7kMTuI6Er09qQSgA/LjnIAJqtu57k+uaU8dAMnr6UXFYtLOQGIPXglSc07z+PlIzjgjNUz0BHT+VODZDDdwe/rRcLFkzln3HY7A8Hofwpd+7cQwyeuBtJ/xqsDgAE/Ke+aUP8AewTgdAeTTvcLEnRsnd7FqfE2W4Bzj5uMH/69RM5zhcc+nGfemswB65Hvzg0XFYt+ZwdxYnHXAwRQCB822MA9Djiqm7J5PPqKkjYBuV+vODSQ7G/4V1VtH1ZLiMkbvlOOn517fGkn/CSL4p0h0bT72ANeWwPMU+0cg9wf5186Bxjjbu6+1ex/Bfxe+X0O7hE0MgOF7474z1HPSuXFU1OLLjTVWLpvqeo2WvXN7o1zeeGlivbgAn7LPJ5e4jO7a3r7VPp+v2FzZwzzFomYeUyuMtE/Xa3+Pesq5il8O3LXOj28MnyPIY0+Uvx95f8Aaxn6/WueuooNd0aW7QPay3BIwGxlgf4h/jXzjrexdnsdlFOMFTmte5U+I2rDV7+KykkK20S5C54J9cV5bc2v2KcvE3y7vu+xpmsRTJqMsMhKPnIdGyCPapr9ZF023llcFslD2OOxrphzRkpc17npRfLTtEW3d5nUtlXVieTkVcKolyjyhsN1PaqtiXKqwAKgckjnFb1hJHOmSnAbK5ORXTJ72PNnUTep2vgG3sl1KQMgeS4TKEgYAx0zXWalpj2ixX2mYh1C1bzI2xw3HKn2IrjPD5NtdQTgAqMqyjgj6V6Zo8zG2AQiRZM/7RAHOT7Vx07xqN9xVbuKv0NzwX4303XFW3d1i1FV/e20hwVYdceorr44zOXK8AnAHc/SvBtV8P3MPiFb+3ZYi5OyQAhc+hI6HtXtWlSsdKgJwzFApJOdjjrXap2koy2MrK14s5Dx5caRc6fE8Erz3trMwMQPK4OMkdPSuK1VLk6Zc2t/vdIroBZw3yNgYVef9rJz7V1+oXWoRahcadbKRcXTgMVUGN4zwxJPPHH61xHxTvoraD7HayxvKzlpMHggEDBHoO3r1rvpqNT34nt16n1fDqle/NseU6tGv22eO/kVSI2jaQDhGUE8AepGOOKxp7p57SBJrdUuIiSz5P7xW5XPpgenXvWnqcjxoVmEGJCWOwYI/wDre1Zk8OIi0pXc3OAQeMcU29TyFY5DW2k+0qXGYSCoyxIX29qr2pG9SDuUsAOMVf8AEUSC2MhBMokAJB+XHNZdm3zqST1HNbROeaPs3QtSgm8l7VklU/KrK2SPXPvXVmfzSuM/L375qz4k8F6PqU8uoR79Mvz8z3dqwTcfVwflb8ea5hDd6Y/lRavpesBRkRw5WYt6fLuX8eK1jG5HtkzrbPoNp78iqWvaiNJnjtrBgs8ylpFA+VORg+zHnnp60xNQk0/SJL6/hS2kCfJCG8whuwJ4B7VheHooFjnvi8l9fPKxMiodyMBg+/PQ849K2irHPUldk0cc97E5ugDdR+XIU3gKcE/dA5GT13d+nFZ+ku9zriC4c2iWru6mWTBBY7ih5+YbgcHjgisA6F4kk1nV9Ttrae0WZohbxl1ELxhw0pk5BBIHAGO/Sup8OXC6r45vHDRzwW8CuP3XG8jDMCfTIHBq/NGSd2F8yXXiNBJE5tREVR3TAlZiM/UYzWjp1hBouqiLTkItbqfzJVLfLCVVsKg7A5x+FZ/jeUC6tsuB5cgkIBxkD3rQ1W2uLb98Y3+yNgx3CndsPUbhXFN2eh30oJ79TSvbgQFRvVFY7ck9z0rOvnWV4pJlLSROFLofmCH735dfwrHvNVtruzkhuyFVlwQucfUGuEv9av55b9YDJLDbSLD56MR2P3gPpWa5pP3TtcKcI/vHY7DxBfbZdLhnvQkbSNEb1MMgyv8AEDgg5wa57wzp2ueNGCS3KxabbyZluHTIZl5C8EH0Oa4tJBeXfn3NyGhUrhjlhnHHHtXqfgyO403w5dEP/wASy6IuYgfle4cDBxkjg7RxRy+9YqU3Tpc0Xe+xu6VHc6RpqTXubzULuXYTHn5Ix6jPv+tVdQ1BI5HK29yqEFWBiJB/Cuqtb2z1CB7y1uI3jnQJAquMkDrx65/lXGa09y99qDC7S2sbBEe4K4DorAncSeg49KJ9rGGHfVs8E+MGqIb2Oys4vs3m5M0YGAQOhA7V5wMAcEenNa3ivVW1rxJfXpYtGXMcRI6oOh/Hr+NZJIJ5q4R5YmeJqc89NhCeSOw701uoxj8aJOnXpUBZlboD/WqMUSc7uOcDNNBwBuHB600S8Hd1/Q0pmPoATz9KFqA45z0AyOgoBKkYGBjuOtR+Y2egBHpT5JEaRjEDsIH3+o9aVwQ5OWwMHnmg5HHryP8APagOqrnOewoZtw7jJ5I4oHYRWz156n/9dOV8EDHXoexpoOS2SCehx0xS4Bxu4XPp0ouKwpJG4YyenHekySeSWHTPSlZRg9wPWhcZOfTHNMAB5yefUdKcuX6FRj86YckADHy8+oowMFsY707hYeNynBAB7g9qv6PqEmnahFdxNhkPB7YNZnXkHPvjPFO9AcY9T1pPUFofWnw61u18QaG0t1dIL+CHADgBWOMjFY1jaQXmp6rZXO+xlMokcY7tyMdvyrw3wdr8+napA28YEgPoAM88V9I+F59M8TWjyHAu/l2ODnaw/l7ivAzDC21gj0oKVWm3HdHnPi7wbLcauFiYlAF2NjnHb/69cl4t8ManpRTzkkljKgllB219IrZ7Y4y0fl3cb7PVWU/0q6LSO5hCzWySZBEkZGc15eHnVVTkutC8PiGopNHz7ouk6Zc6Vb3Ucj/vx5ezIBDAcn2qutnNYajPaIVl+fG4cjivTZfAKWN7dT6NHcwW7NuEcifcPfae4qG502ztLKN0YLKHG7djlicYPpWs8Q4y2diJRVnZmdo+nyR3kREyEgjdGHBIOM/yrv8ATQ9k6RD5CxKYAwQPf6isHT7K2bxBDqt0DsWMR4GAEYkAvnuccfTNdjbhYJZVvpY02A4JPb6/jWVetye+mFGPNG0jORvIvJbExwsJk+/8wD89R2zSo11FrUFpYiQo8m9tpwIlzlvz6Ae9aoWPW44YdOaOVEJJfOdvGOKg1rU49DgaxsW+0azIBkgbljU8F3PsOfQVtRqVsa1poc79ybjDYreMfEY024uDaRm5a2VVlbphCRleOuT8vHvXiHjCUR6lczsXVJHbNuAR5CnlUz3wrYrrvGOoSW9mNPvJWF5FFLbzNLHl9+QSVYcf3QuegbPOa8/1Fo5mnvbhlDuzNIisducrhF44IBx+PtX1EKSpQUCHNzZjyJ5qiUhVI7YPy4OMkfhWTdTBVjdJGyc7+ORz2/Ctq4je51a5s4txjKswcALtjUZyR245NYl2EkjkmSMR7JGGBkrjJxyfp+lQ1Y1T6GHre97eWIjewYMvc+9Y1mcSKQQPmHAro9WxNcyyYJUoCAcL8uAK52GPyrvyxkoHGD6VpDYxmfVuveIb/wAWaiPtpaO23BIbKI5QD1IP3nJru/D2jvaWcYZVhbr5YAAA7ZA6n9KxvCGg/wBmD7dqDh9SdMiPqlsp7e7ep/Kugg1M3j7dNHnKchrr/lmp9j/Efpx71ul1Zk0n7sdixq2lfbUjieVpvMGx7VuFkUkZP+yQM4NY8dvdaVrGPNVYo5AAXLB8YUBSBkPhTkE46c9BXV6XCkecyNJK3Jkc8k1buY47jUIBLGrQ2wEoYj70hyF+uBk898Vop2MJUjz3Wk17UoJ0kWI2xRYmEIaTlig+bdtAyGYcZx37VuaZoMHhnRMRMIpLckxMcN5ad0JH3txyT7nitjxXe40W4cPgh4jwOp8xeKzfGV1sWGIkYaQsw9QP/r4oc3YUafvHnHiq8u31NZLdPOkncReV2LE4UDP1wa9PtF1rS9Ns9HnuLSWaK3DTzGPOVLEBFB64xjJ9K8s1d3R1uVPlyRyCSNz/AHlII4/CvStG8W6b4su4ha5h1C3iDXUcnGFbPC/3hkdR0rCN3c66i5bXWhy+teFoLmbeN5bpkOR+grkZfClzC81xZx3AJYZiWTaXUHkn1Ne0z20YJAkVQeDyOabBpIlmALkDGc+3rWPI07nSsVFxs9jh/CHgWwljjv7iBYrRwHSMHmUZx83pV/XvEGnXV1eeG/7KkmgjxDIWxH5OMZKD6EYIruHEFrGfNysca4QAZJJPQfU/zrzj4hxHSJYvEF1byefKPJkaMghVH3VZep/3hmny8q0OKvWnN37HIap4ZsLfVUFil09vMSyGRAGgYDoXXsex61zPxE1G58K+E9S0uC43HX9scofLOFQ8kN6dua6S61KSTT3u4pXit9pkDuCBx714V4q1658R6u11cuWhRfLhQ9Av/wBenBSbuctO8pXMgfKAvoKQ4DYNPGBTWUE984rY6RnUEA89c1EylTyc88Ec4qVvU49MYpOxz0FSwIB14IH9KGz1x3/OlZOCcc4+lNyOB0HelYq4Egg9MDvmlGSPlyR1570wnsBjnn3pDw3akAuSSTn6UoyAAowKbxkHnI65FO4A46ZxSGOJ6HgADp1zUiybfl79cmo/Q+ntQH5B6Y6HpTCxMSG6E89Bml/iHcA59OahBKgjHGeKcrAdT9f8aExEmABwCaASQM5HFCAnb8uMd/WnkOQODxTAb1OcdeKMc4OfSlwwxxSgEHP+RRcCSDAmTOOeOeMV3/w+16TRb1lVm8uXasmeNvowrzzIxjGOO9asNyrWluEHlyrlXccZ/u/1rOpTU1ys2oVXSleJ9Y6H4w0+909WvdzyoOCin5/cf4V0tnLPfG1utPKxKhAkWRT8698e9fLfgTxJIlwLO7khWMkMWfgjA7EdK+jfhtrlrZM8Ts7GXmMSnkZ5AHHpXjVMCm3zO3mewo0atNzgvf7HZSWxks4pd53u+0LkYI/xry74m2cWm6Xr8sJZXMSzug4+ZTjcPQ4x+Vd9qOoeVf232S3doWUtKzNgoR2A/wAa4/xHYSa9EyGRvI1NCWm2/wCqXpt56+uPWsq8oRio9dDz6kXSV2eZeEPGbajYy2t6S00rIkO0YaXIJYsMYAHFd9qFlqGvmH96FskUGZ1ywC4xyPoOntXO6VpXg7wfdeZqepGa9gGESJD+vHWi+8YXmpiaDToxbabIuGZW2K6g4JJ9sjOO1CwLxE1NK0fxZzyjKpHkvZHYW2qWViU0rw1cmRiQkk7ttHTJY56dD1/CuW8SeI5vDOlXtgo36hdtKjSsCVcOFC7WA5IGfzrmJtak0W6MOmbTdSRokhI/1jHcHxjO4Djn26Vn64L66Rblo5IF2K0JCBskfdVT16dzyTXt4ehCgrx3HyqMVCO34sgEF+0dzLqEmxoU3M+7ccnGWJ7DGB+VZ+sXTsskgX93A24IE2xq7AEL7nhq2dKhkliuSyytaW5aSfcm7YQAd6gd8ZzuIGB61j3ss11p32e1BeEr5zHbtWMsWIA9cZbA9uprdq+oJamDGt1e3TKiFTdRkkvjnYpJwew+U/lVO6d00yC3aVWikHmggghOTx9eSfxq9cJGkIgtXkKsiu0jDDBSWHH4HkdzVG5WOe5WOFyy5JRdoHB/rgD8aykbIozReXCwOCGUYY55HXjNc6BsvNvPyuAM/wBa6y9e1lZwZJY23RrHvGVCYwzHvwcYA965i8+S/UtggkENjhuacexjM+zLy/t7zV4dI86KRhG1xcQ56quAFPoCWz+Fa8Fzt2xRhUUDAVTjb+HpWf4t0bTfDum6LbaVbGORrqV5JCxaWY+WSxZjycnb19BVfSpWlKn7xI+bnOK6HqZU3dXOxtpdsSkZznk/4Us9wUcjdwTk1TjdliyuAemOv41Tu5XjjzIyr3+Y9qWwW5in401ZbXw9LIAHaOaBwhON2JV4rH1G/e/uC0h3KOM+gzWP4i1rS0vYhfR/bLOOTM0O8qJF9vfuPcV1WleFPDN/FDe2moalc2EseYEacqEB9xgk8Y5pSblsPSnq0cVILvxBqU2k6VApmVd7NI4RcA8n3HPavSfC/gix0q0jxCsl2VxLdOPmc98ei+1bGlaZpGjwhdPt7aAYwZMZc/VjyaTUdTVId28Lb5Ku7nG44+6PTPqaErGUpuo7LYfpNlZ+a0sMEflq+FlXnd6mtW+mhttjFsOflRF5L+wFY2lamsuj2MkMJE11EJliPylV7E+g6fWtG1QRsZJmEszcM5HT2A7Cpb1JSGGGaZxczEbkH7uJTkJ7n1P8q4rxnHqNzq1vdw6fc3Flb2pjYxfNh2bLZXqeAORXbSqYJGmgb5DyVPQV438T/jRa+HXudO8KtHeauy7XmVsxW+R1z/Ew9KTV1YTjzaHlvxK8TwQ2dzoWkEgXLbroDOEwfu47HPWvMei844p8zyzTSyzyNJPKxeSRjlmYnJJ9c1FnP/1qqMeVWHGKjoL6fNjP60Hjp1+tNPHrn2NLj2BzTKAPkjJOe46U3PDYOc96GPIGRwfSjGWA6rg846UANkJ7dfeoScg4FSsMg4+vNQMMsRx1xjtikxhuGCGOfrxQDjjO7rk4/SmHk8jj0NLvwflAI9c/pSGPQhvmyeeR7UgJA3cYHP8AjUQcgDgAE9cdKcc98Hntzj1oGP3HqBk98HpQG+U7hgZxQpzk4+nFL1xjkn1osIUFumQMVKoGc/zpFUKckg9/rTsc9TgiiwNjyxA5bjP0pQxznk9zzTAcnnhTxnFBwc9CfrQBLuB5P6UoPPJ9uaYD+Z6mgEAAHge9AD+C3Jx/SnA4JBztPpTFYcDj8BRuySMHnjNAzS3ktDIiBFxtyDgn6mu18L+NrrSbmOMSGbbHsUyOSETHH4g5x9a8/tZ2haUAE7kK8c1Zs7z7OkqhFdG5PrWU4p7nRTm1sfQ/h3x+k64nlkeUuu7JGEUnGOehzjrWjfeLzZ6HMRNagbHW3cuM4z0x16nGa+b0nMkACkpJkkkn7w7Ae9OhguLp2WPLuGHDMByTwBnqSa43gaLd7HV7e6tNXNldXzqk73YErbt6yH5gT6H9auHVJ2QSGS3QFs91HPY4/wA9KxVs7m3mEc6oj4V2IcAhT6k9COmDyDV/TP8ASLsQWKli+1MOuFLEc467Twe/rXbFWVjmk03dbGzp1xbzG3luZ5kuid7P5jRlQDw24Dg/StnT7dCtzJb3M0cAY7GVjIzNxzn0+tZVifLMSgglzv2lwyu3px06DrjtWrHd3EwlsYdO8id/9HUrLhg/OAOgPPXJx+PFWkQ9XoNn1OO1khl1G1jk5DkKqs+zIYLJnOAduQRzyO1YbyzOJj5jsJ3/AHk8sTDCE5yTnksMjHp3rUx9ltLj7U5mn2LE9rGoAGG4+Y/N1OTjnr2p1rqZtrhLq+ls7iZV2S2rxloyABt3gHDH1GRnHJ7U35lpWWiOdke2jtZYI4N1/cTFlmdm/cRD7qKOhJ5OecDAqHSZYbaed5LVmRYvJXaeAzAhd2fUjp/hW3ptqmbCWe1Y2iF2lKnbJvcgIASMk/dwOQOTVJjDb6bah4tyyWzSxhxn9+8wG7d7KjAe4z3rNoq62OUaaD7NAixbZ4i/mS7siTONox2xhvzrB1NdzRSjoG29enpmte4KOsxUFWLZAxwOveqVyB9hc7UbGBk9Rk9f/r0obk1dj7c+IugazqzaZPoUdpJLapPvFwxAGQpGAOpO3GPeuT8MXsN1aQXsbBRIuWHTae4P416XpPiG3vdLtLqFhuZAWAGcEdf1rzvVdAu/7du30GKKTS7pjN5TfJ5Eh+8B6qTk8dCTXTJW1OOlNLR7Gzc6miRt5DIzY+bnBri9Yu2mcmZpYiAecbsD0rXHgjV5zhruK3TnIClz+fFaen/DaEsDf6vdXAAxsRQi/wCNRZ9Db2sF1PNNE0iw1bxNpFlqO6a1uLkJLCr7S4IOOfbgmvdmh0zSovsmnwRRonSKFQoH5d6g07wbomkL5y2cIZDu+0Pgvn13HmnzvHjaHFpZqcSEkCRxjPH90frTjHuYVanPLQr/AH8TXaqF/wCWcQOS59K4jX9X1LWoLtIrJIrOJhCzGbEhH8WByMjkZrp7+WTUCUi3W9oMIduVaYdsDPyj36msHUhFauPJDKoTyiqnj1FKTsa04WKM/ju6sfLs9N0q2s4Yo1GJ5mmeTAwCW4xxXS6B8QdIl0u5udcmi0o26eZIZnyjL6oepP8As4zXj3jvxDaaAgluYvMu3H7m3BwxHqfQV4nq+qXusXbT38hkOflQH5UHoBSir6sqpGMVbqepfFn4x33iuS50nQWew8Pk7S3KzXQHdj/Cv+yPxryZgq44A9h3qOMEkD+farAQ9+nbNWZDFJbgZpCcZIAx7CpGGDkg47UzpyOT9aCRpOepH4U3OTinsOeAAe1MzkknOPekMXkdMZ6+tJz1/hx16YpuODn9aU8cnGM8UMBwGMc9vTrTHjBGVxxxSk54GB369aDyMgY7nmgCrsCggED37UwoSxIx14q06hmBUEMOnvUJxnIB47ZxSKTGqnzngEH36UuzqSSBnoOhpwVmfhcgd6kVBwSRj1oC40BSdoYe4FPxtBIX5hx1p3RRgjGe/WjGBng5OeKCRM7lG0YwOuepo6Enp2FKowuTleM9KAMAfLu4/On0AVcZ4A49TT1Xjnb9ai3cgEYHucilIO7J59xQBIFbsQc/jTcEZwCAOvvQxcFd3Oe2aN4zgrn6n+VFkFxp9cZBpwJAxkEepGaeHUE79v496AT94bcDvjiiwXFicggqxBHI+tWokVnyxAUnBYjiqoYE4wMnn5ePwq4Nm/BDeWSRnrjiolHqjWm76D4SFl2ABt33T3q5FGzgRvIBvIUM+MAnp9PrSwnzJ9iqTI6/L05q3pM0SXPl3Q/0eQFHO3cQMdQD+FZ+R07oJ7eeURC8kJYZCiQ5BAP8LdD171Jp7RxjeYo98T8g/Pu/DoRTjCGjJhlAhH/PQjAHr7HimI05QJHuETMGZSflHYHH4/rTvYXLc0kfzi8seyNuGGGIOBwAOf8A69XkREdp7qO4AxuRzIHBcdj6jJFRQQvFGwligYdF6qSo53AcZz781djYCeMKkQHOFk5XnnHbpmqv3GrrYUQ3VwfOhljMeEAeaYKEJ44PY4B/DNaEi7nlRWjkdSwUwjezsBjj8eOB602KCNHCyQqQVLIcE5PQAY9uOauyBortUVAZ4kACWvLAKfvFuwHXrn+VGoMpxopMbS22biGXdJI7YaJAfu9sOxyBntxxXM6wZJGuoFMcgtISgWP5EiRcDI9cM2B69a6nVpIreDbpijzoW8vrulfbgswPYhs4Y+vtXHXjYFzaW8okluI/MuN2MZA37QevBHJ78UPaw4rqc/JDugAQF1UtyenTt/Os2bLR4HPOT6Vt6iT9i0mNlCfu3ZtgIyAzDOe5wOv0FZJCoVBBPzDOaz2ZM1dH2j8ObOS2srvTLxXC29w8tpI8ZUTwMchxkeuc/wCGK7hIIwcYGKKK6meakidI4wflAAHaor+4hs4g7IDIQQo6Dp1Y9h70UU0iW7I8/wBf8XRW0UxZYb3U7aPdIY1It1X/AHsnH86pXZXULK3H22G51MRi6t0eQOqsBuxjuOSpJ9aKKlvVoqjuyVNYtrvT47qI+WGXlXOCh7hvSvIPiH8S445HsPDa/abiMnfd/ejU4/h/vYz16UUUKK3OuUnFaHi96by8uZLm7eWedz80j5JNMWJs8o4P0oopsxvckiXB5ViPpVgc8bW9enSiilYQyRDxhTg9wOaYyNz8rdemDRRUlEex8n5H+namsjEcKee2OKKKbBDGT1Q9cgelJsbPCt78UUUmwG7W2AbWYdckf1pyBwPuMQckfKeaKKOtgsKIyBwpxjuOlNEBY4CMD6AUUU7WAcI2CgBWz3GKTy25wrc0UUAIFYfwkDHoaUoxH3Tj/dzmiigQMjlRhWz64pAr7uYjgHjAoooGJ5bHB2se3HanbWx91gfXFFFCANrFj8rZ7cHNAVs/db16UUUACo+3G0nB5wOtO2yDkBtw/wBmiimAKGHGxjzyMcVZtzmKRSrAt6L37fhRRUlR0Zcs0keBVdSZARtCjk1o28LTqVhjKXKMSUIPzfQfhRRWSWp1RZpaUjx5E+/yJT5ZC/dD/wAIbPA/wq1bQvNDC7wiCMSum4fxkLgqc5GcdDx160UUIrpcmtZmiuIpJMOSSduDuBzz9M+np3rRjdpoJVijLHO5mfBKjPJ47fX2ooouUtVcvTbGTyYyYvLjVPLKhSzA5Jyfzz34qvLqEckckOzzmOWGTtUfLjLHqR3x+lFFU2JIqQQvPFd7ZJRbrEqIyRlRIvDFD6fKG6+tZF9cQiJIbWzUKlpsneRBudmlMhI9M5VfXapHeiiouXypsxIiI4bsyRu37pooxgkLubOfbocfWslomLRGRXAIwnHf/IooptGc97H/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-standing, progressive ulceration at the left leg of an 11-year-old girl. Earlier attempts to control progression failed, and severe contracture in the knee has already occurred.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tjip S van der Werf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42806=[""].join("\n");
var outline_f41_51_42806=null;
var title_f41_51_42807="Proximal tibial fractures in children";
var content_f41_51_42807=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Proximal tibial fractures in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42807/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42807/contributors\">",
"     Jennifer Chapman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42807/contributors\">",
"     Joanna Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42807/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42807/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42807/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42807/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/51/42807/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, proximal tibial fractures are not as common as diaphyseal and distal tibial fractures. Metaphyseal corner or bucket handle fractures are highly associated with child abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=see_link\">",
"     \"Orthopedic aspects of child abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with proximal tibial fractures often have pain, swelling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deformity at the site of injury. These patients usually are unable to walk. In addition, acute compartment syndrome and popliteal artery injury with vascular compromise are potential complications. Metaphyseal fractures are most common in children under 10 years of age. Physeal fractures and avulsion of the tibial spine or tibial tubercle are more common in older children and adolescents. In patients with closed proximal tibial fractures and no sign of neurovascular compromise, initial management focuses on pain control, immobilization of the fracture, and reduction of swelling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42838?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of tibial fractures in children\", section on 'Initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The care of proximal tibial fractures in children is guided by case series and empirical observation and varies depending on the type of fracture. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Definitive care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evaluation and management of proximal tibial fractures in children is reviewed here. Other pediatric fractures of the tibia or fibula are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24296?source=see_link\">",
"     \"Tibial and fibular shaft fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19527?source=see_link\">",
"     \"Stress fractures of the tibia and fibula\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24345?source=see_link\">",
"     \"Ankle fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal tibial fractures are infrequent in children relative to diaphyseal and distal tibial fractures. In toddlers, metaphyseal corner or bucket handle fractures are highly associated with child abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=see_link\">",
"     \"Orthopedic aspects of child abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other patterns of injury correspond to the age of the child and the type of force [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Young children (three to nine years of age) are at risk for greenstick or complete metaphyseal fractures when valgus or varus stress is applied. Jumping on a trampoline with other children is a common mechanism.",
"     </li>",
"     <li>",
"      Older children (10 to 12 years of age) are at risk for tibial spine avulsion from hyperextension and rotation injury (eg, most commonly a fall from a bicycle or motorbike).",
"     </li>",
"     <li>",
"      Physeal fractures are commonly seen in young adolescents (12 to 14 years of age) and are related to high energy mechanisms (eg, sports injuries, motor vehicle collisions) (",
"      <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tibial tubercle avulsion occurs in older adolescents during active quadriceps contraction with forced flexion of the knee (eg, landing from a jump during basketball, hurdling, high jump or gymnastics or being tackled in American football or rugby).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibia is the major weight-bearing bone of the lower leg (",
"    <a class=\"graphic graphic_picture graphicRef54800 \" href=\"mobipreview.htm?41/14/42213\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"mobipreview.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    ). The proximal portion of the bone, the tibial plateau, forms the lower surface of the knee joint (",
"    <a class=\"graphic graphic_figure graphicRef69611 \" href=\"mobipreview.htm?34/27/35251\">",
"     figure 2",
"    </a>",
"    ). The thicker of the two articular surfaces is the medial tibial condyle, while the lateral tibial condyle is a relatively thinner and weaker portion of the joint. Separating the medial from the lateral tibial condyle is the tibial spine (intercondylar eminence), an important bony prominence that anchors the attachment of the anterior cruciate ligament (ACL).",
"   </p>",
"   <p>",
"    In children, both the tibia and fibula consist of a long portion of bone called the diaphysis. At either end, the bone flares at the metaphysis and terminates in the rounded end of the bone called the epiphysis. The physis, or growth plate, is the active zone of bone lengthening that links the epiphysis to the rest of the bone (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"mobipreview.htm?26/18/26918\">",
"     figure 3",
"    </a>",
"    ). The epiphysis of the proximal tibia is a pressure epiphysis and is subject to compressive forces. Injuries to pressure epiphyses and to growth plates can result in growth disturbances.",
"   </p>",
"   <p>",
"    The tibial tuberosity is another key landmark located on the anterior surface, one to two centimeters below the joint line and the inferior patellar pole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/2\">",
"     2",
"    </a>",
"    ]. As the site of attachment for the patellar tendon, the tubercle is subject to tensile forces and thus, both inflammatory and avulsion injuries. However, injury to the tubercle does not pose a risk of growth disturbance.",
"   </p>",
"   <p>",
"    The interosseous membrane is a strong fibrous structure that connects the tibia and fibula along the length of the two bones. Proximally, this structure, reinforced by strong anterior and posterior ligaments, forms a synovial joint, the proximal tibiofibular articulation.",
"   </p>",
"   <p>",
"    Another fibrous structure, the crural fascia, surrounds the bones and muscles of the lower leg. Fascial extensions and the interosseous membrane separate the muscles, nerves, and vessels of the lower leg into four distinct compartments (",
"    <a class=\"graphic graphic_figure graphicRef66579 \" href=\"mobipreview.htm?4/40/4740\">",
"     figure 4",
"    </a>",
"    ). Three of these, the anterior, posterior, and deep posterior compartments, all border the tibia and can be compromised by tibial injury.",
"   </p>",
"   <p>",
"    Vascular compromise can arise more proximally from the following etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Marked knee effusion",
"     </li>",
"     <li>",
"      Popliteal artery injury before it branches into the anterior and posterior tibial arteries",
"     </li>",
"     <li>",
"      Anterior tibial artery as it branches off the popliteal artery and passes through a gap in the interosseous membrane",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The tibial and common peroneal nerves and their branches provide the key innervation to the muscles of the lower leg and foot. The tibial nerve parallels the course of the posterior tibial artery and courses through the deep posterior compartment. In the popliteal space, branches of the tibial nerve provide innervation to the posterior compartment and to the popliteus muscle. The common peroneal nerve divides to form the superficial and deep peroneal nerves, providing innervation to the muscles in the lateral and anterior lower leg, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different mechanisms account for the different types of proximal tibial fractures seen in children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metaphyseal fractures &ndash; Two types of mechanisms are associated with these injuries:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Metaphyseal corner or bucket handle fractures result from intentional pulling and rotation forces applied to the leg when a toddler is grabbed by the ankle or rapid acceleration and deceleration forces, such as when an infant is shaken violently while the legs are dangling.",
"     </li>",
"     <li>",
"      Metaphyseal greenstick or complete fractures occur from medial (varus stress) or lateral (valgus stress) forces applied to the lower leg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal tibial physeal fractures &ndash; These fractures are most common in young adolescent patients who sustain high energy trauma during sports or motor vehicle collisions.",
"     </li>",
"     <li>",
"      Tibial spine fractures &ndash; This fracture results from a hyperextension of the knee with concurrent rotation of the femur on the tibia. It is the same mechanism as an ACL injury in older patients.",
"     </li>",
"     <li>",
"      Tibial tubercle avulsion fractures &ndash; These injuries typically occur during forced flexion against actively contracting quadriceps (eg, an adolescent planting a leg to dunk a basketball).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeated flexion of the knee occurs in athletes who kick and jump or who climb steps for training. These activities engage the quadriceps muscles and exert force on the patellar tendon and its insertion site, the tibial tubercle. This repeated pulling on the tubercle in young adolescents may lead to an apophysitis (Osgood-Schlatter disease). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12392?source=see_link\">",
"     \"Osgood-Schlatter disease (tibial tuberosity avulsion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of children with suspected tibial fractures is described in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42838?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of tibial fractures in children\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with proximal tibial fractures often have pain, swelling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deformity at the site of injury. These patients usually are unable to walk.",
"   </p>",
"   <p>",
"    Additional findings of specific fractures are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal physeal tibial fractures &ndash; Patients often demonstrate hemarthrosis and tenderness at the knee joint and are unable to lift the leg due to pain and large muscle spasm. Rarely, posterior displacement of the fracture may cause injury to the popliteal artery. Hyperextension of the knee during the exam should also be avoided to prevent vascular compromise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/4\">",
"       4",
"      </a>",
"      ]. These fractures are associated with ipsilateral femoral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tibial shaft fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Metaphyseal fractures &ndash; The toddler with a corner or bucket handle fracture typically limps or refuses to bear weight, but the exam may otherwise not reveal any localized swelling or deformity. Other findings of physical abuse may be present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=see_link&amp;anchor=H7#H7\">",
"       \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Greenstick or complete fractures &ndash; Older children with greenstick or complete fractures typically have severe pain and swelling at the fracture site. Deformity may also be evident. Posterior displacement of the fracture may impinge upon the popliteal artery or anterior tibial artery and cause distal vascular compromise.",
"     </li>",
"     <li>",
"      Tibial spine fractures &ndash; These children will have a hemarthrosis, knee joint tenderness, and a markedly decreased range of motion.",
"     </li>",
"     <li>",
"      Tibial tubercle avulsions &ndash; Patients are unable to move the knee and have proximal displacement of the patella with bunching and spasm of the quadriceps muscles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior-posterior (AP) and lateral plain radiographic views of the lower leg, including the knee and ankle, should be obtained in the child with a suspected proximal tibial fracture.",
"   </p>",
"   <p>",
"    Proximal tibial physeal fractures are classified using the Salter-Harris system (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"     figure 1",
"    </a>",
"    ). Complicated fractures may require additional imaging (eg, computed tomography, magnetic resonance imaging [MRI]) to fully characterize the injury. In addition, fractures that are irreducible may have entrapped periosteum that is best visualized by MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toddlers with abusive tibial metaphyseal injuries may have a small triangle of avulsed bone (the \"corner fracture\") or may show the C-shape of a bucket handle if the x-ray beam is directed obliquely to capture the sub-periosteal layer that is pulled away from the bone (",
"    <a class=\"graphic graphic_figure graphicRef60912 \" href=\"mobipreview.htm?39/2/39983\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=see_link&amp;anchor=H18#H18\">",
"     \"Orthopedic aspects of child abuse\", section on 'Location and type of fracture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with avulsion of the tibial tubercle have a fracture through the base of the tubercle with proximal displacement of the fragment which remains attached to the patellar tendon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with a suspected tibial fracture should undergo evaluation and management appropriate to the patient's mechanism of injury and physical findings. The clinician should evaluate unstable patients and those with a high risk trauma mechanism (",
"    <a class=\"graphic graphic_table graphicRef57293 \" href=\"mobipreview.htm?0/42/684\">",
"     table 1",
"    </a>",
"    ) according to the principles of advanced trauma life support (ATLS) (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"mobipreview.htm?42/51/43834\">",
"     figure 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40119?source=see_link\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with closed proximal tibial fractures and no sign of neurovascular compromise, initial management focuses on pain control, immobilization of the fracture, and reduction of swelling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42838?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of tibial fractures in children\", section on 'Initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vascular compromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal tibial fractures may rarely cause vascular compromise if accompanied by marked effusion of the knee joint",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posterior fracture displacement with impingement of the popliteal or anterior tibial artery (",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"mobipreview.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65878 \" href=\"mobipreview.htm?24/8/24705\">",
"     image 1",
"    </a>",
"    ). In these children, distal pulses and perfusion are diminished and severe ischemic pain is often present.",
"   </p>",
"   <p>",
"    The emergency clinician should promptly identify children with vascular insufficiency and emergently involve an orthopedic surgeon with appropriate pediatric expertise. Rarely, these children will require partial closed reduction in the emergency department in an attempt to restore distal circulation. Patients who display a cold, white, or cyanotic foot despite reduction attempts require operative exploration and vascular repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Open fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to pain management and immobilization, children with an open proximal tibial fracture should receive antibiotics and tetanus prophylaxis (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"     table 2",
"    </a>",
"    ). The antibiotic regimen should target Gram positive and Gram negative pathogens (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9797?source=see_link\">",
"     cefazolin",
"    </a>",
"    and an aminoglycoside) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/7\">",
"     7",
"    </a>",
"    ]. Consultation with a specialist in infectious disease is appropriate for patients whose wounds are contaminated with unusual substances (eg, animal feces, flood water).",
"   </p>",
"   <p>",
"    Open fractures of the proximal tibia warrant prompt orthopedic consultation for operative debridement and repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acute compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compartment syndrome may rarely occur prior to or after definitive orthopedic care of a proximal tibial fracture. When compartment syndrome is suspected based on clinical findings, immediate management includes relieving all external pressure on the compartment. Any dressing, splint, cast, or other restrictive covering should be removed. The limb should NOT be elevated. Elevation can diminish arterial inflow and exacerbate ischemia.",
"   </p>",
"   <p>",
"    Suspected compartment syndrome should prompt emergent orthopedic consultation. Compartment pressure measurement helps identify patients in need of fasciotomy, the definitive treatment for decompression of all involved compartments. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Measurement of compartment pressures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Child protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a metaphyseal fracture (corner or bucket handle fracture) in a toddler is highly suggestive of child abuse and should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for cases of suspected abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children under two years of age with suspected intentional trauma on the basis of concerning injury patterns (eg, corner or bucket handle fracture) must undergo further evaluation. Additional investigations in such cases should include a fundoscopic examination by an ophthalmologist to assess for retinal hemorrhages and a skeletal survey. These measures should be performed after the patient's clinical status is stabilized. The safety of other children in the home must be ensured by local Child Protective Services. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt orthopedic consultation should be obtained in patients with any of the following proximal tibial fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fractures complicated by neurovascular compromise or acute compartment syndrome",
"     </li>",
"     <li>",
"      Open fractures",
"     </li>",
"     <li>",
"      Metaphyseal fractures",
"     </li>",
"     <li>",
"      Displaced physeal fractures Fracture with intra-articular extension",
"     </li>",
"     <li>",
"      Displaced tibial tubercle avulsion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with complete tibial tubercle avulsions or tibial spine fractures may be treated initially with a knee immobilizer and made non-weight bearing. They should have early orthopedic follow-up within one week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DEFINITIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The care of proximal tibial fractures in children is guided by case series and empirical observation and varies depending on the type of fracture:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physeal fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment depends on the severity of the fracture and degree of displacement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nondisplaced Salter-Harris I or II fractures may be splinted in extension. These patients should be nonambulatory and warrant follow-up with an orthopedic surgeon with pediatric expertise within one week. Orthopedic care typically consists of a long leg cast with the knee in extension for four to six weeks with frequent orthopedic visits for assessment of bone healing and cast integrity.",
"     </li>",
"     <li>",
"      Displaced Salter-Harris I or II fractures warrant prompt orthopedic consultation for closed reduction. Once reduced, the child is typically placed in a long leg cast with the knee in extension for six weeks with frequent orthopedic visits for assessment of bone healing and cast integrity.",
"     </li>",
"     <li>",
"      Salter-Harris III or IV fractures warrant prompt orthopedic consultation for closed or open reduction with internal or external fixation. Patients who require fixation are immobilized in a long leg cast until two to three weeks after hardware removal as long as adequate bone healing is present. Patients not requiring fixation are typically casted for six weeks or until adequate bone healing has occurred based on frequent orthopedic follow-up.",
"     </li>",
"     <li>",
"      Salter-Harris V fractures cause a total or partial erasure of the growth plate and are very rare in the proximal tibia. When recognized, they warrant long-term orthopedic follow-up for the expected growth arrest with shortening of the affected extremity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Generally, all physeal fractures require long-term orthopedic follow-up to monitor for growth arrest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Metaphyseal fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metaphyseal fractures warrant prompt orthopedic consultation. Orthopedic treatment of proximal tibial metaphyseal fractures is dictated by the mechanism of injury. Typical low energy mechanisms occur in younger children, age three to six, and manifest as buckle or incomplete fractures through the proximal tibial and fibular metaphyses. These are routinely managed with closed reduction and casting.",
"   </p>",
"   <p>",
"    High energy mechanisms cause complete transverse fractures with displacement and are usually found in an adolescent age group. These often require surgical stabilization and careful, repeated evaluation to exclude the possibility of vascular injury or compartment syndrome.",
"   </p>",
"   <p>",
"    If closed reduction and long leg casting with the knee in extension are performed, radiographs of both tibias should be taken to ensure that the injured tibia is adequately aligned.",
"   </p>",
"   <p>",
"    Toddlers with metaphyseal corner or bucket handle fractures are treated in a long leg cast with the knee in extension. These patients warrant additional evaluation for child abuse. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Child protection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Tibial spine avulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment typically consists of a removable knee immobilizer fitted appropriately for the patient size. The patient should be made non-weightbearing on the affected extremity and given crutches.",
"   </p>",
"   <p>",
"    Significantly displaced anterior tibial spine avulsions require referral for closed or open reduction with internal fixation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-displaced fractures can be treated in a cast and heal in approximately six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/10\">",
"     10",
"    </a>",
"    ]. Radiographs of the casted fracture should be repeated after two weeks and again at the time of cast removal to confirm adequate bone healing. Adolescents typically recover motion rapidly following cast removal. Most younger patients will regain strength and return to sports four weeks after cast removal if they receive proper rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Tibial tubercle avulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of avulsions varies by the degree of displacement and the size of the fragment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fractures with displacement or intra-articular extension merit prompt consultation or referral to assess the need for operative intervention (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65878 \" href=\"mobipreview.htm?24/8/24705\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Minimally displaced tibial tubercle avulsions can be treated initially with a knee immobilizer and subsequently transitioned to a long leg cast in follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial therapy for nondisplaced tibial tubercle avulsion typically consists of an appropriate length knee immobilizer. The patient should be made non-weight bearing on the affected extremity and given crutches.",
"   </p>",
"   <p>",
"    Adolescents heal rapidly and begin rehabilitation and moderate activity after coming out of immobilization. Assessment of quadriceps strength should show a steady gain. Patients should be advised against jumping or returning to full sports activity until they have regained 80 to 90 percent of the quadriceps strength of the unaffected side.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DISCHARGE AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following definitive care, children with proximal tibial fractures should follow up with an orthopedic surgeon. Timing depends on the type of fracture and treatment provided:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nondisplaced physeal fractures &ndash; One week",
"     </li>",
"     <li>",
"      Metaphyseal fractures &ndash; One week",
"     </li>",
"     <li>",
"      Tibial spine fracture &ndash; Two to three days",
"     </li>",
"     <li>",
"      Complete tibial tubercle avulsion &ndash; Two to three days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients should be provided with crutches and instructed to remain nonambulatory. They should also keep the fracture site elevated above the level of the heart as much as possible for the first 48 hours after injury.",
"   </p>",
"   <p>",
"    Children who receive a cast and their caretakers should be given detailed cast care instructions. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=see_link\">",
"     \"Patient information: Cast and splint care (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Home pain management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal tibial injuries are often very painful. Most clinicians choose to provide a prescription for a limited amount of opioid pain medication (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/23/39287?source=see_link\">",
"     oxycodone",
"    </a>",
"    0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four hours; maximum 5 mg per dose). In some cases (eg, children with nondisplaced metaphyseal fractures or Salter-Harris I fractures and minimal pain), opioid medications are not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications of proximal tibial fractures in children are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Valgus deformity &ndash; Fractures of the proximal tibial metaphysis are prone to develop a progressive valgus angular deformity, despite anatomic alignment during the initial treatment. This may be a reflection of altered growth mechanics about the proximal tibial physis. The vast majority of the progressive valgus will resolve spontaneously over three years. However, close orthopedic follow-up is needed for those few cases where osteotomy may be necessary to correct the angulation if it does not resolve.",
"     </li>",
"     <li>",
"      Popliteal artery injury &ndash; With a significant hyperextension injury, a posteriorly displaced proximal tibial shaft can tent the popliteal artery. In one series of 30 proximal tibial epiphyseal injuries, 16 (53 percent) were displaced and three had peripheral ischemia at presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/5\">",
"       5",
"      </a>",
"      ]. In another series of 39 proximal tibial epiphyseal fractures, two patients had popliteal artery disruption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/11\">",
"       11",
"      </a>",
"      ]. Good outcomes require prompt recognition of vascular compromise with emergent operative fracture reduction and vascular exploration.",
"     </li>",
"     <li>",
"      Growth Disturbance &ndash; Accelerated longitudinal growth after a proximal tibial fracture is less common than with femur fractures, but children less than 10 years of age and those with comminution are at potential risk for overgrowth and leg length discrepancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42807/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children have full recovery of function after proximal tibial fractures. Children with complete or greenstick metaphyseal fractures, or fractures complicated by vascular insufficiency, are at the greatest risk for complications. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal tibial fractures are infrequent relative to diaphyseal and distal tibial fractures in children. In toddlers, metaphyseal corner or bucket handle fractures are highly associated with child abuse. Other patterns of injury correspond to the age of the child and the type of force. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Mechanism of injury'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=see_link\">",
"     \"Orthopedic aspects of child abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with proximal tibial fractures have pain, swelling,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deformity at the site of injury. They usually are unable to ambulate. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transverse fractures of the proximal tibia are typically high-energy injuries, so the clinician must be vigilant about compartment syndrome and, less commonly, popliteal artery injury. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anterior-posterior (AP) and lateral plain radiographic views of the lower leg, including the knee and ankle, provide appropriate initial imaging in the child with a suspected proximal tibia fracture. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children under two years of age with metaphyseal corner or bucket handle fractures should undergo a skeletal survey to evaluate for other bony injuries. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=see_link&amp;anchor=H8#H8\">",
"       \"Orthopedic aspects of child abuse\", section on 'Skeletal survey'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with closed proximal tibial fractures and no sign of neurovascular compromise or multiple trauma, initial management focuses on pain management, immobilization of the fracture, and reduction of swelling. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42838?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of tibial fractures in children\", section on 'Initial management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The emergency clinician should promptly identify children with vascular insufficiency and emergently involve an orthopedic surgeon with appropriate pediatric expertise. Rarely, these children will require partial closed reduction in the emergency department in an attempt to restore distal circulation. Patients who display a cold, white or cyanotic foot despite reduction attempts require operative exploration and vascular repair. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Vascular compromise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to pain management and immobilization, patients with open fractures should receive antibiotics and tetanus prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"       table 2",
"      </a>",
"      ). The antibiotic regimen should target Gram positive and Gram negative pathogens (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9797?source=see_link\">",
"       cefazolin",
"      </a>",
"      and an aminoglycoside). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Open fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metaphyseal fractures, most physeal fractures, displaced tibial tubercle fractures, open fractures, fractures involving the articular surface, and fractures complicated by acute compartment syndrome or vascular compromise warrant prompt orthopedic consultation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive management of proximal tibial fractures depends on the bone affected, the type of fracture, and the degree of displacement. Transverse proximal tibial fractures caused by high force mechanisms often warrant reduction, bivalving of the cast, and admission to monitor for compartment syndrome and vascular insufficiency. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Definitive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with nondisplaced proximal tibial fractures should be provided with immobilization (splint or cast), made non-weightbearing, and instructed to keep the fracture site elevated above the level of the heart as much as possible for the first 48 hours after injury. These patients may be discharged home with orthopedic follow-up. The timing of follow-up depends on the type of fracture. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Definitive care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Discharge and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of a metaphyseal corner or bucket handle fracture in a toddler should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for cases of suspected abuse. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"       \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/1\">",
"      Mubarak SJ, Kim JR, Edmonds EW, et al. Classification of proximal tibial fractures in children. J Child Orthop 2009; 3:191.",
"     </a>",
"    </li>",
"    <li>",
"     Moore, KL, Dalley, AF. Clinically Oriented Anatomy, 5th, Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.566.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/3\">",
"      Schmidt AH, Finkemeier CG, Tornetta P 3rd. Treatment of closed tibial fractures. Instr Course Lect 2003; 52:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/4\">",
"      Verzin EJ, Kealey D, Adair A, et al. Salter harris type I fracture of the proximal tibial epiphysis. Ulster Med J 2001; 70:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/5\">",
"      Wozasek GE, Moser KD, Haller H, Capousek M. Trauma involving the proximal tibial epiphysis. Arch Orthop Trauma Surg 1991; 110:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/6\">",
"      Whan A, Breidahl W, Janes G. MRI of trapped periosteum in a proximal tibial physeal injury of a pediatric patient. AJR Am J Roentgenol 2003; 181:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/7\">",
"      Zalavras CG, Patzakis MJ, Holtom PD, Sherman R. Management of open fractures. Infect Dis Clin North Am 2005; 19:915.",
"     </a>",
"    </li>",
"    <li>",
"     Heinrich, SD, Mooney, JF. Fractures of the shaft of the tibia and fibula. In: Rockwood and Wilkins' fractures in Children, 4th, Rockwood, CA, Wilkins, KE, Beaty, BH (Eds), Lippincott-Raven, Philadelphia 2006. p.1033.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/9\">",
"      Pesl T, Havranek P. Acute tibial tubercle avulsion fractures in children: selective use of the closed reduction and internal fixation method. J Child Orthop 2008; 2:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/10\">",
"      Zrig M, Annabi H, Ammari T, et al. Acute tibial tubercle avulsion fractures in the sporting adolescent. Arch Orthop Trauma Surg 2008; 128:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/11\">",
"      Shelton WR, Canale ST. Fractures of the tibia through the proximal tibial epiphyseal cartilage. J Bone Joint Surg Am 1979; 61:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/12\">",
"      Mashru RP, Herman MJ, Pizzutillo PD. Tibial shaft fractures in children and adolescents. J Am Acad Orthop Surg 2005; 13:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42807/abstract/13\">",
"      Shannak AO. Tibial fractures in children: follow-up study. J Pediatr Orthop 1988; 8:306.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6545 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-C08C8C0CB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42807=[""].join("\n");
var outline_f41_51_42807=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vascular compromise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Open fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acute compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Child protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DEFINITIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physeal fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Metaphyseal fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Tibial spine avulsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Tibial tubercle avulsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DISCHARGE AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Home pain management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6545\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6545|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/8/24705\" title=\"diagnostic image 1\">",
"      Tibial tubercle avulsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6545|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/55/21361\" title=\"figure 1\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/27/35251\" title=\"figure 2\">",
"      Anterior anatomy of knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/18/26918\" title=\"figure 3\">",
"      Growth plate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/40/4740\" title=\"figure 4\">",
"      Cross section lower leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/2/39983\" title=\"figure 5\">",
"      Metaphyseal lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/51/43834\" title=\"figure 6\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6545|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/14/42213\" title=\"picture 1\">",
"      Anterior anatomy of tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/45/27349\" title=\"picture 2\">",
"      Lateral anatomy of tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6545|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/42/684\" title=\"table 1\">",
"      High risk trauma mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/52/8013\" title=\"table 2\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24345?source=related_link\">",
"      Ankle fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12392?source=related_link\">",
"      Osgood-Schlatter disease (tibial tuberosity avulsion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42838?source=related_link\">",
"      Overview of tibial fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19527?source=related_link\">",
"      Stress fractures of the tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24296?source=related_link\">",
"      Tibial and fibular shaft fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_51_42808="Cholesteatoma in children";
var content_f41_51_42808=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cholesteatoma in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42808/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42808/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42808/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42808/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42808/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42808/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/51/42808/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cholesteatoma (sometimes called a keratoma) is an abnormal growth of squamous epithelium in the middle ear and mastoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It may progressively enlarge to surround and destroy the ossicles, resulting in conductive hearing loss. Hearing loss also may occur if the cholesteatoma obstructs the eustachian tube orifice, leading to middle ear effusion. Surgical therapy is required for most cholesteatomas. The extent and effectiveness of surgery depends upon the size of the cholesteatoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/3\">",
"     3",
"    </a>",
"    ]. Early diagnosis is crucial to successful outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features and treatment of cholesteatomas in children will be reviewed here. Other complications of otitis media are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H27#H27\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Complications and sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholesteatoma &mdash; A cholesteatoma is an abnormal accumulation of squamous epithelium within the middle ear and mastoid.",
"     </li>",
"     <li>",
"      Congenital cholesteatoma &mdash; The classic definition of a congenital cholesteatoma is a cholesteatoma that develops behind an intact tympanic membrane (TM) in a child with no history of middle ear disease (",
"      <a class=\"graphic graphic_picture graphicRef72870 \" href=\"mobipreview.htm?34/39/35440\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/6\">",
"       6",
"      </a>",
"      ]. However, since most children have some history of middle ear disease during infancy, cholesteatomas are considered to be congenital if they occur in children who have an intact TM and no history of ear surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/4,7,8\">",
"       4,7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acquired cholesteatoma &mdash; Acquired cholesteatomas develop after birth, usually as result of chronic middle ear disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of cholesteatoma is not known. Retrospective data suggest a mean annual incidence of 9.2 cases per 100,000 persons of all ages (range 3.7 to 13.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/9\">",
"     9",
"    </a>",
"    ]. In studies limited to children, the incidence ranges from approximately 5 to 15 per 100,000 children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/2\">",
"     2",
"    </a>",
"    ]. A rate of 1 percent was seen in a retrospective series of 45,980 children who had undergone tympanostomy tube placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/10\">",
"     10",
"    </a>",
"    ]. Congenital cholesteatomas account for 1 to 5 percent of cholesteatomas in most published series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 172 cases of congenital cholesteatoma between 1981 and 2000, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      72 percent of cases occurred in boys",
"     </li>",
"     <li>",
"      The average age was five years",
"     </li>",
"     <li>",
"      Nearly one-half of cases involved &ge;2 quadrants; 82 percent of cases confined to one quadrant were in the anterosuperior quadrant (",
"      <a class=\"graphic graphic_figure graphicRef57110 \" href=\"mobipreview.htm?25/31/26099\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The ossicular chain and mastoid were involved in 43 percent and 23 percent of cases, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cholesteatomas are bilateral in approximately 4 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/9\">",
"     9",
"    </a>",
"    ]. Bilateral congenital cholesteatomas are more common in boys, whereas bilateral acquired cholesteatomas are more common in girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predisposing factors for acquired cholesteatoma include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of recurrent acute otitis media",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic middle ear effusions",
"     </li>",
"     <li>",
"      Older age at first placement of tympanostomy tubes, and increasing number of, and longer interval between, insertions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cleft palate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/9,10,13,14\">",
"       9,10,13,14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Craniofacial anomalies",
"     </li>",
"     <li>",
"      Turner syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Down syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Family history of chronic middle ear disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cholesteatoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Congenital",
"    </span>",
"    &nbsp;&mdash;&nbsp;The origin of the squamous epithelium in congenital cholesteatomas is a matter of debate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/11,20,21\">",
"     11,20,21",
"    </a>",
"    ]. The most widely held theory holds that squamous inclusion cysts arise from epithelial rests in the middle ear and that failed involution leads to cholesteatoma behind the intact TM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/22\">",
"     22",
"    </a>",
"    ]. This theory is supported by the histologic demonstration of single or multiple epidermoid formations in fetal temporal bones that typically disappear before birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/23\">",
"     23",
"    </a>",
"    ]. Alternative theories suggest that the middle ear is seeded by squamous cells in the amniotic fluid or from bits of the outer surface of the TM following infection or microperforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acquired",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retraction pocket &mdash; Acquired cholesteatomas usually arise from focal retractions of the TM. Retraction pockets are invaginations of the TM that form in patients with chronic eustachian tube dysfunction, negative middle ear pressure, and focal collapse of the TM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. As the retraction pocket is progressively pulled into the middle ear space, it forms a large pouch with a narrow neck. The pouch traps desquamating cells, forming a cholesteatoma lined by the metabolically active epithelium of the TM and filled with dead keratin debris (",
"      <a class=\"graphic graphic_figure graphicRef56231 \" href=\"mobipreview.htm?17/47/18160\">",
"       figure 2",
"      </a>",
"      ). The metabolically active squamous epithelium has the ability to erode bone: first the delicate ossicles (",
"      <a class=\"graphic graphic_picture graphicRef75737 \" href=\"mobipreview.htm?1/53/1872\">",
"       picture 2",
"      </a>",
"      ) and then the solid cortices of the temporal bone. The keratin debris may become infected following water exposure or a middle ear infection, resulting in chronic purulent drainage (",
"      <a class=\"graphic graphic_picture graphicRef76079 \" href=\"mobipreview.htm?6/8/6272\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Natural history and complications'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Areas of predilection for retraction pockets include old tympanostomy tube sites, the posterosuperior portion of the TM overlying the entrance to the mastoid, and the pars flaccida at the top of the TM (",
"      <a class=\"graphic graphic_figure graphicRef64096 \" href=\"mobipreview.htm?21/36/22086\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/27\">",
"       27",
"      </a>",
"      ]. Structural variations in the fibrous layer of the tympanic membrane may account for weakness in these areas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other mechanisms &mdash; Less common mechanisms by which squamous epithelium may enter the middle ear include [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/20\">",
"       20",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Through a perforation at the outer edge of the TM (",
"      <a class=\"graphic graphic_picture graphicRef79099 \" href=\"mobipreview.htm?21/32/22016\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Through a temporal bone fracture (",
"      <a class=\"graphic graphic_picture graphicRef53944 \" href=\"mobipreview.htm?19/23/19825\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      As a complication of tympanostomy tube placement (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3978?source=see_link&amp;anchor=H28#H28\">",
"       \"Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes\", section on 'Cholesteatoma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      By creeping along a retained tympanostomy tube (",
"      <a class=\"graphic graphic_picture graphicRef54627 \" href=\"mobipreview.htm?14/46/15077\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesteatomas that are not surgically excised may continue to enlarge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    become secondarily infected.",
"   </p>",
"   <p>",
"    Complications of cholesteatoma include hearing loss, cranial nerve palsies (facial (seventh cranial nerve), abducens (sixth cranial nerve)), other neurologic signs and symptoms (eg, vertigo), venous thrombosis, and potentially life-threatening infections (eg, brain abscess, meningitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/4,5,29-33\">",
"     4,5,29-33",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Congenital cholesteatoma may grow for years without causing symptoms, which highlights the importance of careful examination of the middle ear during routine health care maintenance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/8,34\">",
"     8,34",
"    </a>",
"    ]. In a review of 172 cases of congenital cholesteatoma from a single institution, the average age at diagnosis was five years; the ossicular chain was involved in 43 percent and the mastoid in 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the late stages, cholesteatoma (congenital or acquired) can destroy intratemporal structures, causing sensorineural deafness or paralysis of the facial nerve. It can erode through the walls of the mastoid, compressing the temporal lobe of the brain or presenting as a subcutaneous mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56423 \" href=\"mobipreview.htm?33/46/34531\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25257?source=see_link\">",
"     \"Facial nerve palsy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advanced cholesteatomas may become secondarily infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/35\">",
"     35",
"    </a>",
"    ]. The organisms most commonly cultured from infected cholesteatomas include Pseudomonas aeruginosa, Proteus species, Bacteroides, and Peptococcus-Peptostreptococcus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/2\">",
"     2",
"    </a>",
"    ]. Chronic bacterial infection may result in retrograde thrombosis of the cerebral veins leading to formation of epidural abscess, a surgical emergency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early detection of cholesteatoma requires careful otoscopic examination at routine health-maintenance visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/1,37\">",
"     1,37",
"    </a>",
"    ]. Early detection may avoid hearing loss and the need for extensive surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The otoscope's light source must have adequate brightness. Cerumen removal may be necessary to expose the entire TM. Particular attention should be paid to the posterosuperior quadrant and anterosuperior quadrant (",
"    <a class=\"graphic graphic_figure graphicRef57110 \" href=\"mobipreview.htm?25/31/26099\">",
"     figure 1",
"    </a>",
"    ), the most frequent locations of acquired and congenital cholesteatomas, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12823?source=see_link&amp;anchor=H9#H9\">",
"     \"Cerumen\", section on 'Cerumen removal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otoscopy may be difficult if there is middle ear fluid or the child is not cooperative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/2\">",
"     2",
"    </a>",
"    ]. In such cases, if cholesteatoma is suspected, referral to otolaryngology for examination under anesthesia may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/2\">",
"     2",
"    </a>",
"    ]. Computed tomography (CT) of the temporal bone is another option but is less helpful if there is fluid in the middle ear, since middle ear fluid and cholesteatoma have the same appearance on CT. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Ancillary evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of cholesteatoma should be considered in children with any of the following signs or symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/1,38\">",
"     1,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A white mass behind an intact TM (",
"      <a class=\"graphic graphic_picture graphicRef72870 \" href=\"mobipreview.htm?34/39/35440\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef59937 \" href=\"mobipreview.htm?20/54/21344\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef76079 \" href=\"mobipreview.htm?6/8/6272\">",
"       picture 3",
"      </a>",
"      ); this is the most common presentation for congenital cholesteatomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/8,39\">",
"       8,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A deep retraction pocket with or without granulation and skin debris, as in panel A (",
"      <a class=\"graphic graphic_picture graphicRef54514 \" href=\"mobipreview.htm?41/35/42550\">",
"       picture 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Focal granulation on the surface of the TM, especially at the periphery (",
"      <a class=\"graphic graphic_picture graphicRef72182 \" href=\"mobipreview.htm?35/19/36144\">",
"       picture 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      New-onset hearing loss in an ear that has undergone surgery. It is important to test hearing periodically in children with a history of recurrent or persistent middle ear disease; children rarely complain of hearing loss, particularly if it is unilateral [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ear drainage for more than two weeks despite appropriate treatment. Chronic ear drainage is the most common presentation for acquired cholesteatomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with these findings should be referred to an otolaryngologist for confirmation of the diagnosis and definitive management. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Surgical treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Congenital cholesteatomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital cholesteatomas can occur anywhere in the temporal bone but have a predilection for the anterosuperior quadrant of the middle ear, just above the eustachian tube opening (",
"    <a class=\"graphic graphic_picture graphicRef72870 \" href=\"mobipreview.htm?34/39/35440\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/8,40\">",
"     8,40",
"    </a>",
"    ]. Congenital cholesteatomas in this location may obstruct the eustachian tube opening early in the course, resulting in middle ear effusion, which can complicate the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/8,41\">",
"     8,41",
"    </a>",
"    ]. Congenital cholesteatomas also occur in the posterosuperior quadrant (",
"    <a class=\"graphic graphic_picture graphicRef70826 \" href=\"mobipreview.htm?7/53/8031\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early in development, a congenital cholesteatoma may appear as a subtle whitish discoloration or spherical white cyst behind an otherwise normal-appearing TM (",
"    <a class=\"graphic graphic_picture graphicRef59937 \" href=\"mobipreview.htm?20/54/21344\">",
"     picture 7",
"    </a>",
"    ). As the lesion grows, it makes contact with the underside of the TM and becomes more obvious. With further expansion, the cholesteatoma can replace the middle ear space; the normal variegated appearance of the middle ear space is replaced by a bulging, white mass, which displaces the TM outwardly (",
"    <a class=\"graphic graphic_picture graphicRef50092 \" href=\"mobipreview.htm?1/21/1362\">",
"     picture 11",
"    </a>",
"    ). Perforation of the TM and chronic ear drainage are late findings; they usually follow the onset of hearing loss by months or years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean age of diagnosis is four to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/7,8,42\">",
"     7,8,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acquired cholesteatomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features suggestive of acquired cholesteatomas include deep retraction pockets, as in panel A (",
"    <a class=\"graphic graphic_picture graphicRef54514 \" href=\"mobipreview.htm?41/35/42550\">",
"     picture 8",
"    </a>",
"    ), a white mass behind the TM (",
"    <a class=\"graphic graphic_picture graphicRef76079 \" href=\"mobipreview.htm?6/8/6272\">",
"     picture 3",
"    </a>",
"    ), focal granulation at the periphery of the TM (",
"    <a class=\"graphic graphic_picture graphicRef72182 \" href=\"mobipreview.htm?35/19/36144\">",
"     picture 9",
"    </a>",
"    ), new-onset hearing loss, and ear drainage for more than two weeks despite treatment.",
"   </p>",
"   <p>",
"    Retraction pockets are recognized by careful examination of the TM. They are said to be \"shallow\" when the full extent of the pocket is visible by otoscopy (",
"    <a class=\"graphic graphic_picture graphicRef82650 \" href=\"mobipreview.htm?42/12/43200\">",
"     picture 12",
"    </a>",
"    ). They are \"deep\" when they disappear into the crevices of the middle ear or into the mastoid air spaces, as in panel A (",
"    <a class=\"graphic graphic_picture graphicRef54514 \" href=\"mobipreview.htm?41/35/42550\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Deep pockets can collect debris that cannot be seen with otoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/43\">",
"     43",
"    </a>",
"    ]; they are assumed to be cholesteatomas until proven otherwise. If a retraction pocket expands into the middle ear, its mouth may be visible near the edge of the TM; the cholesteatoma sac, filled with dead keratin debris, may appear as a white mass behind the TM (",
"    <a class=\"graphic graphic_picture graphicRef76079 \" href=\"mobipreview.htm?6/8/6272\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cholesteatoma includes other white lesions of the TM. The following lesions may be easily confused with cholesteatomas (",
"    <a class=\"graphic graphic_picture graphicRef62245 \" href=\"mobipreview.htm?0/50/804\">",
"     picture 13",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tympanosclerosis, or whitish plaques of calcium and phosphate crystals (",
"      <a class=\"graphic graphic_picture graphicRef58460 \" href=\"mobipreview.htm?33/59/34751\">",
"       picture 14",
"      </a>",
"      ). These plaques are firm, contained within the middle layer of the TM, and move with the TM during pneumatic otoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/39\">",
"       39",
"      </a>",
"      ]; however, TM movement may be decreased or absent in patients with tympanosclerosis. In contrast, cholesteatomas are soft, occupy the middle ear space, and do not move with the TM during pneumatic otoscopy.",
"     </li>",
"     <li>",
"      White foreign bodies (",
"      <a class=\"graphic graphic_picture graphicRef73085 \" href=\"mobipreview.htm?2/11/2226\">",
"       picture 15",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Exostoses (",
"      <a class=\"graphic graphic_picture graphicRef53371 \" href=\"mobipreview.htm?7/44/7872\">",
"       picture 16",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prosthetic and graft material in operated ears.",
"     </li>",
"     <li>",
"      Inclusion cysts of TM (",
"      <a class=\"graphic graphic_picture graphicRef54229 \" href=\"mobipreview.htm?39/8/40078\">",
"       picture 17",
"      </a>",
"      ); these lesions occupy the middle layers of the TM but do not extend into the middle ear. Similar to tympanosclerosis lesions, but unlike cholesteatomas, inclusion cysts of the TM move with the TM during pneumatic otoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, a bulging acute otitis media may be hard to differentiate from a large congenital cholesteatoma (",
"    <a class=\"graphic graphic_picture graphicRef76431 \" href=\"mobipreview.htm?41/46/42735\">",
"     picture 18",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The history may be helpful in differentiating cholesteatoma from some of these lesions (eg, foreign body, prosthetic and graft material). Pneumatic otoscopy may help in differentiating others, but should not be attempted if foreign body is suspected. Otomicroscopy with palpation or CT may be necessary to differentiate these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesteatoma should be suspected in children with a white mass behind an intact TM (",
"    <a class=\"graphic graphic_picture graphicRef72870 \" href=\"mobipreview.htm?34/39/35440\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59937 \" href=\"mobipreview.htm?20/54/21344\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76079 \" href=\"mobipreview.htm?6/8/6272\">",
"     picture 3",
"    </a>",
"    ), a deep retraction pocket, as in panel A (",
"    <a class=\"graphic graphic_picture graphicRef54514 \" href=\"mobipreview.htm?41/35/42550\">",
"     picture 8",
"    </a>",
"    ), focal granulation on the surface of the TM especially at the periphery (",
"    <a class=\"graphic graphic_picture graphicRef72182 \" href=\"mobipreview.htm?35/19/36144\">",
"     picture 9",
"    </a>",
"    ), new-onset hearing loss in a previously operated ear, and an ear that continues to drain for more than two weeks despite treatment for acute infection.",
"   </p>",
"   <p>",
"    Careful visual examination of the entire TM and performance of pneumatic otoscopy during routine health maintenance visits are critical to early detection. Early lesions are best detected by inspecting the outer edges of the TM.",
"   </p>",
"   <p>",
"    The diagnosis of cholesteatoma is confirmed by the otolaryngologist using visual examination, palpation under an operating microscope, CT, MRI,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical exploration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/38,44,45\">",
"     38,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ancillary evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ancillary evaluation for suspected cholesteatoma should include audiometric testing to detect associated hearing loss. Cholesteatoma usually is associated with some degree of conductive hearing loss (maximum threshold of 50 dB), although hearing may be normal if the ossicular chain is not involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ancillary evaluation also usually includes CT of the temporal bone to confirm the nature and extent of the lesion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56423 \" href=\"mobipreview.htm?33/46/34531\">",
"     image 1",
"    </a>",
"    ) and presence of complications. However, an experienced otolaryngologist may sometimes remove a small congenital cholesteatoma without performing CT.",
"   </p>",
"   <p>",
"    When an effusion is present, some surgeons prefer to place a tympanostomy tube and examine the ear under anesthesia as a preliminary step [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/39,46\">",
"     39,46",
"    </a>",
"    ]. Tube placement enhances the value of CT by introducing air into the middle ear and mastoid (CT does not permit differentiation between fluid and the soft tissue density of the cholesteatoma). Preliminary tympanostomy tube placement also improves the chance of finding a dry, uninflamed middle ear at the time of cholesteatoma removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of surgical treatment are eradication of the keratinizing squamous epithelium from the temporal bone and preservation or restoration of hearing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two general approaches to surgical treatment of cholesteatoma:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete excision with tympanoplasty and reconstruction of the ossicles (ossiculoplasty) as necessary",
"     </li>",
"     <li>",
"      Exteriorization forming a skin-lined cavity with good access for cleaning of trapped debris",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first approach is desirable when it is feasible. Factors that are considered in decision-making include the skill of the operating surgeon and the availability of the child for regular follow-up to monitor for recurrence. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risks of ear surgery include hearing loss, facial nerve palsy, cerebrospinal fluid leak, and TM perforation, in addition to the general risks of surgery (eg, bleeding, infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/11,39\">",
"     11,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Early cholesteatoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital &mdash; Small, congenital cholesteatomas are usually treated by middle ear exploration and simple excision. Access to the TM is either through the ear canal or via a postauricular incision, reflecting the pinna out of the way for better exposure.",
"      <br/>",
"      <br/>",
"      The TM is reflected downward after incision of the ear canal skin (",
"      <a class=\"graphic graphic_figure graphicRef58365 \" href=\"mobipreview.htm?12/13/12503\">",
"       figure 4",
"      </a>",
"      ) and elevation of the top half of the tympanic annulus. Usually the TM is left attached to the end of the malleus (umbo). The cyst is detached from its mucosal connections and delivered intact. The TM is returned to its normal anatomic position.",
"     </li>",
"     <li>",
"      Retraction pocket &mdash; Early retraction pocket cholesteatomas may be successfully treated with middle ear ventilation and mechanical reduction of the retraction pocket [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/46,48-50\">",
"       46,48-50",
"      </a>",
"      ]. Tympanostomy tube placement (with or without adenoidectomy) releases the vacuum that retracts the TM. Once the middle ear is ventilated, it is often possible to mechanically reduce the pocket by removing debris and sucking the pocket out with a small Frazier ear suction (",
"      <a class=\"graphic graphic_picture graphicRef54514 \" href=\"mobipreview.htm?41/35/42550\">",
"       picture 8",
"      </a>",
"      ). The stretched segment of TM will return to its normal appearance, though it remains thin and will appear hypermobile on pneumatic otoscopy. It may retract again once the tube extrudes, so follow-up is important [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3978?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes\", section on 'Postoperative care'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Retraction pockets that cannot be reduced require excision and grafting of the TM. For lesions limited to the middle ear, exploration of the middle ear and microdissection of the cholesteatoma sac (matrix) is usually sufficient. Otoendoscopes facilitate complete resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/51\">",
"       51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Because the cholesteatoma sac is a retracted portion of the TM, its removal produces a hole that must be repaired, usually with the thin, strong fascia overlying the temporalis muscle. Tympanostomy tube placement (with or without adenoidectomy) at the time of grafting or at the first sign of retraction may prevent recurrent cholesteatoma formation.",
"      <br/>",
"      <br/>",
"      If the ossicles have been damaged by the osteolytic effects of the cholesteatoma or if it was necessary to remove a portion of the ossicles to fully expose the cholesteatoma, the ossicular chain is reconstructed using bone, cartilage, or prosthetic material. Hearing results are generally good if the stapes superstructure can be spared. Conductive hearing losses usually result if only the footplate of the stapes is left [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Advanced cholesteatoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a cholesteatoma (congenital or acquired) has extended beyond the accessible confines of the middle ear, middle ear exploration is usually inadequate to permit complete removal. To reach the temporal bone spaces above and behind the middle ear, it is necessary to remove the overlying plates of cranial bone (",
"    <a class=\"graphic graphic_figure graphicRef71262 \" href=\"mobipreview.htm?7/15/7413\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The pneumatized space just superior to the middle ear is called the epitympanum or attic. The attic contains the head of the malleus and the body of the incus. When cholesteatoma enters the attic, it often encircles the ossicular heads and cannot be freed, even when visualized with a microscope or angled endoscope. In such cases, the overlying bone, called the scutum, must be drilled away for access (",
"    <a class=\"graphic graphic_figure graphicRef71262 \" href=\"mobipreview.htm?7/15/7413\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/53\">",
"     53",
"    </a>",
"    ]. The atticotomy should be reconstructed with cartilage from the pinna to prevent post-operative retraction of the TM.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mastoid disease &mdash; Cholesteatoma involving the mastoid is treated by mastoidectomy (the surgical removal of the mastoid cortical bone and underlying air cells to gain access to the cholesteatoma). There are several variations in surgical approach, but mastoidectomies generally are of two types: canal-wall-up mastoidectomy (complete, simple, cortical mastoidectomy) and canal-wall-down mastoidectomy (modified radical mastoidectomy or radical mastoidectomy). The \"canal\" part of these terms refers to the posterior portion of the external auditory canal that separates the canal from the mastoid air cells.",
"     </li>",
"     <li>",
"      In canal-wall-up surgery (closed-cavity procedures), the posterior portion of the external auditory canal is preserved. In such cases, the healed ear usually looks normal when examined with an otoscope (",
"      <a class=\"graphic graphic_figure graphicRef58420 \" href=\"mobipreview.htm?41/36/42562\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In canal-wall-down surgery (open-cavity procedures), the posterior portion of the external auditory canal is sacrificed. A common cavity (mastoid bowl) is created between the ear canal and mastoid, and often the middle ear. Regular otolaryngology follow-up for cleaning of squamous debris from the mastoid bowl is required, usually for life (",
"      <a class=\"graphic graphic_picture graphicRef52515 \" href=\"mobipreview.htm?14/31/14836\">",
"       picture 19",
"      </a>",
"      ). Canal-wall-down surgery usually includes enlargement of the soft tissue opening of the ear canal (meatoplasty) to facilitate cleaning. Cleaning of the mastoid bowl may be uncomfortable for young children. Older children and adults sometimes complain of discomfort and dizziness, even when the bowl is cleaned skillfully.",
"      <br/>",
"      <br/>",
"      The canal-wall-up approach is usually preferred when it is possible. On the other hand, canal-wall-down surgery is a time-tested, safe alternative for children with large cholesteatomas, destruction of the ear canal, or failure of canal-wall-up surgery, and in whom regular follow-up for assessment of recurrence cannot be assured. Without regular cleaning, a foul-smelling mastoid bowl may result as accumulated squamous debris or wax becomes secondarily infected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence is uncommon in children with small, encapsulated congenital cholesteatomas that are removed intact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/11,39,54\">",
"     11,39,54",
"    </a>",
"    ]. The risk of recurrence is increased with infiltrative lesions that require piecemeal excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/39\">",
"     39",
"    </a>",
"    ]. In a large series of cases of congenital cholesteatoma, recurrence was related to the extent of involvement at the time of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      14 percent when disease was confined to one quadrant",
"     </li>",
"     <li>",
"      33 percent when &gt;1 quadrant was involved but the ossicles and mastoids were not",
"     </li>",
"     <li>",
"      41 percent with ossicular involvement",
"     </li>",
"     <li>",
"      67 percent with mastoid involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another series of patients with congenital cholesteatoma, residual disease was associated with [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher initial stage of disease",
"     </li>",
"     <li>",
"      Ossicular erosion",
"     </li>",
"     <li>",
"      Need for removal of the ossicles",
"     </li>",
"     <li>",
"      Cholesteatoma abutting or enveloping the incus or stapes",
"     </li>",
"     <li>",
"      Cholesteatoma medial to the malleus or incus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrence rates for children with acquired cholesteatoma vary widely depending upon the methodology and the duration of follow-up; the five-year recurrence rate may be as high as 57 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/47,56\">",
"     47,56",
"    </a>",
"    ]. Risk factors for recurrence include age &lt;8 years, poor eustachian tube function, large cholesteatoma, cholesteatoma in the sinus tympani,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erosion or destruction of bones in the ossicular chain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/47,56-59\">",
"     47,56-59",
"    </a>",
"    ]. The increased risk of recurrence highlights the need for regular postoperative follow-up, as described below.",
"   </p>",
"   <p>",
"    Hearing is usually stable or improved if the stapes superstructure is spared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/8,52,60\">",
"     8,52,60",
"    </a>",
"    ]. Factors related to satisfactory hearing outcome include less ossicular damage and better preoperative hearing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/52,60,61\">",
"     52,60,61",
"    </a>",
"    ]. In one series of 349 patients, most of whom underwent canal-down mastoidectomy, hearing improved in 30 percent (mean gain 5 dB), remained unchanged in 55 percent, and worsened in 15 percent at a mean follow-up of 7.3 years; 30 percent of ears had a hearing threshold of 30 dB or better [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients who present with cranial nerve palsies, outcome is related to timeliness of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/62\">",
"     62",
"    </a>",
"    ]. Recovery of function is possible with early intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have been treated for cholesteatoma require regular follow-up postoperatively to prevent and control recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children treated with excision and grafting require careful monitoring for at least two years after surgery. Even tiny fragments of cholesteatoma matrix can grow into a cholesteatoma (residual cholesteatoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/57\">",
"     57",
"    </a>",
"    ]. In addition, the same forces that caused the first cholesteatoma to form can cause the grafted TM to collapse, predisposing to the development of recurrent cholesteatoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up examinations include careful visualization of the ear under the operating microscope, annual audiograms, and imaging (usually by computed tomography) if recurrence is suspected. Clinical manifestations of",
"    <span class=\"nowrap\">",
"     residual/recurrent",
"    </span>",
"    cholesteatoma include chronic otorrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforation of the TM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42808/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children with advanced cholesteatoma who are treated with canal-wall-down surgery require regular follow-up for cleaning of squamous debris from the mastoid bowl, usually for life. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Advanced cholesteatoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cholesteatoma is an abnormal accumulation of squamous epithelium within the middle ear and mastoid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Predisposing factors for acquired cholesteatoma include recurrent acute otitis media",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic middle ear effusions, family history of chronic middle ear disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cholesteatoma, certain syndromes (eg, Down syndrome, Turner syndrome), and congenital anomalies (eg, cleft palate, craniofacial anomalies). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Predisposing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cholesteatomas that are not surgically excised continue to enlarge. Complications may include hearing loss, cranial nerve palsies, vertigo, and potentially life-threatening infection (eg, meningitis, brain abscess). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Natural history and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early detection and treatment of cholesteatoma reduce the risk of complications. Early detection requires careful otoscopic examination at routine health-maintenance visits. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of cholesteatoma should be considered in children with a white mass behind an intact TM (",
"      <a class=\"graphic graphic_picture graphicRef72870 \" href=\"mobipreview.htm?34/39/35440\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef76079 \" href=\"mobipreview.htm?6/8/6272\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef59937 \" href=\"mobipreview.htm?20/54/21344\">",
"       picture 7",
"      </a>",
"      ), deep retraction pocket, as in panel A (",
"      <a class=\"graphic graphic_picture graphicRef54514 \" href=\"mobipreview.htm?41/35/42550\">",
"       picture 8",
"      </a>",
"      ), focal granulation on the surface of the TM, new-onset hearing loss in an ear that has undergone surgery, and ear drainage for more than two weeks despite appropriate treatment. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of cholesteatoma is confirmed by the otolaryngologist using visual examination, palpation under an operating microscope, computed tomography (CT),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical exploration. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of surgical treatment are eradication of the keratinizing squamous epithelium from the temporal bone and preservation or restoration of hearing. Factors that are considered in decision-making include the skill of the operating surgeon and the availability of the child for regular follow-up to monitor for recurrence. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrence of cholesteatoma occurs in more than 50 percent of patients within five years of surgery. Risk factors for recurrence include poor eustachian tube function, large cholesteatoma, and erosion of the ossicular chain. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children require careful monitoring for at least two years after surgery. Signs of recurrence include chronic drainage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      perforation of the TM. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/1\">",
"      Isaacson G. Diagnosis of pediatric cholesteatoma. Pediatrics 2007; 120:603.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestone CD, Klein JO. Intratemporal complications and sequelae of otitis media. In: Pediatric otolaryngology, 4th ed, Bluestone CD, Casselbrant ML, Stool SE, et al (Eds), Saunders, Philadelphia 2003. p.687.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/3\">",
"      Shirazi MA, Muzaffar K, Leonetti JP, Marzo S. Surgical treatment of pediatric cholesteatomas. Laryngoscope 2006; 116:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/4\">",
"      Liu JH, Rutter MJ, Choo DI, Willging JP. Congenital cholesteatoma of the middle ear. Clin Pediatr (Phila) 2000; 39:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/5\">",
"      Greenberg JS, Manolidis S. High incidence of complications encountered in chronic otitis media surgery in a U.S. metropolitan public hospital. Otolaryngol Head Neck Surg 2001; 125:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/6\">",
"      Derlacki EL, Clemis JD. Congenital cholesteatoma of the middle ear and mastoid. Ann Otol Rhinol Laryngol 1965; 74:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/7\">",
"      Levenson MJ, Parisier SC, Chute P, et al. A review of twenty congenital cholesteatomas of the middle ear in children. Otolaryngol Head Neck Surg 1986; 94:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/8\">",
"      Potsic WP, Korman SB, Samadi DS, Wetmore RF. Congenital cholesteatoma: 20 years' experience at The Children's Hospital of Philadelphia. Otolaryngol Head Neck Surg 2002; 126:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/9\">",
"      Kemppainen HO, Puhakka HJ, Laippala PJ, et al. Epidemiology and aetiology of middle ear cholesteatoma. Acta Otolaryngol 1999; 119:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/10\">",
"      Spilsbury K, Miller I, Semmens JB, Lannigan FJ. Factors associated with developing cholesteatoma: a study of 45,980 children with middle ear disease. Laryngoscope 2010; 120:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/11\">",
"      Bennett M, Warren F, Jackson GC, Kaylie D. Congenital cholesteatoma: theories, facts, and 53 patients. Otolaryngol Clin North Am 2006; 39:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/12\">",
"      Lin V, Daniel S, James A, Friedberg J. Bilateral cholesteatomas: the hospital for sick children experience. J Otolaryngol 2004; 33:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/13\">",
"      Sheahan P, Blayney AW, Sheahan JN, Earley MJ. Sequelae of otitis media with effusion among children with cleft lip and/or cleft palate. Clin Otolaryngol Allied Sci 2002; 27:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/14\">",
"      Dominguez S, Harker LA. Incidence of cholesteatoma with cleft palate. Ann Otol Rhinol Laryngol 1988; 97:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/15\">",
"      Dhooge IJ, De Vel E, Verhoye C, et al. Otologic disease in turner syndrome. Otol Neurotol 2005; 26:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/16\">",
"      Bacciu A, Pasanisi E, Vincenti V, et al. Surgical treatment of middle ear cholesteatoma in children with Down syndrome. Otol Neurotol 2005; 26:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/17\">",
"      Prinsley P. Familial cholesteatoma in East Anglia, UK. J Laryngol Otol 2009; 123:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/18\">",
"      Hom&oslash;e P, Rosborg J. Family cluster of cholesteatoma. J Laryngol Otol 2007; 121:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/19\">",
"      Podoshin L, Fradis M, Ben-David Y, et al. Cholesteatoma: an epidemiologic study among members of kibbutzim in northern Israel. Ann Otol Rhinol Laryngol 1986; 95:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/20\">",
"      Semaan MT, Megerian CA. The pathophysiology of cholesteatoma. Otolaryngol Clin North Am 2006; 39:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/21\">",
"      Persaud R, Hajioff D, Trinidade A, et al. Evidence-based review of aetiopathogenic theories of congenital and acquired cholesteatoma. J Laryngol Otol 2007; 121:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/22\">",
"      Liang J, Michaels L, Wright A. Immunohistochemical characterization of the epidermoid formation in the middle ear. Laryngoscope 2003; 113:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/23\">",
"      Kayhan FT, Mutlu C, Schachern PA, et al. Significance of epidermoid formations in the middle ear in fetuses and children. Arch Otolaryngol Head Neck Surg 1997; 123:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/24\">",
"      Mueller DT, Schwetschenau EL, Isaacson G. Occult contralateral congenital cholesteatoma: is the epidermoid formation theory enough? Am J Otolaryngol 2004; 25:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/25\">",
"      Eavey RD, Camacho A, Northrop CC. Chronic ear pathology in a model of neonatal amniotic fluid ear inoculation. Arch Otolaryngol Head Neck Surg 1992; 118:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/26\">",
"      Tos M. A new pathogenesis of mesotympanic (congenital) cholesteatoma. Laryngoscope 2000; 110:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/27\">",
"      Lau T, Tos M. Tensa retraction cholesteatoma: treatment and long-term results. J Laryngol Otol 1989; 103:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/28\">",
"      Pa&ccedil;o J, Branco C, Estibeiro H, Oliveira E Carmo D. The posterosuperior quadrant of the tympanic membrane. Otolaryngol Head Neck Surg 2009; 140:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/29\">",
"      Prescott CA. Cholesteatoma in children--the experience at The Red Cross War Memorial Children's Hospital in South Africa 1988-1996. Int J Pediatr Otorhinolaryngol 1999; 49:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/30\">",
"      Matanda RN, Muyunga KC, Sabue MJ, et al. Chronic suppurative otitis media and related complications at the University Clinic of Kinshasa. B-ENT 2005; 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/31\">",
"      Mustafa A, Heta A, Kastrati B, Dreshaj Sh. Complications of chronic otitis media with cholesteatoma during a 10-year period in Kosovo. Eur Arch Otorhinolaryngol 2008; 265:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/32\">",
"      Maksimovi�� Z, Rukovanjski M. Intracranial complications of cholesteatoma. Acta Otorhinolaryngol Belg 1993; 47:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/33\">",
"      Smith JA, Danner CJ. Complications of chronic otitis media and cholesteatoma. Otolaryngol Clin North Am 2006; 39:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/34\">",
"      Grundfast KM, Ahuja GS, Parisier SC, Culver SM. Delayed diagnosis and fate of congenital cholesteatoma (keratoma). Arch Otolaryngol Head Neck Surg 1995; 121:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/35\">",
"      Migirov L, Yakirevitch A, Kronenberg J. Mastoid subperiosteal abscess: a review of 51 cases. Int J Pediatr Otorhinolaryngol 2005; 69:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/36\">",
"      Manolidis S, Kutz JW Jr. Diagnosis and management of lateral sinus thrombosis. Otol Neurotol 2005; 26:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/37\">",
"      Schwartz RH, Grundfast KM, Feldman B, et al. Cholesteatoma medial to an intact tympanic membrane in 34 young children. Pediatrics 1984; 74:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/38\">",
"      Semple CW, Mahadevan M, Berkowitz RG. Extensive acquired cholesteatoma in children: when the penny drops. Ann Otol Rhinol Laryngol 2005; 114:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/39\">",
"      Sie KC. Cholesteatoma in children. Pediatr Clin North Am 1996; 43:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/40\">",
"      Koltai PJ, Nelson M, Castellon RJ, et al. The natural history of congenital cholesteatoma. Arch Otolaryngol Head Neck Surg 2002; 128:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/41\">",
"      Levenson MJ, Michaels L, Parisier SC. Congenital cholesteatomas of the middle ear in children: origin and management. Otolaryngol Clin North Am 1989; 22:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/42\">",
"      McGill TJ, Merchant S, Healy GB, Friedman EM. Congenital cholesteatoma of the middle ear in children: a clinical and histopathological report. Laryngoscope 1991; 101:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/43\">",
"      Palacios E, Valvassori G. Congenital cholesteatoma of the middle ear. Ear Nose Throat J 1998; 77:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/44\">",
"      De Foer B, Vercruysse JP, Bernaerts A, et al. Middle ear cholesteatoma: non-echo-planar diffusion-weighted MR imaging versus delayed gadolinium-enhanced T1-weighted MR imaging--value in detection. Radiology 2010; 255:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/45\">",
"      Plouin-Gaudon I, Bossard D, Ayari-Khalfallah S, Froehlich P. Fusion of MRIs and CT scans for surgical treatment of cholesteatoma of the middle ear in children. Arch Otolaryngol Head Neck Surg 2010; 136:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/46\">",
"      Mueller DT, Isaacson G. Staged tympanostomy tube placement facilitates pediatric cholesteatoma management. Int J Pediatr Otorhinolaryngol 2008; 72:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/47\">",
"      Rosenfeld RM, Moura RL, Bluestone CD. Predictors of residual-recurrent cholesteatoma in children. Arch Otolaryngol Head Neck Surg 1992; 118:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/48\">",
"      Grimes ER, Isaacson G. The mechanical reduction of early acquired cholesteatomas in children: indications and limitations. Ear Nose Throat J 2006; 85:252, 254, 256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/49\">",
"      Bluestone CD, Cantekin EI, Beery QC, Stool SE. Function of the Eustachian tube related to surgical management of acquired aural cholesteatoma in children. Laryngoscope 1978; 88:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/50\">",
"      Blaney SP, Tierney P, Bowdler DA. The surgical management of the pars tensa retraction pocket in the child--results following simple excision and ventilation tube insertion. Int J Pediatr Otorhinolaryngol 1999; 50:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/51\">",
"      Good GM, Isaacson G. Otoendoscopy for improved pediatric cholesteatoma removal. Ann Otol Rhinol Laryngol 1999; 108:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/52\">",
"      Lin VY, Campisi P, Friedberg J. Why do some children have good hearing results following type III and IV tympanoplasty? Current theories of middle ear mechanics. J Otolaryngol 2006; 35:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/53\">",
"      East DM. Atticotomy with reconstruction for limited cholesteatoma. Clin Otolaryngol Allied Sci 1998; 23:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/54\">",
"      Lazard DS, Roger G, Denoyelle F, et al. Congenital cholesteatoma: risk factors for residual disease and retraction pockets--a report on 117 cases. Laryngoscope 2007; 117:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/55\">",
"      Stapleton AL, Egloff AM, Yellon RF. Congenital cholesteatoma: predictors for residual disease and hearing outcomes. Arch Otolaryngol Head Neck Surg 2012; 138:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/56\">",
"      Stangerup SE, Drozdziewicz D, Tos M, Trabalzini F. Surgery for acquired cholesteatoma in children: long-term results and recurrence of cholesteatoma. J Laryngol Otol 1998; 112:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/57\">",
"      Stangerup SE, Drozdziewicz D, Tos M. Cholesteatoma in children, predictors and calculation of recurrence rates. Int J Pediatr Otorhinolaryngol 1999; 49 Suppl 1:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/58\">",
"      Maassen MM, Plinkert PK, Diedrichs H, et al. [Functional long-term results after open cholesteatoma surgery and ossiculoplasty with allogenic ossicles in adulthood]. Laryngorhinootologie 1998; 77:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/59\">",
"      McRackan TR, Abdellatif WM, Wanna GB, et al. Evaluation of second look procedures for pediatric cholesteatomas. Otolaryngol Head Neck Surg 2011; 145:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/60\">",
"      Vartiainen E, Vartiainen J. Hearing results of surgery for acquired cholesteatoma. Ear Nose Throat J 1995; 74:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/61\">",
"      Chadha NK, Jardine A, Owens D, et al. A multivariate analysis of the factors predicting hearing outcome after surgery for cholesteatoma in children. J Laryngol Otol 2006; 120:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/62\">",
"      Siddiq MA, Hanu-Cernat LM, Irving RM. Facial palsy secondary to cholesteatoma: analysis of outcome following surgery. J Laryngol Otol 2007; 121:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42808/abstract/63\">",
"      Roger G, Denoyelle F, Chauvin P, et al. Predictive risk factors of residual cholesteatoma in children: a study of 256 cases. Am J Otol 1997; 18:550.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6306 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42808=[""].join("\n");
var outline_f41_51_42808=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Congenital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acquired",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NATURAL HISTORY AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Congenital cholesteatomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acquired cholesteatomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ancillary evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Early cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Advanced cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6306|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/46/34531\" title=\"diagnostic image 1\">",
"      Cholesteatoma CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6306|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/31/26099\" title=\"figure 1\">",
"      Tympanic membrane anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/47/18160\" title=\"figure 2\">",
"      Cholesteatoma mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/36/22086\" title=\"figure 3\">",
"      Cholesteatoma extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/13/12503\" title=\"figure 4\">",
"      ME cholesteatoma removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/15/7413\" title=\"figure 5\">",
"      Removal scutum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/36/42562\" title=\"figure 6\">",
"      Removal cholesteatoma with extension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6306|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/39/35440\" title=\"picture 1\">",
"      Congenital cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/53/1872\" title=\"picture 2\">",
"      Erosion incus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/8/6272\" title=\"picture 3\">",
"      Cholesteatoma pars flaccida",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/32/22016\" title=\"picture 4\">",
"      Marginal TM perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/23/19825\" title=\"picture 5\">",
"      Cholesteatoma associated with old temporal bone fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/46/15077\" title=\"picture 6\">",
"      Retained tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/54/21344\" title=\"picture 7\">",
"      Early congenital cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/35/42550\" title=\"picture 8\">",
"      Rtxn pocket cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/19/36144\" title=\"picture 9\">",
"      Focal granulation TM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/53/8031\" title=\"picture 10\">",
"      Congenital cholesteatoma in the superior posterior quadrant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/21/1362\" title=\"picture 11\">",
"      Middle ear cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/12/43200\" title=\"picture 12\">",
"      TM retraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/50/804\" title=\"picture 13\">",
"      TM change not cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/59/34751\" title=\"picture 14\">",
"      Tympanosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/11/2226\" title=\"picture 15\">",
"      Foreign bodies ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/44/7872\" title=\"picture 16\">",
"      Ear canal exostoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/8/40078\" title=\"picture 17\">",
"      Intra TM squamous pearl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/46/42735\" title=\"picture 18\">",
"      Bulging AOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/31/14836\" title=\"picture 19\">",
"      Mastoid bowl",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12823?source=related_link\">",
"      Cerumen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25257?source=related_link\">",
"      Facial nerve palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3978?source=related_link\">",
"      Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_51_42809="Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis";
var content_f41_51_42809=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42809/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42809/contributors\">",
"     Dennis K Ledford, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42809/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42809/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/51/42809/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/51/42809/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/51/42809/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing general anesthesia and surgery can experience complex physiologic changes. Recognition of an allergic reaction that occurs during anesthesia is potentially compromised by variability of vital signs during anesthesia, the inability of the anesthetized patient to communicate early symptoms such as itching, and coverage of the patient by surgical drapes that may obscure detection of cutaneous signs.",
"   </p>",
"   <p>",
"    The prevalence, etiology, risk factors, clinical manifestations, and acute diagnosis of anaphylaxis during general anesthesia will be reviewed here. The evaluation of a patient who has experienced perioperative anaphylaxis and prevention of recurrent reactions, as well as the treatment of anaphylaxis from any cause are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/442?source=see_link\">",
"     \"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Mechanisms of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is an acute, potentially lethal, multisystem syndrome resulting from the sudden release of mast cell- and basophil-derived mediators into the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18778?source=see_link\">",
"     \"Pathophysiology of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this review (and increasingly in the literature), the term anaphylaxis applies to all of the following (",
"    <a class=\"graphic graphic_table graphicRef57346 \" href=\"mobipreview.htm?1/60/1996\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute reactions involving IgE-dependent mechanisms, which account for approximately 60 percent of perioperative anaphylaxis reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute reactions involving immunologic mechanisms other than specific IgE (also termed non-IgE-mediated immunologic anaphylaxis and formerly called anaphylactoid reactions); included in this category are reactions mediated by IgG or IgM antibodies or by antigen:antibody complexes and complement.",
"     </li>",
"     <li>",
"      Acute reactions arising independently of any immunologic mechanism, ie, involving direct release of histamine and other mediators from mast cells and basophils; potential mechanisms for these reactions are numerous [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The various mechanisms leading to activation of mast cells and basophils are increasingly grouped together under the term anaphylaxis because the initial management of these reactions is the same, regardless of the trigger or mechanism involved, and the clinical severity of the reactions may be similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, several of the agents that are commonly implicated in perioperative anaphylaxis, such as neuromuscular blocking agents, are capable of causing reactions through more than one mechanism (",
"    <a class=\"graphic graphic_table graphicRef60805 \" href=\"mobipreview.htm?8/5/8284\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Despite the similarities, there are important differences in the evaluation, prevention, and prognosis of the various types of reactions (",
"    <a class=\"graphic graphic_table graphicRef57346 \" href=\"mobipreview.htm?1/60/1996\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate-type skin testing methods (ie, prick-puncture and intradermal techniques) are only useful in evaluating IgE-mediated reactions.",
"     </li>",
"     <li>",
"      The severity of IgE-mediated reactions can increase with subsequent administration of the causal agent, while the severity of repeat reactions arising from other mechanisms usually remains similar.",
"     </li>",
"     <li>",
"      Some IgE-mediated reactions are amenable to desensitization techniques if retreatment is required.",
"     </li>",
"     <li>",
"      Reactions that are not IgE-mediated (eg, almost all radiocontrast reactions) may be reduced in frequency or intensity by pretreatment with antihistamines and glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin testing, desensitization, and pretreatment medications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/442?source=see_link\">",
"     \"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of anaphylaxis during general anesthesia is 1:10,000 to 1:20,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. The wide variability in estimates of prevalence and incidence reflects the difficulties in determining the denominator (or the total number of anesthesia cases), as well as limitations in diagnosing perianesthetic anaphylaxis. Perioperative anaphylaxis occurs equally in girls and boys, but is more common in women than men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of perioperative anaphylaxis can be divided into two groups (ie, more common and less common), based upon how often they are implicated. In a significant number of cases, however, a specific trigger cannot be identified. The best data about perioperative anaphylaxis are derived from a series of multicenter French surveys, which began in the mid 1990s and have continued to the present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     More common",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among cases in which a trigger could be identified, the most common causes were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/10,11,15\">",
"     10,11,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuromuscular blocking agents",
"     </li>",
"     <li>",
"      Latex",
"     </li>",
"     <li>",
"      Antibiotics (especially penicillins and cephalosporins)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These same groups of medications have been implicated in studies around the world, although the rank order may differ. Specifically, antibiotics appear to be the most common cause of perioperative anaphylaxis in the United States, while neuromuscular blocking agents are the most common cause in European studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Neuromuscular blocking agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fifty to 70 percent of anaphylaxis cases related to anesthesia were due to neuromuscular blocking agents (NMBAs) (also called muscle relaxants) making these agents the most common identifiable trigger in the French surveys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/10,11,15,18\">",
"     10,11,15,18",
"    </a>",
"    ]. However, the high rate of reactions attributed to NMBAs in some studies may be a result of the ability of these drugs to cause nonspecific skin test reactivity, resulting in these agents being misidentified as the cause of anaphylaxis. Skin testing to NMBAs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/442?source=see_link&amp;anchor=H12#H12\">",
"     \"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions\", section on 'Neuromuscular blocking agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NMBAs can cause anaphylaxis through both IgE-mediated and nonimmunologic direct mast cell activation (",
"    <a class=\"graphic graphic_table graphicRef60805 \" href=\"mobipreview.htm?8/5/8284\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Reactions resulting from direct mast cell activation are more common; however, severe reactions are usually IgE-mediated. Histamine release may be more prominent with certain NMBAs, such as tubocurarine, mivacurium,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    , and rapacuronium, and the latter agent was withdrawn from the US market because it was implicated in high rates of severe bronchospasm (without other symptoms) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Commonly implicated agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    (aka, suxamethonium), tubocurarine (no longer available in the United States and Canada, but used elsewhere), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    although this may largely reflect the frequency with which these agents are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/10,15\">",
"     10,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergy to NMBAs is more common in women than men, with three of four reactions occurring in females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. This phenomenon is believed due to cross-reactive tertiary or quaternary ammonium groups found in both NMBAs and a variety of topical cosmetics and personal products, as well as certain over-the-counter cough remedies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. These ammonium groups are highly immunoreactive multivalent epitopes in NMBAs which can induce drug-specific IgE antibodies. Allergic reactions to NMBAs can occur upon initial exposure, presumably following sensitization through exposure to these topical agents.",
"   </p>",
"   <p>",
"    Patients who react to one NMBA may react to others, as cross-reactivity has been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The shared quaternary ammonium group likely underlies this phenomenon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1262939\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics, administered before, during, or immediately after anesthesia, were responsible for 12 to 15 percent of identifiable triggers in the French studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. In an American series, antibiotics accounted for 50 percent of IgE-mediated reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/17\">",
"     17",
"    </a>",
"    ]. Beta lactam antibiotics (specifically penicillins and cephalosporins),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , and quinolones are the most common offenders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/10,15,28\">",
"     10,15,28",
"    </a>",
"    ]. Hypersensitivity reactions to these agents are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11130?source=see_link\">",
"     \"Cephalosporin allergy: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1978?source=see_link\">",
"     \"Vancomycin hypersensitivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Latex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural rubber latex accounted for approximately 20 percent of perioperative anaphylaxis cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/10,11,15\">",
"     10,11,15",
"    </a>",
"    ]. The percentage has been declining as the exposure to latex has been reduced in most surgical suites in the US and other countries.",
"   </p>",
"   <p>",
"    Anaphylaxis to latex is an IgE-mediated process resulting from the formation of specific-IgE against proteins from natural rubber latex. There are a variety of potential sources of latex in surgical and procedural settings (",
"    <a class=\"graphic graphic_table graphicRef51530 \" href=\"mobipreview.htm?18/18/18731\">",
"     table 3",
"    </a>",
"    ). The most common sources of significant latex exposure in the perioperative setting are those items that have prolonged contact with skin or mucosal surfaces, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gloves (sterile and exam)",
"     </li>",
"     <li>",
"      Drains (Penrose and others), and",
"     </li>",
"     <li>",
"      Catheters (indwelling, straight, and condom)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hard rubber items, such as straps, tubing, and blood pressure cuffs, elute little or no latex protein and do not contact patient tissues to the same extent. Items that are now usually latex-free include ambu-bags, catheter leg bag straps, bandages and adhesive pads, tape, electrode pads, endotracheal tubes, infusion sets and ports, and suction catheters.",
"   </p>",
"   <p>",
"    Reactions to latex tend to occur later in surgical procedures (eg, 30 minutes or more after the start of the intervention); symptoms may develop after visceral surfaces have been handled or manipulated by clinicians wearing latex gloves.",
"   </p>",
"   <p>",
"    Latex allergy is more likely in subjects with repeated exposure to latex gloves or catheters from prior surgeries or from occupational use, especially children with spina bifida and healthcare workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/29\">",
"     29",
"    </a>",
"    ]. Sensitization to latex can occur as a result of contact with nonmedical sources of latex as well (eg, condoms, balloons, household gloves) and reactions are not limited to patients in high-risk groups. Latex allergy is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link\">",
"     \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40070?source=see_link\">",
"     \"Latex allergy: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H597059\">",
"    <span class=\"h2\">",
"     Less common",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the French studies mentioned previously, the following groups of agents were implicated in 1 to 5 percent reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypnotic induction agents",
"     </li>",
"     <li>",
"      Opioids",
"     </li>",
"     <li>",
"      Colloids and plasma expanders",
"     </li>",
"     <li>",
"      Other agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hypnotic induction agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypnotic induction agents account for approximately 2 percent of perioperative anaphylaxis cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11\">",
"     11",
"    </a>",
"    ]. There are two types of induction agents: barbiturates (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/15/24823?source=see_link\">",
"     methohexital",
"    </a>",
"    ) and nonbarbiturates (eg, benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    ). Barbiturates are responsible for the majority of reactions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Barbiturates",
"      </strong>",
"      &mdash; Intravenous barbiturates are widely used in anesthesia, and as a class, they account for nearly all reactions to induction agents. Women are affected three times more often than men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/15,19\">",
"       15,19",
"      </a>",
"      ]. Most reactions caused by barbiturate induction agents are IgE-mediated, although direct mast cell activation has also been described (",
"      <a class=\"graphic graphic_table graphicRef60805 \" href=\"mobipreview.htm?8/5/8284\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/6,18,30,31\">",
"       6,18,30,31",
"      </a>",
"      ]. There is some immunologic cross-reactivity among the barbiturates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Nonbarbiturates",
"      </strong>",
"      &mdash; Anaphylaxis to nonbarbiturate induction agents is uncommon.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       Propofol",
"      </a>",
"      is a nonbarbiturate induction agent that was initially solubilized in Cremophor&reg; (polyethoxylated castor oil), a vehicle that was found to cause non-IgE-mediated anaphylactic reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/32\">",
"       32",
"      </a>",
"      ]. Subsequently, the vehicle for propofol was changed to a soybean oil emulsion with egg phosphatide and glycerol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. Allergic reactions to these newer preparations appear to be rare, although allergies to egg or soybean are listed in the product information as contraindications to use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/35\">",
"       35",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Benzodiazepines are also nonbarbiturate induction agents. Hypotension following intravenous administration is a known adverse effect of these agents, although anaphylactic reactions are rare. Benzodiazepines may be capable of activating mast cells in vitro [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/6\">",
"       6",
"      </a>",
"      ] and skin testing has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/36\">",
"       36",
"      </a>",
"      ], although the mechanism of this interaction is not well studied. Cross-reactivity between propofol and benzodiazepines has not been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Narcotics used in",
"    <span class=\"nowrap\">",
"     anesthesia/analgesia",
"    </span>",
"    are a common cause of flushing and urticaria following intravenous administration, although opioids rarely cause life-threatening reactions. Typically, opioids cause limited cutaneous symptoms via a non-IgE-mediated mechanism: dermal mast cells express a receptor for opioids; binding to this receptor stimulates release of histamine and other mediators, leading to flushing, urticaria, and angioedema. Specific-IgE to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    has been implicated in case reports, although skin testing with opioids is not feasible due to false positive results secondary to nonspecific mast cell activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Colloids and plasma expanders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colloids and plasma expanders, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/13/9430?source=see_link\">",
"     hetastarch",
"    </a>",
"    (hydroxyethyl starch, HES), accounted for about 3 percent of identifiable causes of perioperative anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. These agents are capable of causing both IgE-mediated and non-IgE mediated immunologic reactions. Reported rates of anaphylaxis were &lt;0.1 percent of administrations for each of several preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/18,39,40\">",
"     18,39,40",
"    </a>",
"    ]. Hetastarch is used in major surgeries expected to cause significant fluid shifts (eg, trauma). Dextran is less commonly used as a volume expander but its antiplatelet effects make it useful as an adjunct to some cardiovascular procedures.",
"   </p>",
"   <p>",
"    Albumin has also been implicated in rare perioperative anaphylactic reactions, although the mechanisms have not been explored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/26,41\">",
"     26,41",
"    </a>",
"    ]. In addition, gelatin in the plasma expanders polygeline (eg, Haemaccel&reg;) and succinylated gelatins (Gelofusin&reg;) has caused IgE-mediated anaphylactic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Gelatin-containing plasma expanders are not currently in use in the United States, although they are used in other countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other medications and agents have been implicated in anaphylaxis or reactions resembling anaphylaxis in susceptible individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/5\">",
"     5",
"    </a>",
"    ]. Collectively, these other agents account for less than 5 percent of all episodes of perioperative anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiocontrast agents (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31305?source=see_link\">",
"       \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Blood transfusion, including exposure to IgA in blood products in patients with severe IgA deficiency (undetectable IgA levels) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/30998?source=see_link\">",
"       \"Selective IgA deficiency: Management and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link\">",
"       \"Immunologic blood transfusion reactions\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Metabisulfites and bisulfites used as preservatives in medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=see_link\">",
"       \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The topical antiseptic agent and surgical scrub",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/45-49\">",
"       45-49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Povidone in the topical antiseptic povidone-iodine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"       Bacitracin",
"      </a>",
"      used in irrigation solutions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/51-55\">",
"       51-55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The sterilization agents ethylene oxide and ortho-phthalaldehyde (Cidex OPA&reg;) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/56-61\">",
"       56-61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Streptokinase or urokinase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/26/420?source=see_link\">",
"       Isosulfan blue dye",
"      </a>",
"      (used in sentinel node biopsies) and other supravital dyes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chymopapain (used in herniated disc surgery) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Insulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Papain and chymopapain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Local anesthetics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      and other anticoagulants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/74-76\">",
"       74-76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Protamine, used to reverse heparinization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=see_link\">",
"       Aprotinin",
"      </a>",
"      , administered either intravenously or as a component of biologic sealants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11,79-81\">",
"       11,79-81",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"       Hyaluronidase",
"      </a>",
"      , used to enhance the diffusion of other drugs and agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/82-84\">",
"       82-84",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for perioperative anaphylaxis include asthma, greater duration of anesthesia, female sex (for certain medications), past history of anaphylaxis, allergic drug reactions, other allergic conditions such as eczema or hay fever, multiple past surgeries or procedures (especially for latex and ethylene oxide), and mast cell disorders. However, even in patients at increased risk, perioperative anaphylaxis is still an uncommon event.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with asthma may be at higher risk for perioperative anaphylaxis (data are mixed), and have more severe respiratory symptoms during reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11,85,86\">",
"       11,85,86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women are at higher risk than men for reactions to NMBAs and hypnotic induction agents, although reactions are equal for males and females before adolescence.",
"     </li>",
"     <li>",
"      Previous medication reactions nonspecifically increase the possibility of future adverse medication reactions, and multiple previous drug reactions pose a proportionately greater risk.",
"     </li>",
"     <li>",
"      Patients with multiple past surgeries or other procedures may be at increased risk for latex allergy and reactions to NMBAs. Preoperative evaluation for latex allergy should be considered in patients with symptoms that suggest possible IgE-mediated latex hypersensitivity.",
"     </li>",
"     <li>",
"      Patients with mast cell disorders, including mast cell activation syndrome, monoclonal mast cell activation disorder, and systemic mastocytosis, are at increased risk for clinically significant mast cell mediator release from a variety of stimuli, including the administration of medications that cause nonspecific mast cell activation, and physiologic events during surgery (eg, handling of the bowel, extremes of temperature) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/87\">",
"       87",
"      </a>",
"      ]. Thus, these patients require specific precautionary management prior to procedures or surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39817?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment and prognosis of systemic mastocytosis\", section on 'Preparation for medical and surgical procedures'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20937?source=see_link&amp;anchor=H4290513#H4290513\">",
"       \"Mast cell activation disorders\", section on 'Clinical manifestations of mast cell activation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative anaphylaxis most commonly presents with cardiovascular, cutaneous, and respiratory signs and symptoms (if the patient is conscious), with variable involvement of other organ systems (",
"    <a class=\"graphic graphic_table graphicRef51806 \" href=\"mobipreview.htm?39/34/40491\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/88\">",
"     88",
"    </a>",
"    ]. Cardiovascular collapse is the first detected manifestation in up to 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachycardia is a classic cardiovascular sign of anaphylaxis, although bradycardia occasionally develops later in the reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bronchospasm may present as a sudden increase in the ventilatory pressure required to inflate the lungs, increase in end-tidal carbon dioxide, or decrease in arterial oxygen saturation.",
"     </li>",
"     <li>",
"      Rapidly developing laryngeal edema may present as difficulty with intubation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anaphylaxis during anesthesia may be particularly difficult to recognize for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early or mild symptoms, such as itching or shortness of breath, may go unnoticed because the patient cannot communicate.",
"     </li>",
"     <li>",
"      Cutaneous signs, such as flushing, urticaria, and angioedema, may be missed because the patient is draped for surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these factors, the reaction may be detected only when dramatic respiratory and hemodynamic changes develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis due to an IgE-mediated reaction usually develops within a few seconds to one hour of exposure to the trigger. Intravenous medications typically cause symptoms more rapidly than exposures through tissues or skin (eg, latex). Timing of the reaction with respect to the onset of anesthesia may provide additional clues to the underlying cause:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic reactions occurring during the first 30 minutes of anesthesia are more likely due to NMBAs or hypnotic induction agents, because these agents are given at the start of the procedure.",
"     </li>",
"     <li>",
"      Reactions presenting after the first 30 minutes are more likely due to antibiotics, latex, or miscellaneous agents such as protamine, plasma expanders, or supravital dyes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reactions may also occur after sudden shifts in blood or other fluids, such as removal of a tourniquet, unclamping of blood vessels, or after uterine manipulation followed by administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/10,90,91\">",
"     10,90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of mortality due to perioperative anaphylaxis range from 3 to 6 percent, with another 2 percent of patients surviving with brain damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/4,86\">",
"     4,86",
"    </a>",
"    ]. In contrast, anaphylaxis from all causes has been estimated to be fatal in 0.7 to 2 percent of cases, suggesting that perioperative reactions represent the severe end of the spectrum. This may be attributable to the intravenous route of drug administration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the factors that impair early recognition of reactions, as noted above. Another possibility is that individuals receiving anesthesia may be more vulnerable to physiologic perturbations. IgE-mediated anaphylaxis is generally more severe than non-IgE-mediated anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11\">",
"     11",
"    </a>",
"    ], although both types can be fatal. A review of fatal anaphylaxis from all causes is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ACUTE DIAGNOSIS AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of perioperative anaphylaxis is clinical and based upon the presence of characteristic signs and symptoms and a plausible time course. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment of anaphylaxis during anesthesia is the same as the management of anaphylaxis in other settings and is based upon prompt administration of epinephrine and fluid resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent evaluation for drug allergy should take place after the patient has recovered fully. This evaluation is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/442?source=see_link\">",
"     \"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Laboratory tests at the time of the reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood collected at the time of the reaction or shortly after may reveal elevations in mediators released by mast cells, such as tryptase or histamine. Instructions for proper collection of samples are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef72041 \" href=\"mobipreview.htm?21/8/21644\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Mediator release occurs transiently following massive mast cell activation in some patients, particularly those with hypotension. Elevations of mast cell mediators in the blood can help to distinguish anaphylaxis from other disorders that present similarly, although normal levels do not exclude anaphylaxis. Tryptase was elevated in 68 percent of IgE-mediated reactions and 4 percent of non-IgE-mediated reactions in the largest French study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11\">",
"     11",
"    </a>",
"    ]. The interpretation of laboratory tests in patients with anaphylaxis is discussed briefly here and in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum tryptase has a half-life of approximately two hours. Blood for serum tryptase should be collected as soon as possible after the onset of symptoms. Thirty minutes to three hours after the onset of symptoms is optimal, although very high elevations may be detectable for longer. Serum that was collected at the time of the reaction for other reasons can sometimes be retrieved at a later time and assayed. Tryptase is stable in frozen serum for up to a year.",
"     </li>",
"     <li>",
"      Plasma histamine is another mediator released from mast cells, which may be even more sensitive than tryptase for identifying anaphylaxis. However, the half-life of histamine is several minutes and elevations usually normalize within 30 minutes from the onset of symptoms, so blood should be drawn as near as possible to the peak of the reaction and the sample frozen to limit degradation of histamine if analysis is not immediate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/442?source=see_link\">",
"       \"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinary histamine metabolites",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prostaglandin metabolites may be increased following anaphylaxis. The primary degradation product of histamine is N-methylhistamine, and this compound has a longer half-life than histamine. Once the urine is collected, it can be refrigerated for up to 8 days before assay, 14 days if frozen. Prostaglandin D",
"      <sub>",
"       2",
"      </sub>",
"      and its primary metabolite, 11-&beta;-Prostaglandin F",
"      <sub>",
"       2",
"      </sub>",
"      , are also increased following mast cell activation. Some commercial laboratories perform these assays [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/92\">",
"       92",
"      </a>",
"      ]. Twenty-four urine collections are preferred, but limited urine collections may also be assayed. Normal results do not exclude the diagnosis but increased levels do support the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link&amp;anchor=H19#H19\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\", section on 'Histamine metabolites'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of an allergic or anaphylactic reaction during or following general anesthesia includes a broad list of reactions and physiologic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/28,93\">",
"     28,93",
"    </a>",
"    ]. Tryptase or histamine levels should be normal in ALL of these other disorders:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other causes of respiratory symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Malignant hyperthermia (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link\">",
"       \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myotonias and masseter spasm (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Post extubation stridor",
"     </li>",
"     <li>",
"      Pulmonary edema",
"     </li>",
"     <li>",
"      Pulmonary embolus",
"     </li>",
"     <li>",
"      Tension pneumothorax",
"     </li>",
"     <li>",
"      Transfusion related acute lung injury (TRALI)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21991?source=see_link\">",
"     \"Assessment of respiratory distress in the mechanically ventilated patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other causes of hypotension",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmia",
"     </li>",
"     <li>",
"      Cardiogenic shock",
"     </li>",
"     <li>",
"      Hemorrhage",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Hyperkalemia (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mastocytosis or mast cell activation disorder",
"     </li>",
"     <li>",
"      Overdosage of vasoactive drug",
"     </li>",
"     <li>",
"      Pericardial tamponade",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Vasovagal reaction",
"     </li>",
"     <li>",
"      Venous air embolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other causes of angioedema",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary or acquired angioedema (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=see_link\">",
"       \"Hereditary angioedema: Treatment of acute attacks\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment with ACE inhibitors and possibly angiotensin receptor blockers (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38391?source=see_link\">",
"       \"An overview of angioedema: Pathogenesis and causes\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other causes of urticaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold urticaria can occasionally be mistaken for perioperative anaphylaxis or a drug reaction. Cold urticaria can usually be excluded by negative results in an ice-cube challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/51/42809/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/22/15721?source=see_link\">",
"     \"Cold urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylaxis is a potentially lethal reaction resulting from the sudden, clinically significant release of mast cell-",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      basophil-derived mediators into the circulation. Both IgE-and non-IgE-mediated mechanisms have been implicated, and some agents may cause reactions by more than one mechanism (",
"      <a class=\"graphic graphic_table graphicRef57346 \" href=\"mobipreview.htm?1/60/1996\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60805 \" href=\"mobipreview.htm?8/5/8284\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common identifiable causes of",
"      <span class=\"nowrap\">",
"       perioperative/perianesthesia",
"      </span>",
"      anaphylaxis are NMBAs, antibiotics, latex, hypnotic induction agents (primarily barbiturates), opioids, and colloids. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors include asthma, female sex (for certain medications), other allergic conditions such as eczema or hay fever, multiple past surgeries or procedures (especially for latex), and mast cell disorders including mast cell activation syndrome, monoclonal mast cell activation syndrome, and systemic mastocytosis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perioperative anaphylaxis presents with cutaneous, respiratory, and cardiovascular signs and symptoms, as well as variable involvement of other organ systems (",
"      <a class=\"graphic graphic_table graphicRef51806 \" href=\"mobipreview.htm?39/34/40491\">",
"       table 4",
"      </a>",
"      ). One-half of cases are initially detected as sudden cardiovascular collapse. Bronchospasm may present as an increase in the ventilatory pressure required to inflate the lungs or as a decrease in arterial oxygen saturation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perioperative anaphylaxis tends to be severe and has a higher mortality rate than anaphylaxis occurring in other settings. This is at least partly attributable to factors that impair early recognition of anaphylaxis, such as the inability of the patient to report initial symptoms and coverage of the skin with surgical drapes. The intravenous administration of drugs and concomitant stresses of surgery or illness may also contribute. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of perioperative anaphylaxis is clinical. An elevated serum total tryptase, plasma histamine level, or elevated histamine metabolites in the urine, obtained at appropriate time intervals during and after the reaction are highly suggestive of anaphylaxis, although normal levels do not exclude the diagnosis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Acute diagnosis and treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/1\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/2\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/3\">",
"      Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/4\">",
"      Mertes PM, Laxenaire MC, Lienhart A, et al. Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice. J Investig Allergol Clin Immunol 2005; 15:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/5\">",
"      Chacko T, Ledford D. Peri-anesthetic anaphylaxis. Immunol Allergy Clin North Am 2007; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/6\">",
"      Genovese A, Stellato C, Marsella CV, et al. Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Int Arch Allergy Immunol 1996; 110:13.",
"     </a>",
"    </li>",
"    <li>",
"     Levy J. Complement and contact activation. In: Anaphylactic reactions in anesthesia and intensive care, Levy J (Ed), Butterworth-Heinemann, Boston 1992. p.51.",
"    </li>",
"    <li>",
"     Lieberman P. Anaphylaxis and anaphylactoid reactions. In: Middleton's allergy: Principles and practice, 6th ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St. Louis 2003. p.1497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/9\">",
"      Fisher MM, Baldo BA. The incidence and clinical features of anaphylactic reactions during anesthesia in Australia. Ann Fr Anesth Reanim 1993; 12:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/10\">",
"      Laxenaire MC. [Epidemiology of anesthetic anaphylactoid reactions. Fourth multicenter survey (July 1994-December 1996)]. Ann Fr Anesth Reanim 1999; 18:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/11\">",
"      Mertes PM, Alla F, Tr&eacute;chot P, et al. Anaphylaxis during anesthesia in France: an 8-year national survey. J Allergy Clin Immunol 2011; 128:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/12\">",
"      Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol 2011; 21:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/13\">",
"      Dong SW, Mertes PM, Petitpain N, et al. Hypersensitivity reactions during anesthesia. Results from the ninth French survey (2005-2007). Minerva Anestesiol 2012; 78:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/14\">",
"      Mertes PM, Demoly P, Malinovsky JM. Hypersensitivity reactions in the anesthesia setting/allergic reactions to anesthetics. Curr Opin Allergy Clin Immunol 2012; 12:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/15\">",
"      Mertes PM, Laxenaire MC, Alla F, Groupe d'Etudes des R&eacute;actions Anaphylacto&iuml;des Peranesth&eacute;siques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 2003; 99:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/16\">",
"      Harboe T, Guttormsen AB, Irgens A, et al. Anaphylaxis during anesthesia in Norway: a 6-year single-center follow-up study. Anesthesiology 2005; 102:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/17\">",
"      Gurrieri C, Weingarten TN, Martin DP, et al. Allergic reactions during anesthesia at a large United States referral center. Anesth Analg 2011; 113:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/18\">",
"      Birnbaum J, Porri F, Pradal M, et al. Allergy during anaesthesia. Clin Exp Allergy 1994; 24:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/19\">",
"      Baldo BA, Fisher MM. Mechanisms in IgE-dependent anaphylaxis to anesthetic drugs. Ann Fr Anesth Reanim 1993; 12:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/20\">",
"      Koppert W, Blunk JA, Petersen LJ, et al. Different patterns of mast cell activation by muscle relaxants in human skin. Anesthesiology 2001; 95:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/21\">",
"      Doenicke AW, Czeslick E, Moss J, Hoernecke R. Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration. Anesth Analg 1998; 87:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/22\">",
"      Veien M, Szlam F, Holden JT, et al. Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology 2000; 92:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/23\">",
"      Jooste E, Klafter F, Hirshman CA, Emala CW. A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism. Anesthesiology 2003; 98:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/24\">",
"      Baldo BA, Fisher MM. Substituted ammonium ions as allergenic determinants in drug allergy. Nature 1983; 306:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/25\">",
"      Harboe T, Johansson SG, Florvaag E, Oman H. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. Allergy 2007; 62:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/26\">",
"      Leynadier F, Sansarricq M, Didier JM, Dry J. Prick tests in the diagnosis of anaphylaxis to general anaesthetics. Br J Anaesth 1987; 59:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/27\">",
"      Baldo BA, Fisher MM. Anaphylaxis to muscle relaxant drugs: cross-reactivity and molecular basis of binding of IgE antibodies detected by radioimmunoassay. Mol Immunol 1983; 20:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/28\">",
"      Mertes PM, Tajima K, Regnier-Kimmoun MA, et al. Perioperative anaphylaxis. Med Clin North Am 2010; 94:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/29\">",
"      Chaiear N, Foulds I, Burge PS. Prevalence and risk factors for latex allergy. Occup Environ Med 2000; 57:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/30\">",
"      Moscicki RA, Sockin SM, Corsello BF, et al. Anaphylaxis during induction of general anesthesia: subsequent evaluation and management. J Allergy Clin Immunol 1990; 86:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/31\">",
"      Hirshman CA, Edelstein RA, Ebertz JM, Hanifin JM. Thiobarbiturate-induced histamine release in human skin mast cells. Anesthesiology 1985; 63:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/32\">",
"      Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology 2005; 103:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/33\">",
"      Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des 2004; 10:3639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/34\">",
"      Wang H, Cork R, Rao A. Development of a new generation of propofol. Curr Opin Anaesthesiol 2007; 20:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/35\">",
"      Hofer KN, McCarthy MW, Buck ML, Hendrick AE. Possible anaphylaxis after propofol in a child with food allergy. Ann Pharmacother 2003; 37:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/36\">",
"      Palacios Benito R, Dom&iacute;nguez Ortega J, Alonso Llamazares A, et al. Adverse reaction to tetrazepam. J Investig Allergol Clin Immunol 2001; 11:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/37\">",
"      Gooch I, Gwinnutt C. Anaphylaxis to intrathecal diamorphine. Resuscitation 2006; 70:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/38\">",
"      Bennett MJ, Anderson LK, McMillan JC, et al. Anaphylactic reaction during anaesthesia associated with positive intradermal skin test to fentanyl. Can Anaesth Soc J 1986; 33:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/39\">",
"      Zinderman CE, Landow L, Wise RP. Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. J Vasc Surg 2006; 43:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/40\">",
"      Wiedermann CJ. Hydroxyethyl starch--can the safety problems be ignored? Wien Klin Wochenschr 2004; 116:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/41\">",
"      Fujita A, Kitayama M, Hirota K. Anaphylactoid shock in a patient following 5% human serum albumin infusion during off-pump coronary artery bypass grafting. J Anesth 2007; 21:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/42\">",
"      Vervloet D, Senft M, Dugue P, et al. Anaphylactic reactions to modified fluid gelatins. J Allergy Clin Immunol 1983; 71:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/43\">",
"      Russell WJ, Fenwick DG. Anaphylaxis to Haemaccel and cross reactivity to Gelofusin. Anaesth Intensive Care 2002; 30:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/44\">",
"      Yang WH, Purchase EC, Rivington RN. Positive skin tests and Prausnitz-K&uuml;stner reactions in metabisulfite-sensitive subjects. J Allergy Clin Immunol 1986; 78:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/45\">",
"      Thong CL, Lambros M, Stewart MG, Kam PC. An unexpected cause of an acute hypersensitivity reaction during recovery from anaesthesia. Anaesth Intensive Care 2005; 33:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/46\">",
"      Knight BA, Puy R, Douglass J, et al. Chlorhexidine anaphylaxis: a case report and review of the literature. Intern Med J 2001; 31:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/47\">",
"      Garvey LH, Roed-Petersen J, Menn&eacute; T, Husum B. Danish Anaesthesia Allergy Centre - preliminary results. Acta Anaesthesiol Scand 2001; 45:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/48\">",
"      Parkes AW, Harper N, Herwadkar A, Pumphrey R. Anaphylaxis to the chlorhexidine component of Instillagel: a case series. Br J Anaesth 2009; 102:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/49\">",
"      Garvey LH, Kr&oslash;igaard M, Poulsen LK, et al. IgE-mediated allergy to chlorhexidine. J Allergy Clin Immunol 2007; 120:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/50\">",
"      L&oacute;pez S&aacute;ez MP, de Barrio M, Zubeldia JM, et al. Acute IgE-mediated generalized urticaria-angioedema after topical application of povidone-iodine. Allergol Immunopathol (Madr) 1998; 26:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/51\">",
"      Blas M, Briesacher KS, Lobato EB. Bacitracin irrigation: a cause of anaphylaxis in the operating room. Anesth Analg 2000; 91:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/52\">",
"      Sprung J, Schedewie HK, Kampine JP. Intraoperative anaphylactic shock after bacitracin irrigation. Anesth Analg 1990; 71:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/53\">",
"      Damm S. Intraoperative anaphylaxis associated with bacitracin irrigation. Am J Health Syst Pharm 2011; 68:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/54\">",
"      Sharif S, Goldberg B. Detection of IgE antibodies to bacitracin using a commercially available streptavidin-linked solid phase in a patient with anaphylaxis to triple antibiotic ointment. Ann Allergy Asthma Immunol 2007; 98:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/55\">",
"      Freiler JF, Steel KE, Hagan LL, et al. Intraoperative anaphylaxis to bacitracin during pacemaker change and laser lead extraction. Ann Allergy Asthma Immunol 2005; 95:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/56\">",
"      Ebo DG, Bosmans JL, Couttenye MM, Stevens WJ. Haemodialysis-associated anaphylactic and anaphylactoid reactions. Allergy 2006; 61:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/57\">",
"      Grammer LC, Roberts M, Wiggins CA, et al. A comparison of cutaneous testing and ELISA testing for assessing reactivity to ethylene oxide-human serum albumin in hemodialysis patients with anaphylactic reactions. J Allergy Clin Immunol 1991; 87:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/58\">",
"      Suzukawa M, Komiya A, Koketsu R, et al. Three cases of ortho-phthalaldehyde-induced anaphylaxis after laryngoscopy: detection of specific IgE in serum. Allergol Int 2007; 56:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/59\">",
"      Sokol WN. Nine episodes of anaphylaxis following cystoscopy caused by Cidex OPA (ortho-phthalaldehyde) high-level disinfectant in 4 patients after cytoscopy. J Allergy Clin Immunol 2004; 114:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/60\">",
"      Cooper DE, White AA, Werkema AN, Auge BK. Anaphylaxis following cystoscopy with equipment sterilized with Cidex OPA (ortho-phthalaldehyde): a review of two cases. J Endourol 2008; 22:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/61\">",
"      Suzukawa M, Yamaguchi M, Komiya A, et al. Ortho-phthalaldehyde-induced anaphylaxis after laryngoscopy. J Allergy Clin Immunol 2006; 117:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/62\">",
"      McGrath KG, Patterson R. Anaphylactic reactivity to streptokinase. JAMA 1984; 252:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/63\">",
"      Pechlaner C, Knapp E, Wiedermann CJ. Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase. Blood Coagul Fibrinolysis 2001; 12:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/64\">",
"      Haque RA, Wagner A, Whisken JA, et al. Anaphylaxis to patent blue V: a case series and proposed diagnostic protocol. Allergy 2010; 65:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/65\">",
"      Scherer K, Studer W, Figueiredo V, Bircher AJ. Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: case report and review of the nomenclature of vital blue dyes. Ann Allergy Asthma Immunol 2006; 96:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/66\">",
"      Pinkowski JL, Leeson MC. Anaphylactic shock associated with chymopapain skin test. A case report and review of the literature. Clin Orthop Relat Res 1990; :186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/67\">",
"      Smith MB, Hofmann VC. Anaphylactoid reaction to chymopapain. Anaesthesia 1989; 44:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/68\">",
"      Wonders J, Eekhoff EM, Heine R, et al. [Insulin allergy: background, diagnosis and treatment]. Ned Tijdschr Geneeskd 2005; 149:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/69\">",
"      Grammer L. Insulin allergy. Clin Rev Allergy 1986; 4:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/70\">",
"      Nordby EJ, Wright PH, Schofield SR. Safety of chemonucleolysis. Adverse effects reported in the United States, 1982-1991. Clin Orthop Relat Res 1993; :122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/71\">",
"      Moneret-Vautrin DA, Feldmann L, Kanny G, et al. Incidence and risk factors for latent sensitization to chymopapain: predictive skin-prick tests in 700 candidates for chemonucleolysis. Clin Exp Allergy 1994; 24:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/72\">",
"      Phillips JF, Yates AB, Deshazo RD. Approach to patients with suspected hypersensitivity to local anesthetics. Am J Med Sci 2007; 334:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/73\">",
"      Ring J, Franz R, Brockow K. Anaphylactic reactions to local anesthetics. Chem Immunol Allergy 2010; 95:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/74\">",
"      Veach SA, Franks AM, Allan MC. Severe anaphylactic reaction after repeated intermittent exposure to lepirudin. Pharmacotherapy 2007; 27:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/75\">",
"      Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 2006; 61:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/76\">",
"      Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin-induced recurrent anaphylaxis. Clin Exp Allergy 2004; 34:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/77\">",
"      Park KW. Protamine and protamine reactions. Int Anesthesiol Clin 2004; 42:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/78\">",
"      Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol 2008; 103:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/79\">",
"      Kober BJ, Scheule AM, Voth V, et al. Anaphylactic reaction after systemic application of aprotinin triggered by aprotinin-containing fibrin sealant. Anesth Analg 2008; 107:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/80\">",
"      Levy JH, Adkinson NF Jr. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg 2008; 106:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/81\">",
"      Dietrich W, Ebell A, Busley R, Boulesteix AL. Aprotinin and anaphylaxis: analysis of 12,403 exposures to aprotinin in cardiac surgery. Ann Thorac Surg 2007; 84:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/82\">",
"      Ebo DG, Goossens S, Opsomer F, et al. Flow-assisted diagnosis of anaphylaxis to hyaluronidase. Allergy 2005; 60:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/83\">",
"      Quhill F, Bowling B, Packard RB. Hyaluronidase allergy after peribulbar anesthesia with orbital inflammation. J Cataract Refract Surg 2004; 30:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/84\">",
"      Eberhart AH, Weiler CR, Erie JC. Angioedema related to the use of hyaluronidase in cataract surgery. Am J Ophthalmol 2004; 138:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/85\">",
"      Fisher MM, More DG. The epidemiology and clinical features of anaphylactic reactions in anaesthesia. Anaesth Intensive Care 1981; 9:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/86\">",
"      Fisher M. Anaphylaxis to anaesthetic drugs. Novartis Found Symp 2004; 257:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/87\">",
"      Bridgman DE, Clarke R, Sadleir PH, et al. Systemic mastocytosis presenting as intraoperative anaphylaxis with atypical features: a report of two cases. Anaesth Intensive Care 2013; 41:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/88\">",
"      Laxenaire MC, Mertes PM, Groupe d'Etudes des R&eacute;actions Anaphylacto&iuml;des Peranesth&eacute;siques. Anaphylaxis during anaesthesia. Results of a two-year survey in France. Br J Anaesth 2001; 87:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/89\">",
"      Jacobsen J, Secher NH. Slowing of the heart during anaphylactic shock. A report of five cases. Acta Anaesthesiol Scand 1988; 32:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/90\">",
"      Laxenaire MC, Mouton C, Fr&eacute;d&eacute;ric A, et al. [Anaphylactic shock after tourniquet removal in orthopedic surgery]. Ann Fr Anesth Reanim 1996; 15:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/91\">",
"      Anderson A, Eilers H, Yost CS. Anaphylaxis complicating graft reperfusion during orthotopic liver transplantation: a case report. Transplant Proc 2010; 42:1967.",
"     </a>",
"    </li>",
"    <li>",
"     At the time of this review, this test was available at Mayo Medical Laboratories. Other laboratories may also perform it. file://www.mayomedicallaboratories.com (Accessed on June 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/93\">",
"      Ledford DK. Allergy, anaphylaxis and general anesthesia. Immunology Allergy Clin North Am 2001; 21:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/51/42809/abstract/94\">",
"      Siebenhaar F, Weller K, Mlynek A, et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol 2007; 32:241.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2077 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42809=[""].join("\n");
var outline_f41_51_42809=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Mechanisms of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      More common",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Neuromuscular blocking agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1262939\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Latex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H597059\">",
"      Less common",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hypnotic induction agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Opioids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Colloids and plasma expanders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ACUTE DIAGNOSIS AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Laboratory tests at the time of the reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other causes of respiratory symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other causes of hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other causes of angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other causes of urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2077\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2077|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/60/1996\" title=\"table 1\">",
"      Imm and nonimm anaphylx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/5/8284\" title=\"table 2\">",
"      Periop ana agents mech",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/18/18731\" title=\"table 3\">",
"      Articles containing latex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/34/40491\" title=\"table 4\">",
"      Perioperative anaphylaxis vs general",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/8/21644\" title=\"table 5\">",
"      Tryptase and histamine collection instructions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21991?source=related_link\">",
"      Assessment of respiratory distress in the mechanically ventilated patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11130?source=related_link\">",
"      Cephalosporin allergy: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/22/15721?source=related_link\">",
"      Cold urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40070?source=related_link\">",
"      Latex allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20937?source=related_link\">",
"      Mast cell activation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18778?source=related_link\">",
"      Pathophysiology of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/442?source=related_link\">",
"      Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/30998?source=related_link\">",
"      Selective IgA deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1978?source=related_link\">",
"      Vancomycin hypersensitivity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_51_42810="Biventricular enlarge tutorial";
var content_f41_51_42810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1239px;\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Combined ventricular hypertrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ECG satisfies voltage criteria for left ventricular hypertrophy (S in V2 + R in V5 &gt;35 mm), combined with a prominent R wave in V1 and right axis deviation (suggestive of right ventricular hypertrophy).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42810=[""].join("\n");
var outline_f41_51_42810=null;
var title_f41_51_42811="Chylous ascites features";
var content_f41_51_42811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of ascitic fluid in chylous ascites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Color",
"       </td>",
"       <td>",
"        Milky and cloudy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Triglyceride level",
"       </td>",
"       <td>",
"        Above 200 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Cell count",
"       </td>",
"       <td>",
"        Above 500 (predominance of lymphocytes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Total protein",
"       </td>",
"       <td>",
"        Between 2.5 - 7.0 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        SAAG",
"       </td>",
"       <td>",
"        Below 1.1 g/dL*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Cholesterol",
"       </td>",
"       <td>",
"        Low (ascites/serum ratio &lt;1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Lactate dehydrogenase",
"       </td>",
"       <td>",
"        Between 110 - 200 IU/liter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Culture",
"       </td>",
"       <td>",
"        Positive in selected cases of tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Adenosine deaminase",
"       </td>",
"       <td>",
"        Elevated in cases of tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Cytology",
"       </td>",
"       <td>",
"        Positive in malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Glucose",
"       </td>",
"       <td>",
"        Under 100 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Amylase",
"       </td>",
"       <td>",
"        Elevated (&gt;40 IU/liter) in cases of acute or chronic pancreatitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SAAG: serum-ascites albumin gradient; IU: international units.",
"     <br>",
"      * Level above 1.1 g/dL in chylous ascites secondary to cirrhosis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42811=[""].join("\n");
var outline_f41_51_42811=null;
var title_f41_51_42812="AMA impairment classification";
var content_f41_51_42812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The American Medical Association classification scheme for respiratory impairment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class 1 (no impairment of the",
"whole person)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class 2 (10 to 25%, moderate",
"impairment of the whole person)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class 3 (30 to 45%, moderate",
"impairment of the whole person)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class 4 (50 to 100%, severe",
"impairment of the whole person)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        FVC",
"       </td>",
"       <td>",
"        &ge;80%",
"predicted",
"       </td>",
"       <td>",
"        60 to 79% predicted",
"       </td>",
"       <td>",
"        51 to 59% predicted",
"       </td>",
"       <td>",
"        &le;50%",
"predicted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        FEV1 predicted",
"       </td>",
"       <td>",
"        &ge;80%",
"predicted",
"       </td>",
"       <td>",
"        60 to 79% predicted",
"       </td>",
"       <td>",
"        51 to 59% predicted",
"       </td>",
"       <td>",
"        &le;40%",
"predicted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        FEV1/FVC x 100",
"       </td>",
"       <td>",
"        &ge;70%",
"       </td>",
"       <td>",
"        60 to 69%",
"       </td>",
"       <td>",
"        41 to 59%",
"       </td>",
"       <td>",
"        &le;40%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        DLCOsb",
"       </td>",
"       <td>",
"        &ge;80%",
"predicted",
"       </td>",
"       <td>",
"        60 to 79% predicted",
"       </td>",
"       <td>",
"        41 to 59% predicted",
"       </td>",
"       <td>",
"        &le;40%",
"predicted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VO2 max",
"       </td>",
"       <td>",
"        &ge;25",
"mL/(kg min)",
"       </td>",
"       <td>",
"        Between 20 and 25 mL/(kg min)",
"       </td>",
"       <td>",
"        Between 15 and 20 mL/(kg min)",
"       </td>",
"       <td>",
"        &lt;15 mL/(kg min)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; DLCOsb: single-breath carbon monoxide diffusing capacity of the lungs; V02 max: maximum aerobic power.",
"     <br>",
"      *&nbsp;Predicted values based on height, age, and sex of white Americans. These prediction values should be used when applying the American Medical Association criteria for respiratory impairment.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Guidelines to the Evaluation of Permanent Impairment, 3. Chicago, American Medical Association, 1988, p.107.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42812=[""].join("\n");
var outline_f41_51_42812=null;
var title_f41_51_42813="Buddy taping toe PI";
var content_f41_51_42813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Buddy taping of the toes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 180px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Buddy taping involves taping the injured toe to the toe next to it. Some cotton or other soft material should be put between the toes so they don't rub together.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42813=[""].join("\n");
var outline_f41_51_42813=null;
var title_f41_51_42814="Trim toenails PI";
var content_f41_51_42814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F80053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F80053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trim your toenails",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 222px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADeASsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAG7/ajf7UyigB+/wBqN/tTKKAH7/ak3+1NooAduNJuPrSUUALuPrRuPrSUUALuPrSFyO9G7A56GsG51mJWZY2G0HA5p2A3WmCDLdKha8UHrXJ3euKAPmHX1rKm14ZO1ufrTsK56CL1SRyKm89a84i19+PmFbWn63k8sKTVgudeGJGQaNx9azYNTWQD5hmrS3SNwcE0guWNx9aNxpgZDShl7GgDB8UeM9I8MMg1k38SMExLDptzcRZZtiqXjjZQxbACk55HHIrT0bVoNXs/tNrHeJHuK4u7Oa1fI/2JVVse+MVy/wAQ7O61fVfB+nQW8z2v9rJfXcyoSkcdujSKGI4G6QRgZ64NYOvaIl94i8aeJNQ0KTULjSrOK20hJrUy73jiaYtChHzEySqoYAnKEA9aBnplhfR31sJ4UnVCzLieB4WyrEH5XAOMjg4wRgjIINWd/tXguq+CR/Y9/Fe+HX1P/hHvDENhp0Mtu0ouLyRXaR1GMMQRFkjODk8EV1vg7wfD4e+IMRsLF4YbTQY7e5vfLYfbZ3l6u5/1jqIc8klRIBxkUAem7xRvFeSeNLLUNQ+KL6No0phTWtHij1S4jfD21tFNJ8w9HcSPGp7cn+GsHVfDjXd/rumP4fvm1xb+C20K7Fo/2fTrFBEUeK4xsj24kLKGDseMGgD3neKXcK8Q231/c32gz6PrEdxq3io3N9MbGUW62kLqUPnEbCHjt41+Un7xBx3634X+GrWGxfxFqOkpD4i1K5ubuSa4hxcRJJKxSP5huQCPYCvHTmgDtY9VspNYm0pJs38MCXMkQVvljdmVSTjHJR+M54q7uFeFeKNHkuNV+It/Z+HrkeJ2kh/s68TTGMn2ZYYUkkguNm3zSGmwobf8o44qjr+hXcdnq134A0XUNF0OZLGyuVSwmjnuVWZmml+z5SV8IyqW4dwXweMkA+hAQelFeBaT4Qa/ij0xdPl/sPVtXtzc2sGiTaTbRw20TyNJ5TyM673WJcts3FeM9SahpNzbfa9JOgXNr4Uv9Yu5fKt9CF79nWFIooligZHSMSssriRk29D0OaAPdbu7jtWtxKs7GeUQp5ULyYYgnLbQdq8H5mwo4GeRVTwzrVv4i0O11WyjmS2uQWjEoAYqGIDcEjBxkc9COnSvEtE0vXdM8K6M8Gl6s0um6RqupQQtZ7HS6uJClvCERQqMqPJlFAC56AcU7W/Cxtte0qwtNGudXNnbWGlC0vtKmMMcSY33FteowWA4J3Z+YlOmMUAe/UUUUAFFFFAEVFFFABRRRQAUUUUAFFFFABRRRQBj+MtXj0DwtqOpygH7PEWAPc9BXi+n6693bxOzHLKGI9yM1sftO6y1v4d0jQ4GPnapdgsF/wCeceC2f++hXEaOMQKcfh6VSJudJJeMWOCcVE05b1zUUfrinHpTAcJmH8RqxDqhi6Nis9zjNZ91IF6UwOytPEflkbj0rSXxjFHgs2PxryO+1AwoSzEY6Vy1/wCIHdyodsAjkGh2C59I2/jaJ2AV8k9BXQ6Hrh1SRo7VRIY+ZJF6L7fWvl7wXFrni7X4NH0Mt5nDXdyfu20eeSfc9hX1p4a0O08O6RDp1jny0GWZvvSN3YnvmpdhmqFG1SD+NFHAHArlviJeaxb6PBD4adBqlxcIgRZIVnaIHMpgEx2NIFBwG46k1IzqaK8R0ee78ceI/Ci2/inWVS2gv9SEz2tpHcRsrraqrDy3jZhvnBZRtI6Doat2viHXrjQ7DUDrmp3F94kvLiHR7Czjs4Y4ogzujNLJExOIo87jnO7G0nBoA9chs7aG6uLmG2hjubjb50qIA8u0YXcepwOBnpU9eG6f4o1a+0Wxg12a11SP+3bpjKUiulktLOEyMQwhjVj5ybVdY1xxjkZN3T/FWuR3Xh3Vr/xC00N5pN1r2oaXFFb/AGe2tliUoocJ5nDSKNxc7irdBxQB6/aXVveRGWzniniDvGXicOAysVZcjuGBBHYgipq8O0K81vwVoFlb3OtS3CN4cvtavkNvEos5BsdTEduSxeWTO8uDtzgdK7nwLZHwV8NoZ9V1W9voLWwF3N5qRfusR75AmxFJGdx+YsfegDuKK8Ll8e+J9HvrzUrhpbnTRol1rIsLm4t5ZIUGzyQwhgTy8l/+ekmVBPBHO/rF14k0/TdPgtvGqXesarPaWu37Jbstq0r72ljVVBKeVHNhX3ZxndxQB6xH3p1eOa7rWuWbeMIE8XXVpH4Zs45VmktrV5r24lQuisPKC+X91FVFDMxPzZHMl14r12DxVaPrWqS6ZpM91BbW72SWk9oXWPdcQ3G4maNwyyDKkKoAJzg5APX6K8u+HWueILvxV/Z3ie/vI9SNm99JZeVayWTxGXbG9vLEfMC4xxLknORjFeo0AFFFFABQelFI/wB2gCOiiigAooo7UAFGajdhnrTSwoAlz7GjPsah3D/Io3D/ACKAJsijIyB61Durn/iN4gTwt4H1XV5WG+GErEO7SN8qgfiQaAPA/itq3/CS/Fq4Fu4e10aIWceOQZD8zn9VH4VoWUHlwoAMcfnXH+DLCRYo5bli9w5Mkrnqzsctn8T+ld8sYUKFOVx1qyB6jIprDtUowBUTnBzQBUuG25rF1CURpkmtS9yMmuM8Q3uyMru+b0pgY/iDUWdvLU/hWTo2m32va3Z6TpMXnX92cJkfLGO7t7DrVbUp1jje4kH3efx9K9k/ZV1fR7fVNRsNQt1h8S3g8yK4Y582If8ALNfQj070mCPbfht4K0/wH4ci02xIlnf95dXLfenkPcn09BXWAjsDn3ppIGME49DTSwHepKJSeDjrVDWNG0vXLVbfWtNstQgB3CK7gSZQfXDAisfxp4nTw3YwPGLWa9uJPLgtZpZVabudgiildiOOAh69RXO6P8R9Q1220RNE8PRz6hqJvGeO4vHgigS2lETSF2h3lSzKADGrdcjg0hnaT+GtCnewefRdMlawGLMvaRsbYcf6vI+ToOmOlLfeHdEv9Kg0y+0fTbnTbcKIbSa1R4Ywowu1CMDA4GBwK5Gz+Is+rwaWmgaNHPqF1YvqE8d3eiCG1hVygZpAjk7mVguF5CknbVvwFq11D8LYvEWrG7up7i3n1d4wTI+yQtMkSA9ghVVUY6CgDol8P6ZBaLBp1la6e0Uc0dvLa20Stbeby5jBUqCThiCCCQMg1g+F/htoGgHUWWCO+fUIvIuPtFrbRo8eSShjhiSMgk8kqScDJOBWHY/FG5vPDT6ta6Tpl6ZJLWG0hsNZScyTTyKghkPlgxSKG3MCCBg/N1wsvxG1y1TVJLzwvZrDpV/b2F3JDqpcM8xiwIcwguw85chtg7AmgD0SfTbGeWaWeytpJJoPs0jPEpLxc/uySOV5Pynjk0zTdH0zS9O/s/TNOs7Ow+b/AEa3gWOL5uvygAc9641fiHLJPb3sWkIfDM+o/wBmJqLXe2VnDMhkEOzHlb1K7i4Pfbik0j4g3WoXGizPoiW+i62Zhp1295+8cJE8qvLFswiOkbEEMxHGQM0AdTpXhbw/pCyjSdC0qxEyGKQW1pHFvQ9VO0DI9jRpfhbw/pPl/wBlaFpVl5cnnJ9ms449r7Su4bQMNtZlz1wSO9eW23ibxrqvhTwm81nbm/1vUoru1+z6g0bPaBpLgpKRCojQRrEnG8uGORk4Ppvg3Xm8Q6VNczWn2S4t7qezmjWXzU8yKQoxR8DcuVOCVU+woAu3GgaPe6pb6neaTp9xqVtjybuW2R5oscja5GR1PQ01fDOgpqk+pLomlrqM6skt0LSMSyK33gz4yQe+TzXlMvinxlqfgmKf7LbCbWtZWDTGtL9lm8kTlmT/AFSBV8mGQh9xJByQOlbmpfFqDS4ktdTtNPstafUZtOEdzqaw2YMSI7ym4dAdgEij7m4scBe9AHfaLoGj6EJhomk6fpwnbdL9ktkh8w+rbQMn61p15ppfxLu9ch0aPQNGsr3UL97xZF/tPFtEltIqNKsyxtvjYsu1gozu6dam8IfELUdduvDZu/D0VjZa9BLLbyC/82RfLQMWZBGBsOQAwbPIyozQB6LRRRQAUj/dpaa/SgBlFFFABTXbimyScVWLjJ60ASMcmkNMLUm6gB9FM3Ub/TP4UASdelfO/wAe/EY8QeLLTw3aOXsNJfzrrB4ecj5V/wCAjJP1Fe3eMNbHhzwtqesMFxZWzyKCeGYD5R75OK+WPCVtNeobm7Yvc3EjXMsjdWZzk5/QU4COu0S22xZK4zW4owgFVoV2KFznFT7sYq2IkHeoJelOL4FQyS4yaQjK1iby0fFec63cGRz35rs9fuP3LZ6V5rr+opZWrzEbpCdqL/tHpTAoz/6VeCI/6i3be/u3pVq1vbjSdVtNVtBi50+VbmM5xkqc7fxHFR2sQisYlB3SH53Pqx5Oagviq2k7HlVQ8epoYI+89E1aHWdFsNSt2zHdwrMAevIq6GrwrwH4sGleEdG0+RwJLa3WNvrXpOh+JY70LucEEVJRb8S+FYdc1PT9RTUtR02+so5YY5rJowTHLt3qd6MOdi8gBhjgiofDngbT9EWIWl3ftJFpp01JZJELqhdnaTIUfvGZgSenyjjrnokkBRSvQ1Bf6tZ6Utu9/N5S3E8drGdpO6SRtqLwD1JxnpUjOYu/hfpr20UGnatrOlRrpUejSfYpYgZ7ePOzcWjbDDc3zLtJyc5HFdXc6PFJoC6Ta3N1YwpEkUctpJsljCYxtOD6AcjkVn2/jbw7csqwanHIWvZdOGxHP7+JC8i9OiqpJb7o9axNH+JVnfazYWEtnOFutPTUPtVtBczQokrkQ7mMC7VZAzF32hSpHOCaALdl8PtPh1VNTu9Q1K/1H7ZHezXFw0QM7xxPHErrGirtUSMQFC84JJq4fBenG3MLzXbo2r/20+51+eYSeYqn5fuKQuB1+Reazvhr4/svF2l2JlkEWqXUL3Sw/ZpYVeIPgGNnGJMBkDFWOGPbpXQ+IPEVhoCRvqKagY3Vm32un3F0qBcZLmJGCDn+LGecdDQBg6Z8OdLsZ4Va81K7022nmuLXTbiRDb20kpYsVAQO2N7gb2bbuOMUaL8OdN0yCGCTUNVv7e1tJLGyiu5kK2cLjaVj2IpJ24UM+5gOAetdNc6xYW2hS6zNcoNLitjdtcDJXygu4vxyRt54rL0fxroeswXUmnXFzKbeAXLRGynSV4jnEkcbIHkU7SAUDAkYGTQBX8P+CrfSJdGkk1TU9QOkW8lrZi78kBEcRryI40yQsQAJ5wzZzkY1/DeiW3h/RINLs3mkhiLt5krDe7O7OzEqAMlmJ4A61j3PjnTG0bULuxd/tFo8ULW+oW9xZt5krBYgytEZAGLABgjD8ji54U1m51m78QGVIFtLLUWsrbywdzBI03ljnBPmFwMAYCigCj4b8AWWix6HGNT1S9g0R3awiuTDti3RmPHyRqWwrNgkk/Mck01/h3YJLZ3Vhqmq2Gp2txd3K38DRNKxuX3yqweNkZc7QAV4CLg9zieG/iNca3qzy2wgj0qbUv7MsoLuwu7eWcgtvlWcoUJAim/dbBjaN7oeK0tH+I+nDQYL/X51ilu3uZ4ILK1muHW0SV1SV1jDkLsUEuQFyT0oA14fBtok0s8uoancXUmmtpnnzzK8gRnZ2cHb98lh/s4RQAMVY0/wpp9hf6NdQtOTpOntptpExXYkbeXlsAfexEgznGM8c1t2s8V1bRXFtIssEqCSN1OQykZBHsRUlABRRRQAUjHBpaZKcAUARs2GqJ5PeoppCD1qIuD1oAfI3FR7uKaWz1pOKAH7qM00Yqtf6hZaVp9zf6lcRW9pAN0krthVH1o3DYtjkjrmuS8YfEbwx4Tm8rUdQEl+RkWVsPMlz7gfd/GvGfHPxX1vxPcS2XhQy6Xoh+Q3BGLicHuP7g/WuU0/w0kKkndv+8WY5Zj3Jb1p8ouYf8TPiHrPxC1200iONrDQQ4m+xg/OyryGlI9T/D0rqNCtvJgUkccVladocMM5mEQ80gAseuB0FdNAQqBR0FUSXSRngCguMVAXAFRtLwc0ASPMBnNULq4G1ucU2ecdzXP6tfGMMFIxTApa9do25Q3Qetee+JQJ4IlC/vHlAQenqa1dXvXjzIUeVicBEGayreC4ec3N9t83GEQHAjH+NMReI2cAfMflFUWDTajBanBiQ+bLjvjotM1S/a2CrEPMuXJwo/h+tSaBaSCU4yzE7iT3NIZ2NvdyMw+boeK9K8A3Nw06A7iua43QdCmu3Qsv5CvZ/Bfhw2saOw5oYI9B05ibdd1YfxF0TUPEPhlrLRbuGz1FLm3uILiXJWMxzI5bABycA4Hrjp1HQJGVRMdO9P4qCzy2L4Z3mnz+Kf7HurWO3urA2mkRSM3+jSSW8UM0rkD7xECEEZP3um41rXfhfXrZvFNton9li01XTIbC0uJp3SW28uExqCgjIYZZmzuHXGK73Ipc0gMGw0J7TxfZ34aL+ztP0gadaR5O9WZwZCRjAG2KIDBz16d+S+JPgfWvFGp6y8UOh39reWSW1k2qTSn+zWw4keOERsjO24EPkEFR1Ar0o4Jz3pc0AY/izw+2qeCj4e0wwRQOILZvOJwLdXTzAMA5PlhgBwMkZIrA8ZeDta1nVtXv7O4tP9JNjBHbvcyQCa1hd3lheRFLJvaQjIDZCgHqRXciQipUccHPNAHmfh34bXtlKJJLTQdOjm16HUp7bTdwijt4IcRRoNi7n80BmYgZyT1wK7XwVo17oHhGOznNtJqhae5mZGYxvPLI8jfMQCRufrjOO1dDE27rTqAPN7PwNrFno/hm3tbmxN1o+m3mZHdgJNQmjChxheEy8xJ+98w4PNYs3wq1Oxvw2l/Zbm2fSbTTPn1i9sDB5KlT8tvxMjZ3bWKnOeeSa9lTpTqAMTw5Y6hpj3FjKmnxaHaxwQaXHb+YZVjWMBvNLEj7wwuM8DkkmtuiigAooooAKZMMpT6bL/q2+lAGTcnBIqvn3p103z4qHNNICXdSFx7/AP16jQl87TnAzWV4o8R6b4X0h9R1mcRWyjCoOZJW7Kg7mnYVy7rWr2Gi6Rc6nqtwLeygXdJIf0AHck9BXzF4y8T6h8Q9YM92Xg0SJv8AQ7Icbh/z0kHdj6dqZ4x8U3/xB1RJLxXtdJhbNrYhsgf7b+rfyq7p1ksUaggcCmlYTDT7KOBFAUZ9a1oF2LgA4PqaREGRjpVpEGKomwiA9uKkXg05Ux1pHUryakYSPhc1UkmwppbiTANZF9chVIyaYgvboAde/rXNajc73J/kaLu6O5stxWDczsxZi2AvJzTAbMS7Ng5I6sD0rOu75gxhhCtMBk+i+5qvLfPd7orMlV/im6Z+grY8O+Hpbx1QIcNyW7k+9IZlaXpk1xcKY/3kjn5mPrXsXg3wS77HlTk9eK6DwJ4ESIK8iLxg5Ir1zTdNt7KNfMaKPIGN7Kp/U0hmPoHhuG0jRmQAj2rrreJIo8KMUkezamCpB6MOR+dPIIUEdKAsSBjjrRuqLNGaQyXdRuqPJpM0WAl3UbqizS5NFgJC3FSRnOOarc1IjYIFIZqW5qaqlu1W156UgHIe1PpijDU+gAooooAKKKKACo5/uVJUVx/q6AMO9OHzmq+78qmvP9Z/9bNUL6/t9N0+e6u5Y7W0t1MksshwqDvmqQmWiVjQu7hI1BZnzwoHJzXyb4x8R3fjjxbLfyNutImMNlEp+WOMHhsep7mui8ffEzWfGAutL0BBp2gygoZiuZ7mM8H/AHVP4cVh+GdJitIolVSAqgAE5NMRpaRp6Qxr8gXHYVsRrk4xgChFAwF6VYRaYh0cYq1HH0psK8iraLxQBHsFV7kEDnir22s3UJMA0gMjUZditg1yeo3h3EbucVrazcld49K4XW9U8hSqKJJjyqH+ZpisM1HUEj5lfGei92rIBn1GQLJGyJniNTyfqaSxs5bycyzbpLiQ/Mx6AegFen+DvCDSEMybs459KB2Mvwl4Se7kXehxx/DgD6V7j4S8IxWyozoAR6itTwx4ais44y8Y6eldfDDGp2RilcdipPLZaLpFze3RCW1uhkcnjOOgHvXzbod7P4u8T3XiXV7ea8Go3Js9MsmmZIiVGWbOcAAA/jXYfHzxFc6vd2fg7Q3LT3EqwSFDjLnHH4A/hXW6d4X0mz8L22i3lvE1tZx/KZAPlIGS+ex75oA5P4f6zPY+LhBp1zOujXEDmewnkMgt5VIAKE8888dK9uspTNArjPTOK+aPATNq3iy9u7NBHAX2xqvAEYOBx2r6O0pDHbocH2570gL+/k89OvtSs2373Fcd4g8f6Xo2sLpNvb3mqaio3zQWC7zbj1fsCfStbQ/EFjrdkJ7F2ZATGyuhVo2HVGB5BFAzb3UZNRbqXdRcCTJo3Go91G6gCTdjqfanAtnPPHWoC3sCBzz0FeaeLPiza2F7PaeHrQajNEdr3LPiBT3UEct+FJhc9eglwQCeTWjGTmvHvA3xRGsalb6brFklldTbvJmhfMTtjO3nkHAP5V6rZ3G9sUAmaK/ep9MT71PpDCiiigAooooAKjuOImqSo7kgQnNAHOXrD7QNxIHqK+afjF4pl8U+Kn0a0mxoGnPiSJTxczD7xPqAePqDXvfi7UPskEpQ/OUYD3ODivjnRra6vry4iRDDdR3MhuLknlCWJKr71SRLOmvrz7FbiC0Tzb9x8kK9R7t6D61r+GvtIijS6OZQBvI9aSCLStHsVe4fbJKckt88kje2Of6Vf025R4PtJhmgDHhJQAfrweKoRsqvIqdF5qtbzLI3GCParced5z0oAtxL8tWEGFpkf3aeW+U0ARyNXP61OI1Na95MI0z0Ncfr13uVl3HJPBoA5rxFqEcEMkznhRk+57CuLtY2urgyzL+9k+ZgO3oKs6xdfbdSMStujgOB6Fq2vDuml5E3DmmBv+DtCE0keUNe9eFdFW0gUhcHFcr4H0UARMVH5V6paxGKLHHpUtjRPEmyICsjxfrieH9HlvDgXDjy4QecvWuzqEy77QnzMe2B1NfP/wAS/Fk+v3ch047kef7Hp6/3m6M/4c/pRuBR+H7NdeLL3xFd5aO2doIHbvIf9Y4/l+Fdh8YvEkA8KRW9nJi7v/3ChTyEx8x/LNatp4QtbbwlaWmnSgyWkW3JH+sb+Jj9Tk14wko1HxPLPfzqtlZMYkZuRgdSPqaAPV/hH4dSzso5mRQxXkn09T6AVt6xr+q+IkudK8DSeXZQEpf6yR8ieqQ/3m9xwKw7LRNa8VaBv/faV4YUfKuds97/APEqea0PE/xC03wL4Oh0TSbSFtUdNsFsg+WEf35Pf26mkBiXuqaR4L8NDSNHjVtVuX3nccuzHrLK1a3w5UwRkIS7TyebNL3dz1avL/Beh3et6rJe35eWWRtzO3cn+ntXv+haWlhaqixgHHYUDOgh/wBXTl6VGGAGB0pyvkHGMjgCiwh2W7Y69On61X1PVbLRrGe+1a7htrSPkyOwAJ9AOpP0rnfG3jnTvCsCxEfa9VkH7uyjPJB7sf4R+teH+IdV1DxHf/2hrkglkHEcC/6mIdgo9fc07Bc3vGvxAvfE7vb6f59lomMFPuzXI/2/7q+1cmsSxhYoVUR54VegHpT15Yscbh6Vha54hj0/baWSi5uycgHoh9Saa0An13WDpNxpot8rei6jdAOcAHkmvob4Y+JZtWlzKTzXzR4Y0C/1i/E907SSFy/zc7c+lfTfw00P+zLdSVweKUho9ahOWyDkYqaqtkcj8KtVAwooooAKKKKACoroAxYJqWorkZhbNAHzv8fvEFzp1rb2um4+23svkRHH3fVq8htrhtMS2sLO1abVOd8bvwD3kdsdDXqH7Qlh59ut0oKzWzGaNh2I/pXlWg3+y1truSTzby9X/SA4+ZQOn0GMVaJZ1egafFAzXmoOk16y4aRhwg/ur6Cm+JL+0gjP75UTOcdc/TuTXGa54tkS/NpawvcP0AQjG4/w/Wtfw7o8zMt3qnz3Z53HlYx/dX0piOn8P7vKQsDzzzXRoRmsaGaCEjBAFaEUm/5geKANNHG3B6UjyqM88VSMuFqpcXICtz2oC5Hq92vlMcjivPPEd/5cEj5Hyjj6+lbet3u1WXJOfeuA1yfzrtLYHIGJH/p/WmBFotmzOpbJZjlvrmvWPCOlmSaPchx61yPhnT2kxgZJ9q9w8HaV5SReYoB+lK4WOt0CzSC1jwMFa2GO77xwKbEixRBM4A71V1G/g0+yubq7YJBAhdmPQ47VLGjlfipq0tvpSaLp0hW6vjiSTP8Aqou5/GvErK9g/tSfUhn+z9NU2lgOm5/45P6VsfEXxDKmnXWpZIvtTIgtkzkoh6kfhXEaRY3moSW2m6bGZmUBF9Ae5PqaEB1D/ELWIoJbTTwZLm6Xyo1UZ5PGa9L+C3wliVY9U8UMJ5gQ8Vl1Ud9z+p9q0vAnw+sPDdg1zchLjVXG4yNz5Rx0X3965TxZ8UbrQI7vRvDj+Zq0uUec/MLYH+bfypsDvPjP8V7LwrE+haEkV1rbJtIAzHaqehIHf0FeGeEvC19ruoNeX5klaZt7u/3i1aXgXwRc3l0LvUmlllmbzJGc5LHuSev517noukQ6dboscYAz+VICHw7oMWm2yRxoqADoK6FTj+VN+XIY/Lx0NUtX1ay0i0+0X8wjQnagAyzt2VR3NAzQciNN7sFUDLFuAB9e1eY+NPiSolk07woyPKMpJqDDKRn/AKZj+I+549q534meINcv59OtJiNO0i6Vz9kU/vJAoJ/eN74+6PxrkYYxGpC48vH3ccD/AOtTsSNUN5jyzu008rFnmkOXc+rH0pSVG+Rnwi/eLHg1Vvb+KwhL3Ddecdz9fQVzktxe6zIFhBSDtt4/z9aYE+sa3JITBYfKM4LdyP6Vb8J+Epru581kYhzlie9dH4Q8ENNseaPKj2617T4f8Ow2kAxGF470mMy/BvhVbNY8KM4716RpcQiAUE4qnDGsQAXHAxV6ybEmKTGjpLI5FW6qWPSrdSMKKKKACiiigAqG6/1ftnmpqhu/9UaAPM/HGjRapHLE6hgQRzXzT478JS+G4J5YbqZLXdtVOnLHgAnoK+sNVAecr61538SfC6+JNCntYSI5gVeJmHG4dM+xq0JngHgzSLGBpJzKZbxBk7gQAD/d9R710Ot+JLTTwsTMTKV3BEHJH9Kw9S0rX9EDTXttFbtACiS+YNmD39/ocVgaXpFxq0jTTzlYmYgyN99ye+Ow9KaJZ0nhnW7vV9QmdFVbROD6g+h9TXoFsSkCniub0TTrfSrOOK3TagGTnqfrV2W9CKCh+92zTEa8tyAp+bpWFqF8dpKtwap3WoEq2W4rndQ1WKP53fAHO3v+VAD9XvQI2kdwEXkmsbQ7Nr28eZ1JMz5+g7CmRxT6xdIGUrBu3bPU+pr07wR4XYFWcd/SkM3fBOg4ZSwx04r16wtVggTP3scVmaFpqW8IO3nHpW5uDKMDGBikUSo5yMc15J8WdbfUPEFv4XtiyQxILu8GCPNHYe4z1r1bJH3eD6jtXnXxg0DVNZt7YaFo1rd3+wxtfyOFe3QnkKOMk9ueKQHg+u3kut+LrS2tjiFXNtET90cZZ89ugH517d4Y0/StJ0WNNMZZJwMPcA53n2rzyHwDO2owW1nN9l1OzQSf2RqK+Ubzbk/u5RlWyT0yDXPyvqaeKDYaXBqGl3l7Ew1CC4XYsZzz5YyeAMAGmhHp3ir4i3P9ny6D4bJbUX/dzXY5WEHqF9W/lWd4D8AiMrNeBy5OSGOST3JNbPgLwhBbBGeMMevt9frXqdjZw26rGoAIHagBmk6fDaRKqgBgDWhCpI45PYGoHOxHdmCRryXY7QB9a5TUNdvdVle00Jjb2anEt+45b1EQ9f8AaPH1pDNTXfEcdjN9hsUN1qZXKwIeEH96Q/wj2PJrCtrKR7sajq032vUn+VXYYjhHpGO316nvUlhYwWMZhtVILfM5Y5Zj6se5qWe4SCKS4uHW1jiG9zIcKooA4P4rZGu6L8uW8uVst1PWuC1bV4rZXiGDN3wMgH+pqf4i+K08R61bpo7P5NvGYi+P9bk9QewpvhbwfNqE2+56HmqJMbTNIvNYvFklDNuO7nmvXPCXgqKFVZ044Jro/DPhOKzVB5YGB6V21vbRxRKoAoGUtM0yK1jxGtbAChBhuR2qIMAMAUbjUsCXdV2zP71azd1XrNv3q0ho6qy6CrdU7D7oq5SGFFFFABRRRQAVFdf6k1LUV1/qWoA4rUDiZjWfJH5hq3qZPntzVHJ9TVCZ4R43EHiP4sR6Dq8rxaLbyKgjjO3zXKbgWPueAK0/E/hGwsIlXR7dbR4RmM5JD+zZrQ+L/gO71aUa9oEbSagMCeBG2tJt+66ejjA+teca3491HUdMXTNQX7FcR/JcyupV5ccY/wBn3poTFTUw8AYHr15zzVOfUCysowc9awhqcJAjgzIAMBYxTQl/qEght4/IB+83Vse1UIW+1NnkMVqd8g6k/dT/ABNT6J4em1G5MkgeWUj5nP8AngV0vhrwS03lh4zsB/HPvXsXhrwtDZqg8sKcelIDkPCfgryvLeSLtXp+j6QloufLFXobVYBhcYFWt3GKkY5GAUADApwaotwo3UDJt3+c0b8c4J9hUO72NLu9qQFHxBpFpr2lm21GIsq/NFIpxJE/Z0bqCK5638Kbrz7ZfXU+oX2wRPdT43si9BgV15bPXmkyPSmBDp9pFaLhMUzVtVttKtxJcyne5xHEnLyH0Uf5FZ3i/Xjo1pbJZwCbVLxvJs4WIAZu7N/sjqaybDTngmN5qE32zUnXDXDDG3PUIvRV+n40CFuPtmuMsmtL5dqG3RWCudox0aRv4j7cD61eUrGoCLkdNo4A+lLwzZHyr/eI61wPjv4iQ6BcPp2jRrfaw3BAOY4R6t7+1AHR+KvEumeFrL7Vqc2GP+rhQgyO3YAV4xrWta748uAJwbeyVv3VpHngernuado/hzUfE2qNf6xNJdXTHmRui+yjsPpXsvhbwfBYooZADimBxfg7wGqmN504/wB2vWtJ0O3s1GxBwKuwWq24+XGKshqQx0eFXAGKfuqPdRu9/wBKQEm6jdUW4f3v0o3D+9+lAEu7/OKu6e370Vnbvf8ASr1h/raAOxsORn2q3VPT/uj6VcpDCiiigAooooAKiuv9Q/0qWo7lWeFlUZJoA4HUz+/bPTNUtw/ya6C+0O9llZkjBB/2h/jVT/hHdR/55D/vtf8AGmhGRLypB6HrXJ+JPDdrqikyQxu3bcoOK9Ebw7qB/wCWQ/77X/Gm/wDCN3+P9SP++1/xqkwPCJfAMSS7hEPwFbOl+D44sEp+Yr15vDV6y4MAz671/wAaB4avgMCBf++1/wAaOYLHJ6bpEVtGCAMDsOK148KPfGK118O6gDnyl/77X/Gkbw5qJOfKH/fa/wCNK4WMsECjitT/AIR3UP8AnkP++1/xo/4R3UP+eQ/77X/GgDL4pOK1f+Ed1D/nkP8Avtf8aP8AhHdQ/wCeQ/77X/GgDL496Pz/AFrU/wCEd1D/AJ5D/vtf8aP+Ed1D/nkP++1/xoAy/wAP0o4rU/4R3UP+eQ/77X/Gj/hHdQ/55D/vtf8AGkB5d8Sp49L17wzrl4P+JZbtLbzyg58kyABWPoPereo+ItHsrJbu5v7cQMMqyvu3+gAHWvQ5/DF5cW7wT2scsLjDRuVZT9RmuQk+C+krdefbaDbRSA5BDLt/LNNMDyDxF4y1nxMGtPDFvPp+nKSr3jjEkvsvoDT/AAh4AKYeVMsW3MWGSxPc+9e52nw9lgcMtqigYAUMuP51pw+E7yIjZbqoHoy/407oDltH0O3skAWMDA9K2woHQAVrr4d1AEnyQc/7Y/xpf+Ee1D/niP8Avtf8aVwMjpS8ehrW/wCEf1D/AJ4j/vtf8aafD2o/88v/AB9f8aAMvI//AF0Z9P51qf8ACPaj/wA8v/H1/wAaUeHtR/55D/vtf8aAMrJ9aMn1rW/4R/UP+eI/77X/ABo/4R/UP+eI/wC+1/xoAycn1q/prEzDPep/+Ef1D/niP++1/wAat2WiXsThnjH/AH0P8aTA6DTjxj2q7VWyieNR5gwccjNWqQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42814=[""].join("\n");
var outline_f41_51_42814=null;
var title_f41_51_42815="Cafe au lait spots";
var content_f41_51_42815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cafe-au-lait spots in McCune-Albright syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) A typical lesion on the face, chest, and arm of a 5-year-old girl with McCune-Albright syndrome, which demonstrates jagged \"coast of Maine\" borders and the tendency for the lesions to both respect the midline and follow the developmental lines of Blaschko (a configuration of skin lesions characterized by arcs on the upper chest, S shapes on the abdomen, and V shapes over the posterior midline, caused by patterns of x-chromosome inactivation).",
"    <br>",
"     B) Typical lesions that are often found on the nape of the neck and crease of the buttocks are shown (arrows).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis 2008; 3:12. Copyright &copy;2008 BioMed Central Ltd.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_51_42815=[""].join("\n");
var outline_f41_51_42815=null;
        